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Identifying distinct trajectories of health behaviors after a breast cancer diagnosis 
Zaixing Shi 
Breast cancer (BC) survivors are at increased risk of cancer recurrence, a second cancer, and 
non-cancer comorbidities. Previous studies suggest that many women adopt a spontaneous change in 
lifestyle after a BC diagnosis in hope of achieving a better survival outcome. While this observation has 
led to the suggestion that a BC diagnosis is a “teachable moment” for improving health behaviors, other 
conflicting studies report that BC survivors do not make positive changes in health behaviors following a 
breast cancer diagnosis. Although previous studies suggest that receipt of cancer chemotherapy and 
hormonal therapy is associated with weight loss or weight gain, the association between post-diagnosis 
weight change with changes in lifestyle has not been studied in detail. The majority of prior studies of 
post-diagnosis changes in behavior and weight have examined the mean change between two time 
points, and therefore may over simplify the trajectory of change over time due to lack of more granular 
data. New methods are needed to examine the distribution and correlates of behavior/weight trajectories 
following the BC diagnosis. 
In my dissertation, a systematic literature review was conducted to evaluate the evidence 
regarding the frequency, magnitude and pattern of post-diagnosis changes in diet [fruit/vegetable (F/V), 
dietary fat], physical activity [moderate to vigorous physical activity (MVPA) and sedentary behaviors], 
alcohol intake, and body weight among BC survivors. A total of 66 studies were included in the systematic 
review. These studies suggest that after a breast cancer diagnosis, women are less likely to engage in 
MVPA and more likely to reduce alcohol intake. Previous studies suggested that women may experience 
weight change after a BC diagnosis, although there were strong evidence showing both weight gain and 
weight loss were common. The reports of changes in diet and sedentary behavior following a BC 
diagnosis are limited and inconclusive about the direction of change. The results of the review suggested 
that there is wide variation in post-diagnosis lifestyle changes among BC survivors. However, very few 
studies have investigated the variability in multiple behavior trajectories following a BC diagnosis. 
 
In this dissertation, I made use of a population of 4,505 women newly diagnosed with a BC and 
enrolled in the Kaiser Permanente Northern California Pathways Study.  I used a combination of 
statistical methods, including a semi-parametric, group-based trajectory modeling and a non-parametric 
K-means for longitudinal data analysis, to identify latent trajectories groups that are unobserved clusters 
of individuals following similar trajectories of a behavior. These analyses tested the hypotheses that in the 
24 months following a breast cancer diagnosis, women follow a mixture of lifestyle (F/V, dietary fat, 
MVPA, sedentary behavior, alcohol) and body mass index (BMI) trajectories, which can be stable, 
temporarily increase or temporarily decrease. My analysis identified multiple distinct trajectories of 
lifestyle behaviors and BMI during the first 24 months after a BC diagnosis.  The trajectory analysis 
results suggest that the large majority of women maintained their lifestyles following a BC diagnosis. 
Socioeconomic status, dispositional optimism, perceived social support, and the severity of CIPN during 
active treatment were associated with the post-diagnosis trajectories of. Furthermore, the BMI trajectories 
were stable over the first 24 months following a BC diagnosis. The BMI trajectories were associated with 
trajectories of F/V, dietary fat intake, MVPA, sedentary behavior and alcohol intake over the same period, 
independent of demographic characteristics, tumor characteristics and cancer treatment received.    
In summary, previous studies suggest that women may spent fewer time on MVPA and drink less 
alcohol after a BC diagnosis, while both weight gain and loss are common post diagnosis. In a trajectory 
analysis of 4505 BC survivors enrolled in the Pathways Study, I did not observe any latent trajectory of 
meaningful change in health behavior or BMI in the first 24 months after a BC diagnosis in the Pathways 
Study. Instead, my analysis suggests that most women maintained their body weight following a BC 
diagnosis. The BMI trajectories were strongly associated with trajectory of F/V, dietary fat intake, MVPA, 
sedentary behavior, and alcohol intake over the same period, independent of demographic 
characteristics, tumor characteristics and receipt of cancer therapies. These results suggest that there is 
an absence of spontaneous changes in lifestyle behaviors after BC diagnosis and the importance of 
maintaining a healthy lifestyle in weight management after a BC diagnosis. Future studies should 
examine the associations of these health behaviors and BMI trajectories and BC prognosis to better 
understand the effect of post-diagnosis changes in lifestyle and weight on BC-specific and all-cause 
mortality.  
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CHAPTER 1: INTRODUCTION 
 
Emerging evidence suggests that a healthy diet and exercise are associated with better long-term 
outcomes and quality of life for breast cancer (BC) survivors.1-6 Previous studies have suggested that BC 
patients may adopt healthier lifestyle changes following a cancer diagnosis, such as eating more fruit and 
vegetables, increasing physical activity, and reducing alcohol intake.7-10 These observations suggest that 
a cancer diagnosis might be a “teachable moment” for BC survivors.11 However, other studies have 
suggested that the favorable behavior changes in response to a cancer diagnosis may not be 
sustainable,12 and some studies reported unfavorable changes, such as an increase in time spent on 
sedentary behaviors.13,14 Although the reasons for unfavorable behavior change remain poorly 
understood, breast cancer survivors usually experience side effects of cancer treatment, which are known 
to disrupt lifestyle behaviors.15-17 Furthermore, BC survivors usually experience acute emotional distress 
at the time of diagnosis and early treatment, which may adversely affect lifestyle choices.18-20    
Favorable changes in health behaviors post-diagnosis are associated with BC prognosis and 
survival. For example, an observational study among breast cancer survivors in the Women’s Health 
Initiative Study and Nurses' Health Study suggest that women who had better diet quality after diagnosis 
had a 26% lower all-cause mortality and 28-42% lower non-cancer mortality.21,22 In addition, breast 
cancer survivors who reported increased physical activity after diagnosis have 22% lower all-cause and 
39% lower non-cancer mortality,23 whereas women who decreased their physical activity level after a 
breast cancer diagnosis have 200-400% increase in all-cause mortality and two-fold increases in breast 
cancer mortality.24,25 Currently, few studies have examined the survival benefits associated with reducing 
smoking and alcohol intake for breast cancer survivors.   
Previous studies have suggested that unfavorable changes in health behaviors after a BC 
diagnosis may account for post-diagnosis weight gain in breast cancer patients, which is associated with 
worse prognosis.26 Weight gain is a common and persistent problem for many BC survivors during and 
after cancer treatment.27 Weight gain is also known to negatively impact on quality of life and to increase 
the risk of developing comorbid conditions.28-30 Furthermore, unfavorable changes in body composition 
have been observed in  BC survivors, including gain in adipose tissue and loss of lean tissue, which is 
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known as sarcopenic obesity.31,32 Loss of lean tissue, combined with gains in adipose tissue, may lead to 
metabolic disturbance, treatment complications, and poor survival outcomes in BC survivors.33,34   
The causes of weight change in the after a diagnosis of BC are not well understood. Diet and 
exercise patterns after diagnosis and possible treatment-related reductions in resting energy expenditure 
are plausible causes.31,32,35 However, the extent to which these individual components of energy balance 
contribute to weight change is not yet clear. Although poorer diet and physical inactivity have been 
implicated in weight gain among breast cancer survivors, there are significant gaps in knowledge, such as 
the longitudinal pattern of behavior change and the causes of change. The limited reports on longitudinal 
change in health behavior after BC diagnosis have important methodological limitations, as they failed to 
assess the variability of behavior change trajectories and reported mixed results regarding the direction of 
behavior change. Most prior studies examined the average change in behaviors and assumed all women 
would follow a uniform trajectory of change, thereby ignoring the variability in behavior change 
trajectories. In reality, women may follow a mixture of behavior change trajectories after a BC diagnosis. 
However, the existence of latent behavior change trajectories, where individuals can undergo trajectories 
that are unobserved (latent), has rarely been evaluated. Understanding latent behavior change 
trajectories can help identify populations engaged in unfavorable behavior trajectories who may be worthy 
of targeted intervention. Furthermore, few studies have evaluated the predictors of behavior change, and 
associations of behavior changes with the change in body weight in BC survivors. Prospective cohort 
studies with repeated measures of health-related behaviors and novel analytical methods that identify the 
latent trajectories of behavior change are needed to understand the dynamics and effects of behavior 
change following a cancer diagnosis.  
Given these gaps in the literature, in this dissertation I examined the longitudinal trajectory of 
health behaviors and body mass index (BMI) among BC survivors enrolled in the Pathways Study 
(R01CA105274/U01CA195565, MPI: Kushi/Ambrosone). The Pathways Study is an ongoing population-
based cohort of women newly diagnosed with invasive breast cancer within Kaiser Permanente Northern 
California (KPNC).36 Recruitment began in 2006 and a total of 4,505 participants were enrolled. The 
Pathways Study collected longitudinal information about lifestyle factors up to 5 years after diagnosis, 
providing a unique opportunity to observe the natural history of behavior changes after diagnosis. This 
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analysis focused on health behaviors included in the American Cancer Society37 and American Institute 
for  Cancer Research38 lifestyle recommendations for cancer survivors, namely, fruit/vegetable (F/V) 
intake, dietary fat, moderate to vigorous physical activity (MVPA), physical inactivity, alcohol intake, and 
BMI.  
In this dissertation, Chapter Two provides a systematic review of the current literature related to 
changes in diet (F/V, dietary fat), physical activity (time spent on MVPA and sedentary behaviors), alcohol 
intake, and BMI after a BC diagnosis. Following the literature review, Chapter Three examines the 
trajectory of diet, physical activity, and alcohol intake from the time of diagnosis to 24 months after 
diagnosis among Pathways Study participants.  Specifically, Chapter Three estimates the shape of latent 
classes of behavior trajectories after a BC diagnosis using a semi-parametric, group-based trajectory 
modeling (GBTM)39 and the fully non-parametric method, K-means for longitudinal data (KmL).40  I 
hypothesized that women would follow six different trajectories of BMI after a breast cancer diagnosis, 
which include: 1) maintain a healthy lifestyle, 2) make a persistently positive change, 3) make a 
temporarily positive change, 4) make a persistently negative change, 5) make a temporarily negative 
change, and 6) maintain an unhealthy lifestyle. In addition, I hypothesized that lower socioeconomic 
status, greater cancer treatment side effects, and worse cancer stress coping would be associated with 
the decline in health behaviors post-diagnosis. Using a similar trajectory analysis, Chapter Four evaluates 
the trajectory of BMI during the first 24 months after a BC diagnosis among Pathways Study participants, 
which may include: 1) maintaining a high weight, 2) losing weight persistently, 3) losing weight 
temporarily, also known as weight cycling, 4) gaining weight persistently, 5) gaining weight temporarily, 
and 6) maintaining a low weight. In Chapter Four, I also test the hypothesis that women who followed 
unfavorable behavior trajectories are likely to maintain a high BMI or experience weight gain. 
The overall goal of my dissertation is to provide a more detailed picture of the experience and 
correlates of lifestyle trajectories in the first 24 months following a BC diagnosis. The use of novel 
statistical analysis such as GBTM and KmL may unveil important latent trajectories of behavior/BMI 
trajectories that are difficult to observe when using a comparison of mean changes. Results from these 
analyses will facilitate physicians and researchers to better understand the challenges of achieving and/or 
maintaining a healthy lifestyle and a healthy BMI during and after the active cancer treatment period. The 
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latent trajectories analysis will specifically subtype BC survivors based on their trajectories of health 





CHAPTER 2: A SYSTEMATIC REVIEW OF CHANGES IN HEALTH BEHAVIORS AND BODY WEIGHT 
FOLLOWING A BREAST CANCER DIAGNOSIS 
 
2.1 ABSTRACT 
Background: Changes in health behaviors and body weight is common among breast cancer (BC) 
survivors and is associated with BC prognosis. This review presents a summary of the literature on the 
frequency, magnitude and patterns of post-diagnosis changes in diet [fruit/vegetable (F/V), dietary fat], 
physical activity [sedentary and moderate to vigorous physical activity (MVPA) time], smoking, alcohol 
intake, and body weight among breast cancer survivors. 
Methods: A systematic review was conducted by searching Pubmed, Web of Science, PsycINFO, 
Embase, and Medline databases through February 2017, reviewing bibliographies of eligible articles, and 
searching the author’s personal databases using search terms for F/V, dietary fat, time spent on 
sedentary and MVPA, alcohol intake, and body weight. Eligible articles reported on cohort studies that 
included women previously diagnosed with BC, collected repeated measures of behavior data, and were 
published in English.  
Results: A total of 2,552 publications were screened and 66 studies were included in this review. These 
studies suggest that there is strong evidence that women generally reduce alcohol intake following a BC 
diagnosis, and that women are at increased risk of both weight gain and weight loss. There is moderate 
evidence suggesting that there is a decrease in time spent on MVPA after a BC diagnosis. However, 
there is insufficient evidence to determine the change in F/V and dietary fat intake and time spent on 
sedentary behavior after a BC diagnosis. 
Conclusion: A systematic review of the literature suggests that women are less likely to engage in MVPA 
and are more likely to reduce alcohol intake and gain weight after a breast cancer diagnosis. More 
research is needed to determine changes in diet and sedentary time among BC survivors. Future studies 
should aim to understand the heterogeneity and determinants of behavior change among BC survivors, 
which can help identify women who have difficulty meeting the health behavior guidelines and can guide 




Breast cancer is the most common cancer among women in the United States.41 With advances 
in early detection, and improvements in breast cancer therapies, the five-year survival rate for women 
with early-stage breast cancer has increased to approximately 90%, leading to a growing population of 
long-term breast cancer survivors.42 In the United States there are more than 3 million breast cancer 
survivors; approximately 246,660 new cases of invasive breast cancer were diagnosed in 2016.43,44 
Despite the improvements in breast cancer survival, breast cancer survivors are often at increased risk for 
recurrence, secondary cancers, late effects of treatment, and other chronic conditions.29,44,45 While breast 
cancer-specific mortality has steadily decreased in recent years, deaths due to other causes account for 
60%-83% of overall mortality in breast cancer survivors.46,47  
With a growing population of breast cancer survivors, there is considerable interest among health 
practitioners and breast cancer survivors to promote health and well-being. Health-related behaviors have 
emerged as important modifiable risk factors that play a key role in both the prevention and treatment of 
breast cancer. The American Cancer Society and the American Institute of Cancer Research have 
developed physical activity (PA), nutrition, and tobacco recommendations for cancer survivors.  
Specifically, the recommendations advise that cancer survivors (1) engage in at least 150 minutes of 
moderate-to-vigorous or 60 minutes of vigorous PA per week, (2) consume a healthy diet, with an 
emphasis on fruit and vegetable (F/V) intake, (3) limit alcohol drinking, (4) quit smoking, and (5) maintain 
a healthy body weight.37,48  
A cancer diagnosis has been referred to as a possible “teachable moment” when cancer 
survivors are likely to be motivated to make lifestyle changes to improve health outcomes7,11,49, however, 
few cancer survivors are actually making these changes. A large cross-sectional study using the National 
Health Interview Survey reported that US cancer survivors are less likely to meet recommended lifestyles 
guidelines compared to US adults who do not have cancer.50 Recent population-based studies in the 
United States have shown that up to 70% of cancer survivors are not meeting the PA recommendation, 
48% to 74% are not meeting the diet recommendation and 20% to 24% continue to smoke after 
diagnosis.51 Lynch et al. analyzed and objectively determined that PA collected in the National Health and 
Nutrition Examination Survey 2003-2004, and 2005-2006 data, had demonstrated that cancer survivors 
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spend less than 4 minutes/day on moderate to vigorous PA. Given the conflicting reports on changes in 
health behaviors after a cancer diagnosis, a systematic review of literature regarding lifestyle changes 
among BC survivors helps determine whether there is a deficit in health behaviors in this population.  
A number of observational studies have reported on post-diagnosis changes in body weight, PA, 
and diet in breast cancer survivors.10,12,14,52 53 Collectively, these findings suggest that women are likely to 
eat a healthier diet, quit smoking, and reduce alcohol drinking yet become more sedentary after a breast 
cancer diagnosis. These lifestyle factors are considered important for both cancer prevention54 and 
cancer survival.37 However, no systematic review has evaluated the direction and magnitude of changes 
in these health behaviors following a breast cancer diagnosis.  As differences across studies may be due 
to study designs, study population, data collection methods, and analytical methods, I propose to 
compare and contrast these characteristics in previous studies. This chapter will systematically review 
literature on post-diagnosis change in lifestyle, including diet (F/V and dietary fat), physical activity 
(sedentary and MVPA time), smoking, alcohol intake, and body weight.  
 
2.3 METHODS 
2.3.1 Identification and selection of literature 
A literature search was conducted in the major electronic bibliographic databases, including: 
Pubmed, Web of Science, PsycINFO, Embase, and Medline.  The key words used referred to the 
exposure (“breast cancer” or “breast neoplasms”), the health behavior outcomes (“diet” or “fruit” or 
“vegetable” or “dietary fat” or “total calories” or “caloric intake” or “alcohol” or “drinking” or “physical 
activity” or “moderate to vigorous activity” or “sedentary activity” or “exercise” or “smoking” or “cigarette”), 
and the analytical methods (“change” or “longitudinal” or “difference”). The search was limited to 
publications in English published from inception through February 2017. In addition, the author’s personal 
collection of relevant previous publications was also included. These articles were identified through 
searches outside of the systematic database search using the structured query terms, and through the 
references of included studies.   
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Study relevance was assessed first by filtering through title and abstract. Relevant publications 
were then included for full text review. Studies were chosen for the systematic review based on the 
following inclusion criteria:  
1. Use of prospective cohort design among breast cancer survivors.  
2. Collected behavior and/or weight data in a longitudinal method, i.e. over at least two time 
intervals.  
3. Reported longitudinal data on diet (fruit/vegetable and/or dietary fat intake), physical activity 
(time spent on moderate to vigorous activity and/or sedentary behaviors), cigarette smoking, 
alcohol intake, or body weight.  
Studies were excluded if: 1) the study population was not restricted to breast cancer survivors or 
did not perform subgroup analysis in breast cancer survivors when the overall population was survivors of 
multiple types of cancer; 2) only used cross-sectional design, or used the control arm of a randomized 
controlled trial of health behavior interventions as a surrogate for a cohort study; 3) did not collect 
behavior data at a minimum of two time points; 4) did not assess behavior variables for the main 
question; 5) results were only reported in an abstract; 6) published in language other than English. The 
control arm of randomized controlled trials of healthy behaviors were excluded from the review because 
these groups usually received educational support to adopt healthier lifestyles, and therefore their 
behavior changes were likely driven by health education rather than the cancer diagnosis. The literature 
search followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
guidelines.55  
2.3.2 Data extraction and quality assessment 
Publications included in the systematic review were appraised based on the eligibility criteria. The 
following characteristics were extracted from each study: 1) study design (i.e., author, geographic 
location, age, follow-up period, sample size, and measurement of health behavior); 2) study findings (i.e., 
average change in health behaviors, percent developing positive/negative behavior change, predictors of 
negative behavior changes, and covariates adjusted). 
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Study quality was assessed using the Critical Appraisal Skills Program (CASP),56 which has been 
used as a risk of bias assessment tool in previous systematic reviews of cohort studies.57 The CASP 
assesses both internal and external validity by addressing seven methodological issues: 1) selection bias; 
2) time from breast cancer diagnosis to behavior data collection; 3) behavior variable measurement bias; 
4) accounted for confounding variables; 5) length of follow-up; 6) handling of loss to follow-up; and 7) 
handling of missing data.  The specific questions used to assess each criterion are included in Appendix 
2. Each issue was assessed and assigned a score of 1 (satisfied) or 0 (unsatisfied) based on the scoring 
system described by Barnett et al.58 The assigned scores were summed to give each study a composite 
score ranging from 0 to 7, with each score representing a quality level: 0-2, low; 3-4, modest; and 5-7, 
high.  
2.3.3 Level of scientific evidence 
Quality assessment of included publications suggested that the studies were heterogeneous with 
regard to the type and measurement of health behaviors. The timing of behavior assessment, length of 
follow-up, and the statistical analyses varied significantly among studies that reported the same health 
behavior outcome. Therefore, to synthesize the methodological quality of the studies and to be able to 
draw conclusions regarding the direction and magnitude of health behavior change, a best-evidence 
synthesis was applied59 that consists of the following three levels:  
1. Strong evidence: consistent findings in ≥2 high-quality studies; 
2. Moderate evidence: consistent findings in one high-quality studies, and at least one modest 
to low-quality study, or consistent findings in multiple modest to low-quality studies; 
3. Insufficient evidence: only one study available or inconsistent findings in ≥2 studies. 
Study findings were considered consistent if ≥75% of the studies reported changes in the same 
direction. When two or more high-quality studies existed for a behavior outcome, the modest to low-





2.4.1 Search and selection 
The search resulted in a total of 2,552 records (1,637 from Pubmed, 37 from Web of Science, 6 
from PsycINFO, 576 from Embase, and 250 from Medline, 21 from the author’s sources). The search 
terms and results are shown in Appendix 1. After removing duplicate publications, a total of 2,054 
publications remained. After screening the titles and abstracts, 145 full papers were read. Of those, 79 
were excluded because the studies did not conduct analyses separately in breast cancer survivors, did 
not measure the desired health behaviors, applied a cross-sectional design, had less than 2 times of 
behavior measures, or were only published in an abstract. Ultimately, 66 different prospective cohort 
studies were included in the systematic review. The literature search and selection flow diagram is 
presented according to the 2009 PRISMA guidelines55 (Figure 1).  
2.4.2 Study design and population characteristics 
Of the 66 studies, 7 reported changes in diet, 13 reported changes in physical activity, 3 reported 
changes in cigarette smoking, 4 reported changes in alcohol intake, and 48 reported changes in body 
weight and/or BMI. The characteristics of these studies are summarized in Tables 2-5. The majority of 
studies used prospective cohort design to collect self-reported health behaviors and body weight, while 
the remaining studies collected data on weight or BMI retrospectively from electronic medical records 
prior to the study enrollment.60-64 The majority of studies were conducted among early stage BC survivors 
diagnosed at the mean age of 50-60 years in the United States, Europe and East Asia. Most studies 
included both premenopausal and postmenopausal women; only a few studies restricted to 
premenopausal65,66 or postmenopausal67 women. Most studies directly recruited participants from 
hospitals or clinics, while the large-scale studies typically used a subsample of participants from a 
population-based cohort study of BC survivors [i.e., the Health, Eating, Activity, and Lifestyle (HEAL) 
study68, Long Island Breast Cancer Study Project69, Pathways Study36, Shanghai Breast Cancer Survival 
Study70] or a healthy population (i.e., Nurses' Health Study71, Danish Diet, Cancer and Health cohort 
study72), or through regional and national cancer registries.   
Timing of study entry relative to BC diagnosis and the course of cancer treatment varied greatly 
by study design. Hospital-based studies generally enrolled participants within the first 6 weeks after 
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diagnosis, and some specifically recruited patients either at the start73-75 or the end76-78 of cancer 
treatment to assess the effect of treatment on health behavior or weight. Population-based BC cohort 
studies typically recruited participants 2-6 months after diagnosis.79-85 In contrast, the behavior and weight 
measurement for BC patients identified from a cohort of general population were generally obtained from 
follow-up surveys administered before and after the diagnosis, which may span over a long period of 
time.86-89 The length of follow-up varied greatly as well. Most hospital-based studies followed participants 
up to one year after study enrollment, while population-based studies followed participants for 2-10 years 
after diagnosis.61,63,67,79,83,85,90-99 
2.4.3 Measurement of health behaviors and body weight 
The included studies primarily measured diet using food frequency questionnaires 
(FFQs),65,78,84,85,100,101 and one study used a single question to assess self-reported changes after 
diagnosis (e.g. does the participant eat more fruits and vegetables?) at each assessment point.102 Among 
studies that used an FFQ, the majority used validated FFQs, such as the Women’s Health Initiative 
FFQ,65,85 the FFQ used in the European Prospective Investigation into Cancer and Nutrition (EPIC) 
Study,84 and the FFQ used in the Norwegian Women and Cancer Study.101 However, two studies 
measured diet with a short FFQ that was not validated in previous research.78,100 These FFQs assessed 
the frequency and/or portion size of dietary intake of common food items in the US and Europe during the 
past 12 months. The FFQ used in the Norwegian Women and Cancer Study101 included more items on 
fish intake compared to other FFQs used in the US and European cohorts.  Although FFQs assessed 
intake of specific foods, most studies only reported changes in total intake of food groups (i.e. total 
vegetable intake), with only two studies reporting changes in individual food items (i.e. legumes, 
fruit/vegetable juice).84,101 In analyzing changes in specific food items, only one study adjusted for the total 
energy intake using the nutrient density model.84 
In measuring physical activity, the majority of included studies used validated physical activity 
questionnaires that included the Modifiable Activity Questionnaire,103 Godin Leisure-Time Exercise 
Questionnaire (LTEQ),104 International Physical Activity Questionnaire (IPAQ),105 Arizona Activity 
Frequency Questionnaire,106 and the Behavioral Risk Factor Surveillance System (BRFSS) Historical 
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Questions.107 More recent studies also assessed objectively measured physical activity using an 
accelerometer.76,108 The physical activity questionnaires measured the amount of MVPA and sedentary 
time by asking participants about the time and frequency of engagement in various daily activities. Based 
on the Compendium of Physical Activity,109 each activity was classified as light, moderate and vigorous-
intensity activity, and time spent on each level of activity was converted to metabolic equivalent (MET) 
hours.109 Many studies expressed the amount of MVPA and sedentary time as hours or minutes per day 
or per week, while others expressed as MET-hours per day or per week. Although most studies reported 
data on total MVPA or sedentary time, only a few reported changes in types of MVPA or sedentary 
activities.79,82,110  
 Alcohol intake and cigarette smoking were commonly assessed using questions that asked about 
the current use, as well as the frequency and amount of use during the past 12 months. One study 
assessed alcohol intake using the EPIC study FFQ.84 Alcohol intake was analyzed as average change in 
number of drinks per occasion or grams of alcohol intake per day. Additionally, risky drinking behavior 
such as intake of >4 alcoholic beverages per occasion was also analyzed.90 Studies of cigarette smoking 
often reported average number of cigarette smoked per day and percent of women who quit smoking 
following a BC diagnosis. 
Measurement of body weight was highly dependent on study design. Hospital-based studies 
obtained clinically measured weight and height at each clinic visit,65,67,74-77,94-97,99,111,112 or utilized the 
electronic medical records (EMR) to retrospectively collect clinically measured weight and height pre and 
post-diagnosis.60-64 In contrast, large-scale population-based cohort studies often relied on self-reported 
weight and height,91-93,113-116 although a few population-based studies collected clinically measured weight 
and height through EMR,92,95,96 and some collected both self-reported and clinically measured 
anthropometric data.93,114,115 Very few studies measured body composition, only two studies assessed 
body composition using bioelectrical impedance analyzer (BIA).95,117 Only four studies collected data on 
waist circumference,92,115,117,118 and one study measured waist-to-hop ratio.115 In analyzing weight 
change, most studies reported average weight change from baseline to follow-up, and a few studies 
reported the average percent weight change from baseline. In addition, some studies examined the 
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percent of women experiencing weight gain and weight loss using 5% or 10% change in weight as cutoff 
values.64,93,95,111,113,116 
2.4.4 Statistical analysis of change in health behaviors and body weight 
 The majority of included studies analyzed changes in health behaviors and body weight using 
paired t-tests to compare the mean value at follow-up with the mean value at baseline - or to test whether 
the mean change was statistically different from 0. However, many studies only reported descriptive data 
on the percent of women who experienced change without statistical analysis.64,67,78,79,90,113 Only two 
studies used regression analyses to evaluate the non-linear trend of behavior change over time.99,119 
Because many of the studies that had reported the changes in health behaviors and body weight after a 
BC diagnosis were not uniform among BC survivors, a recent study explored the heterogeneous 
trajectories of change in physical activity using trajectory analysis.119,120 However, none of the included 
studies assessed potential bias to the observed change in health behaviors; such as selection bias, loss 
to follow-up and missing data.  
2.4.5 Dietary change – fruit/vegetable intake 
Five prospective studies78,84,85,101,102 examined the change in F/V intake after a breast cancer 
diagnosis, of which three were of high quality78,84,85 (Table 2). The three high-quality studies showed 
inconsistent results regarding change in F/V intake. In a German cohort study (n=229), Steinhilper et al.78 
reported that BC survivors increased fruit intake by 0.4 serving/day at 1 year post-surgery, and increased 
the frequency of fruit and vegetable intake by 0.9 and 0.7 times/week, respectively. Women who were 
non-smokers were more likely to report increase in daily fruit intake. Similarly, the British DietCompLyf 
cohort study (n=1,560)84 reported that BC survivors increased approximately 0.5 serving/1000 kcal/day of 
fruit and 0.5 serving/1000 kcal/day of vegetable at 1 year after diagnosis after adjusting for total energy 
intake. However, in the HEAL study (n=260), Wayne et al.85 examined changes in F/V intake from 
baseline to 2 years post-diagnosis and reported no increase in daily F/V intake, although the percent of 
BC survivors eating 5 servings/day or more F/V increased from 20% to 24%. Although the average 
change in F/V intake differed by study, these studies suggested that approximately 40% to 50% BC 
survivors increased their F/V intake after diagnosis.78,85 Based on the inconsistent findings among the 
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prospective studies, there is insufficient evidence to conclude that F/V intake changes after a BC 
diagnosis - although the evidence indicated the increase in F/V is most likely short term during the first 
year after diagnosis. 
2.4.6 Dietary change – dietary fat intake 
Six studies65,84,85,100-102 reported the longitudinal change in dietary fat intake or percent energy 
intake from fat after a breast cancer diagnosis (Table 2). Of the six studies, three high-quality 
studies65,84,85 found inconsistent results regarding change in dietary fat intake. The HEAL study (n=260)85 
reported that BC survivors on average reduced 3.6 g/day of fat intake and 1% of energy from fat at 2 
years post-diagnosis. The reduction in dietary fat intake was greater in women diagnosed at a younger 
age. Similarly, the DietCompLyf study (n=1,560)84 reported a decrease of 4 g/1000 kcal/day in total fat 
intake at 1 year after diagnosis, of which 2 g/1000 kcal/day was reduced in saturated fat, and 1.2 g/1000 
kcal/day was reduced in monounsaturated fat. In a study to understand energy imbalance during adjuvant 
chemotherapy among 53 premenopausal BC survivors,65 there was no significant change in percent 
energy from fat as assessed by 2-day dietary recall and FFQ from 3 weeks to 1 year after diagnosis, 
although the study did not report change in total and specific type of fat intake. Based on the inconsistent 
findings, there is insufficient evidence to describe the change in dietary fat after a BC diagnosis. More 
studies are needed to understand how women change dietary fat intake in response to a BC diagnosis. 
2.4.7 Physical activity change – moderate to vigorous physical activity 
 There were 12 studies73,76,78,79,81-83,98,100,108,110,119,121, of which seven76,78,79,81-83,98,119 were of high 
quality, that reported the longitudinal change in MVPA after a BC diagnosis (Table 3). The majority of the 
seven studies reported decrease in MVPA over time. In the Pathways Study (n=1,696), Kwan et al. 
reported that MVPA decreased by1.28 hour/week from 2 to 8 months after BC diagnosis. The decrease 
was primarily in household (-0.44 hour/week) and recreational (-0.74 hour/week) MVPA.82 Among studies 
that reported moderate and vigorous activities separately, a population-based cohort study of 287 
Australian BC survivors showed that participants spent 17 more minutes/week on vigorous PA but 55 less 
minutes/week on moderate PA from 6 to 18 months after diagnosis. In contrast, a population-based 
cohort study of BC survivors in the US (n=315) reported that vigorous PA decreased by 5 MET-h/week 
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and moderate PA decreased by 2.6 MET-h/week at 12 months post-diagnosis. Both groups returned to 
pre-diagnosis level at around 19-30 months.98 Only one study examined the long-term change in MVPA 
up to 10 years after diagnosis: the HEAL study (n=631) reported that MVPA level remained stable during 
the 5 years after baseline, but decreased by 4.9 MET-h/week between 5 to 10 years post-diagnosis.83 In 
contrary to these studies indicating a decrease in MVPA following a BC diagnosis, a German study of 229 
BC survivors reported that women increased 48 minutes/week of MVPA and 12% more women achieved 
recommended level of MVPA at 14 months after diagnosis.78  
Previous studies also suggested that the change in MVPA after a BC diagnosis is not uniform. 
For instance, the HEAL study (n=545) reported that, at 30 months after diagnosis, 35% women 
decreased time on MVPA, while 26% maintained and 39% increased time on MVPA.79 Using a hospital 
sample of 199 BC patients, Brunet et al. further demonstrated that women may follow five distinct 
trajectories of change in MVPA during the first year after diagnosis: 5.5% of women were consistently 
inactive, 9.5% increased MVPA, 10.5% were inactive but increased MVPA, 25% were somewhat inactive 
over time, and 49% were consistently active.119  These studies also suggested that women who were 
younger at diagnosis, received chemotherapy, or had greater treatment complications were more likely to 
decrease their MVPA, while women who were both overweight and had healthy weight at baseline were 
associated with decrease in MVPA.82,98 Collectively, the results suggest that there is moderate evidence 
to conclude that women may decrease time spent on MVPA during the first 24 months following a BC 
diagnosis. 
2.4.8 Physical activity change – sedentary activity 
 Only two high-quality studies examined the change in sedentary behavior following a BC 
diagnosis (Table 3),76,82 which reported inconsistent results. In the Pathways Study (n=1,696), Kwan et al. 
reported that BC survivors on average spent 0.83 fewer hours/week in sedentary behavior at 6 months 
after diagnosis.82 Specifically, their findings suggested that BC survivors reduced time spent on doing 
crafts (-0.15 hour/week), reading (-0.16 hour/week), socializing (-0.28 hour/week), and attending group 
events (-0.08 hour/week), but spent more time on TV watching (+0.32 hour/week). However, a study of 24 
BC survivors in Ireland measured accelerometer-assessed PA data and suggested that BC survivors 
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spent more time on sedentary behavior and less time on light PA after treatment, and the change 
maintained at 1 year later.76 Neither study identified significant predictor of change in sedentary time. 
Given the limited yet conflicting results, there is insufficient evidence to make any conclusions about the 
change in sedentary behavior following a BC diagnosis. 
2.4.9 Change in alcohol intake 
 Four studies examined change in alcohol intake after a BC diagnosis (Table 4).84,86,90,102 Two of 
the four studies were of high quality.84,90 The two studies assessed alcohol intake using different methods 
but reported similar findings on changes in alcohol intake. Using the EPIC study FFQ, the British 
DietCompLyf cohort study (n=1,560) reported that BC survivors decreased an average of 0.7g/1000 
kcal/day of alcohol intake at 1 year after diagnosis, which was primarily due to decrease in wine and 
alcoholic beverages other than beer.84 In a large cohort study of Australian BC survivors (n=1,588), Bell et 
al. reported that, compared to their drinking behaviors at baseline, BC survivors were less likely to report 
ever consuming >4 drinks per occasion (OR=0.78, 95% CI:0.67-0.90) and less likely to report drinking >4 
drinks per occasion at least weekly (OR=0.63, 95% CI: 0.49-0.81) at 2 years after diagnosis, suggesting 
that BC survivors may reduce the frequency and amount of alcohol intake after diagnosis.90 It is 
noteworthy that the two studies employed different assessments of alcohol intake: Bell et al. assessed the 
frequency, amount, and occasions of alcohol intake at diagnosis and in the past 12 months at 2 years, 
while Veletzis et al. assessed alcohol intake using a FFQ. However, both studies asked the intake of 
beer, wine and other alcoholic beverages. The two studies collected data on alcohol intake during the 
similar time window after diagnosis: Bell et al. enrolled patients at an average of 41 weeks (10 months) 
after a BC diagnosis, and followed up at one year after the enrollment; the study by Veletzis recruited 
patients at 9-15 months post diagnosis and followed up at 24 months following the baseline visit. Because 
of the consistent findings in these two studies, there is sufficient evidence to conclude that BC survivors 
reduce alcohol intake following a BC diagnosis. 
2.4.10 Change in cigarette smoking 
Three studies reported change in cigarette smoking after a BC diagnosis (Table 4).78,86,90 Two 
high-quality studies78,90 reported the percent of women who quit smoking after a BC diagnosis. In a 
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German study of BC survivors (n=229), Steinhilper et al. reported that 16% of women were current 
smokers at baseline, of whom, only 10% quit smoking at 1 year after a BC diagnosis; the majority of 
women did not change smoking behavior or start smoking. However, an Australian study of 1,588 BC 
survivors, in which 12% were current smokers at baseline, suggested that 32% of current smokers quit 
smoking after diagnosis and 25% of current smokers reduced the number of cigarettes smoked per day at 
2 years after diagnosis). Because of the inconsistent and relatively low smoking cessation rates reported 
by these studies, there is insufficient evidence to suggest that women tend to quit smoking following a BC 
diagnosis. 
2.4.11 Weight change 
A total of 48 studies assessed weight change after a BC diagnosis (Table 5).60-67,74,75,77,80,86-89,91-
97,99,112,114-118,122-135 Of these studies, 25 high-quality studies were identified.60-65,67,74,76,77,80,91-97,99,112,114-
116,122 Overall, approximately 19%-84% of women diagnosed with BC experienced significant weight gain 
during the 1-2 years after diagnosis,77,80,91,92,112,122 and the weight gain was maintained in 30% of BC 
survivors long-term.93,95 Four population-based cohort studies in the US and China measured self-
reported weight and height among BC survivors.80,91,113,116 The After Breast Cancer Pooling Project 
(n=12,915 stage I-IV BC survivors) compared weight at 1 year prior to BC diagnosis and weight at 18-48 
months post-diagnosis, and reported an average of 1.6 (SD=6.3) kg increase in body weight.91 
Approximately 34.7% of women gained weight while 14.7% lost weight during this period. A recent study 
using data from the LACE and the Pathways Study (n=3,109 stage I-III BC survivors) reported similar 
findings, with 25% of women reporting weight gain and 14% reporting weight loss at 24 months after 
diagnosis.92 However, results from the Long Island Breast Cancer Study Project (n=1,436) suggested that 
weight gain (23%) and weight loss (22%) were equally common in BC survivors at 1 year after 
diagnosis.113 Few studies examined whether BC survivors followed similar trajectory of weight gain as 
women without BC. One study followed 345 early stage BC survivors who received chemotherapy after 
diagnosis and 305 healthy women over 6 years and reported that 42% of BC survivors and 32% of 
healthy women experienced weight gain of ≥5% baseline weight.116  
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For studies that collected clinically measured weight and height, the average weight gain ranged 
from 1.0 kg to 5.9 kg during the first 24 months after diagnosis.61-63,74,77,93,96,99,114,115 Studies that followed 
participants beyond the first 24 months post-diagnosis showed that weight gain reduced over time, and 
the mean weight gain ranged from 0.3 kg to 2.8 kg at ≥3 years post-diagnosis.63,93,97 Among the included 
studies, Camoriano et al. first examined the effect of cancer treatment on weight change in a cohort of 
656 BC patients undergoing treatment of chemotherapy or chemohormonal therapy or not and reported 
that, at 60 weeks after treatment initiation, postmenopausal women gained an average of 3.6 kg of weight 
and premenopausal women gained 5.9 kg. In comparison, untreated women only gained 1.8 kg during 
the same period.74 A similar finding was reported in another study by Goodwin et al. among 535 
locoregional BC survivors,77 which estimated that 84% women gained weight at 1 year after surgery, and 
the mean weight gain was greater among those receiving chemotherapy (+2.5 kg) and hormonal therapy 
(+1.3 kg) than that among untreated women (+0.5 kg). Other studies that monitored weight change over 
the course of chemotherapy 62,64,75,99 or hormonal therapy 67 reported similar increases in body weight. 
Although the a large group of BC survivors showed weight gain, 10%-52% of women experienced weight 
loss during the first 24 months after a BC diagnosis.80,91,92,95,112,122 For example, a large study of 1,002 BC 
survivors over 19 months of systematic treatment reported that 48% of women gained weight and 52% 
lost weight.112 Similarly, another study that compared weight change from diagnosis to 18 months post-
diagnosis among 12,590 BC survivors within the Kaiser Permanente Northern California network reported 
that 19% of women gained and 19% of women lost ≥5% body weight, and the amount of weight changes 
were comparable between women who gained and lost weight.111 Furthermore, in a Korean study of 260 
BC survivors, Han et al. only observed a temporary weight increase of 0.3 kg during the first 3 months of 
adjuvant chemotherapy, and there was an overall weight loss by the end of 12 months.94 Consistent with 
their findings, another study of 53 BC survivors also reported no statistically significant trend in body 
weight over the first year post-diagnosis.65  
Based on the included studies, except for cancer treatment, factors associated with weight gain 
after cancer diagnosis also include age,60,63,93,96,97,114 advanced disease stage,60,63,93,96,97,114 decreased 
physical activity96  and increased energy intake.114 However, the evidence is limited and inconsistent. For 
example, both younger63,93,96,114 and older97 age at diagnosis were associated with greater weight gain, 
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and both premenopausal74,114 and postmenopausal60,96 status were associated with weight gain. Given 
the large body of consistent evidence suggesting both weight gain and weight loss after a BC diagnosis 
across multiple BC populations, there is strong evidence that both weight gain and loss are commonly 
seen in women after a BC diagnosis, although the evidence that supported a weight gain outweighed the 




 This review aimed to systematically summarize the literature on changes in health behaviors after 
a BC diagnosis, taking into account the methodological quality of the studies. Based on the studies 
identified, there is strong evidence suggesting that women are likely to reduce alcohol intake and 
experience weight gain after a BC diagnosis. Further, there is moderate evidence suggesting that women 
spend less time on MVPA after a BC diagnosis. However, in contrast to previous studies that suggested a 
BC diagnosis may encourage women to seek healthier diet,7,11,49,53,136-138 there is insufficient evidence to 
conclude that BC survivors increase F/V and decrease dietary fat after diagnosis. Evidence regarding 
changes in cigarette smoking and sedentary behavior was scarce and inconsistent. To my knowledge, 
this review is the first to systematically summarize the literature regarding the change in key health 
behaviors following a BC diagnosis across multiple cohorts. Collectively, the results suggest that a BC 
diagnosis may not effectively motivate women to make positive change in health behaviors.  
Amid the inconsistent reports of dietary change after a BC diagnosis, several things were 
noteworthy. First, the reported amount of increase in F/V intake and decrease in dietary fat intake were 
indeed very small. On average, the increase in F/V intake at one year after BC diagnosis was estimated 
to be less than 1 serving/day. That is equivalent to less than 1 medium-size apple or 1 cup of spinach. 
With regard to dietary fat, the reported decrease of 4 g/day is equivalent to approximately 1 teaspoon of 
butter, which is relatively small compared to the American Heart Association’s recommended dietary fat 
intake of 44-78 g/day.139 The small change in dietary fat intake could be due to the low dietary fat intake 
at baseline in this population (mean=37.18 g, SD=6.88 g). Second, the included studies showed that BC 
survivors on average consumed less than five servings/day of F/V as recommended by the ACS and 
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AICR.44,48 For instance, the HEAL study reported that BC survivors consumed approximately 3.6 
servings/day of F/V at baseline.85 Therefore, a small increase in F/V intake is unlikely to substantially 
change the percent of women meeting the recommended five servings per day. In fact, less than 25% of 
women reported consuming five servings/day of F/V in the HEAL study. Third, the comparisons may be 
problematic if different FFQs have inconsistent definitions of what counts as a fruit or vegetable, or used 
different measurement units. Among the FFQs used by the included studies, the Women’s Health 
Initiative (WHI) and the EPIC study FFQ have more than 100 food items,84,85 which assessed more fruit 
and vegetable items than a 19-item FFQ used in a German study.78  
Unlike the mild change in diet, the observed fluctuation in MVPA was considerably large. The 
reported decrease in MVPA ranged from a decrease in 38-90 minutes/week, which is approximately 25%-
60% of the ACS-recommended 150 minutes/week of MVPA. The amount of decrease is worrisome, given 
that many studies reported that BC survivors on average spent less than 150 minutes/week of MVPA at 
baseline.73,76,119 On the other hand, a number of studies reported increases in MVPA, mostly after 
treatment.73,98,110 These results suggest that the teachable moment for physical activity may come after 
the completion of cancer treatment, when the physical discomfort due to treatment lessens. The 
decreased time spent on MVPA often transferred to increases in time spent on sedentary activities. 
However, the two studies of changes in sedentary behaviors after a BC diagnosis reported both increases 
and decreases in sedentary time. Although accelerometer data suggested that women increased the time 
spent on sedentary activities from 6.8 hours/day to 7.6 hours/day after diagnosis,76 data collected using 
the Arizona Activity Questionnaire suggested the sedentary time decreased from 17.6 hours/week to 16.8 
hours/week, or from 2.5 hours/day to 2.4 hours/day.82 The amount of objectively measured sedentary 
time was comparable with that reported in BC survivors enrolled in NHANES.140 It is known that the 
physical activity questionnaires may not accurately measure true sedentary time and even significantly 
under report sedentary time than accelerometer-based estimates.141 Although this limitation is unlikely to 
affect the analysis of change in sedentary time if the same questionnaire was used consistently over time, 
the study by Kwan et al. revealed that the overall reduction in sedentary time was primarily due to 
reduction in time spent on doing crafts, reading, socializing, and attending group events, but women 
spent statistically significantly more time on TV watching after a diagnosis.82 Reduction in regular social 
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and leisure activities and increase in TV watching in fact supports the hypothesis that BC survivors suffer 
from physical discomfort due to cancer treatment. Previous studies suggested that cancer treatments may 
disrupt health behaviors, and many cancer patients report reduction in physical activity during the phase 
of active treatment.105,106 Although cancer treatment may present barriers to the adoption of healthy 
behaviors, few studies formally investigated the impact of cancer treatment and treatment related side 
effect, such as nausea, pain and peripheral neuropathy, on changes in health behaviors in breast cancer 
survivors.  
 Although most included studies were considered to be of high quality, there are a few important 
methodological issues that undermine the internal validity of the estimated longitudinal changes. Although 
hospital-based studies generally have better control of the timing of baseline and follow-up data 
collection, they are generally limited by small sample sizes, short follow-up period, and limited 
generalizability. In contrast, large population-based cohort studies are generally limited by varying times 
between cancer diagnosis and baseline behavior data collection, and varying times between baseline and 
follow-ups. Very few studies were designed to follow a cohort of BC survivors. Even in these studies, 
enrollment often occurred 2 to 6-months post-diagnosis. Therefore, data collected at baseline may not 
reflect pre-diagnosis diet and physical activity. For studies that had relied on breast cancer survivors 
identified through a population-based cohort study of healthy individuals, such as the Nurses’ Health 
Study88 and Norwegian Women and Cancer study,101 the follow-up visits were scheduled based on the 
parent study’s enrollment date, instead of time of diagnosis. As such, data were not collected regularly 
enough to reflect the natural history of behavior change after a BC diagnosis - especially the period 
immediately following diagnosis when patients were actively undergoing cancer treatment.  
Another major limitation of previous studies of behavior change is the use of the overall mean 
change to make inference about individual behavior change, which assumed that all women would follow 
the same behavior change. In fact, the included studies suggested that not all women make the same 
behavior change. Rather, this data supports the hypothesis that there is considerable heterogeneity in 
women’s diet changes and physical activity. However, only one study examined the heterogeneous 
trajectories of change in MVPA during the first year after a BC diagnosis. Furthermore, most studies 
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described mean changes between two time points at set interval, and therefore assume monotonic trend 
in behavior change over this period. Little is known about the non-linear trend in health behaviors, such 
as temporary decreases or increases in physical activity. Additionally, no study has examined the 
trajectory of dietary change or change in alcohol intake after a BC diagnosis. Future studies should give 
more attention to novel analytical techniques such as growth mixture modelling142 and group based 
trajectory modelling120 to investigate patterns of behavior change trajectories, rather than masking these 
unique trajectories.   
An additional methodological limitation of prior studies is that few studies considered the influence 
of loss to follow-up and missing data on the observed behavior change. Since most studies used paired t-
tests to compare change in health behavior pre- and post-diagnosis, they implicitly restricted the analyses 
to participants who had complete data at baseline and follow-up. This type of analysis may overestimate 
the increase in beneficial health behaviors if participants who completed follow-up questionnaire were 
more health conscious women. Furthermore, few studies used energy adjustment in analyzing dietary 
change. Since many breast cancer patients experience anorexia or reduced food intake during active 
treatment,143 dietary changes may occur simply as a result of lost appetite and overall reduced energy 
consumption. Energy-adjusted residual of dietary intake144 will produce an estimate of dietary intake 
independent of total energy intake, and therefore is more suitable for future analysis of dietary change.  
The causes of health behavior changes remain unclear. Cancer treatments may disrupt normal 
health behaviors. For example, cancer patients report reduction in physical activity during the phase of 
active treatment,35,145 and changes in taste sensitivity induced by chemotherapy may alter food 
preferences and nutritional intake.146-149 In addition, the diagnosis and treatment of cancer is a significant 
stressor in itself that could contribute to changes in appetite and sleep and may disrupt health behaviors 
and potentially increase unhealthy behaviors.150,151 Previous studies explained the individual differences 
in lifestyle choices after a breast cancer diagnosis using the stress and coping model.152,153 Many BC 
survivors live with the fear of cancer and its consequences. It is unclear how this sense of continued 
stress affects the adjustment in lifestyle following a BC diagnosis. The stress and coping model posits 
that the management of stressful feelings may influence cancer survivors’ ability to make and sustain 
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health behavior change.154 In particular, this model proposes that the use of adaptive coping to deal with 
cancer diagnosis stressors will be related to positive health behavior change. In breast cancer survivors, 
depressive symptoms are the most common stress-related symptoms.151,155-157 Depressive symptoms are 
associated with smoking and physical inactivity in general population158,159 and testis cancer survivors.160 
In contrast, greater dispositional optimism, a generalized expectancy that the future holds positive 
outcomes,161 has been associated with not smoking, moderate alcohol consumption, brisk walking, and 
vigorous physical activities in older women. In addition, higher perceived social support may facilitate 
stress coping and is linked to increased health behavior, specifically exercise, in cancer survivors.162,163 
The causes of weight change are also complex. Previous studies generally hypothesized that 
weight gain may be caused by breast cancer treatment regimens, most notably chemotherapy and 
hormonal therapy.26,27,164,165 However, the mechanism of weight gain in breast cancer survivors remains 
unclear. Behaviors changes that cause energy imbalance may contribute to the weight gain after a breast 
cancer diagnosis. The study by Chen et al. found that higher baseline dietary intake was associated with 
weight gain after BC diagnosis,114 and findings of Irwin et al. suggest that a decrease in physical activity 
was associated with weight gain.96 The causal relationship between behavior change and weight change 
after a BC diagnosis needs further investigation. 
This systematic review has several limitations. The use of quality assessment of observational 
study in this systematic review is controversial and may bias the conclusions of this review.166,167 The 
rationale for including study quality assessment into this systematic review was to exclude studies of low 
methodological quality which tend to report larger effect sizes than higher quality studies.168-170  However, 
some studies reported no relationship between quality score and effect size and that the quality of 
included study is unlikely to affect the conclusion of a systematic review.166 Some suggest that the 
number of studies categorized as high quality or low quality depended specifically on the scale that was 
applied.167 Therefore, the choice of scale will have a significant impact regarding what studies are eligible. 
Another problem with quality assessment is the lack of clear cut-off criteria for quality categories studies. 
This poses a significant methodological limitation to the implementation of these scales. In addition, 
because the type of quantitative measures of behavior change were not uniform among the included 
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studies, I was not able to provide a quantitative synthesis of the behavior change. Therefore, this review 
was only able to make conclusions on the direction of behavior change.  
2.6 CONCLUSION 
This review of prospective cohort studies showed strong evidence that many women reduce 
alcohol intake and gain weight after a BC diagnosis, and showed moderate evidence for a decrease in 
time spent on MVPA after a BC diagnosis. There is insufficient evidence to make any conclusion about 
the change in F/V, dietary fat, and time spent on sedentary behaviors after a BC diagnosis.  Future 
studies should examine the heterogeneity of behavior change after a BC diagnosis using trajectory 
analysis, while accounting for potential bias due to loss to follow-up and missing data in key behavior 
variables. Future studies of dietary change should also use energy adjustment methods to control for 
change in total food intake. Finally, more studies are needed to understand the causes of change in 
health behaviors, and to investigate the relationship between behavior change and weight change, and 
how these changes ultimately affect breast cancer prognosis and survival.   
25 
 
2.7 FIGURES AND TABLES 
 
Figures 1. Literature search and screen flow diagram 
 
Records identified through 
database searching  





























Additional records identified 
through other sources  
(n = 21) 
Records after duplicates removed  
(n = 2,054) 
Records screened  
(n = 2,054) 
Records excluded  
(n = 1,909) 
Full-text articles 
assessed for eligibility  
(n = 145) 
Full-text articles 
excluded  
(n = 79) 
Reasons 
 Wrong behavior 
outcomes (n=26) 
 Abstract only (n=15) 
 Had fewer than 2 data 
collection points (n=13) 
 Duplicate (n=10) 




 Not in breast cancer 
survivors (n=4) 
 
Studies included in 
qualitative synthesis  
(n = 66) 
Figure 1. Literature search and screen flow diagram 
 
Figure 2. Literature search and screen flow diagram 
 
Figure 3. Literature search and screen flow diagram 
 
Figure 4. Literature search and screen flow diagram 
 
Figure 5. Literature search and screen flow diagram 
 
Figure 6. Literature search and screen flow diagram 
 
Figure 7. Literature search and screen flow diagram 
 
Figure 8. Literature search and screen flow diagram 
 
Figure 9. Literature search and screen flow diagram 
 
Figure 10. Literature search and screen flow diagram 
 
Figure 11. Literature search and screen flow diagram 
 
Figure 12. Literature search and screen flow diagram 
 
Figure 13. Literature search and screen flow diagram 
 
Figure 14. Literature search and screen flow diagram 
 




























Have the authors 
identified and 
taken account of 
the confounding 



















data? Total Score 
Alfano 200779  1 1 1 0 1 1 0 5 
Andrykowski 200773  1 1 1 0 1 0 0 4 
Bell 201290  1 1 1 1 1 1 0 6 
Bidstrup 201386 1 0 1 0 1 1 0 4 
Bradshaw 2012113  1 1 0 0 1 1 1 5 
Broderick 201476  1 1 1 0 1 1 0 5 
Brooks 2016123  1 0 1 0 1 1 0 4 
Brunet 2013108  1 1 1 0 1 0 0 4 
Brunet 2014119  1 1 1 1 1 1 0 6 
Caan 201291  1 1 1 0 1 1 0 5 
Camoriano 199074  1 1 1 0 1 1 0 5 
Cespedes Feliciano 201780  1 1 1 0 1 1 0 5 
Cespedes Feliciano 201792  1 1 1 0 1 1 0 5 
Chaudhary 201460  1 1 1 0 1 1 0 5 
Chen 2010115  1 1 1 0 1 1 0 5 
Chen 2011114  1 1 1 0 1 1 0 5 
Costa 2002124  1 1 1 0 1 0 0 4 
Costanzo 2011102  1 1 0 1 1 0 0 4 
Demark-Wahnefried 200165  1 1 1 1 1 1 0 6 
Freedman 2004125  1 1 1 0 1 0 0 4 
Goodwin 199977  1 1 1 1 1 1 0 6 
Gross 2015126 1 0 1 0 1 1 0 4 
Gu 201093 1 1 1 0 1 1 0 5 
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data? Total Score 
Han 200494 1 1 1 0 1 1 0 5 
Hatch 2014127 1 0 1 0 1 1 0 4 
Heideman 200961 1 1 1 1 1 1 0 6 
Huy 2012110 1 1 0 0 1 1 0 4 
Imayama 201395 1 1 1 0 1 1 0 5 
Ingram 200466 1 0 1 0 1 0 0 3 
Irwin 200596 1 1 1 0 1 1 0 5 
Jammallo 2013128 1 1 1 0 1 0 0 4 
Jeon 201462 1 1 1 0 1 1 0 5 
Jernström 199987 1 0 1 0 1 1 0 4 
Kogawa 2015112 1 1 1 0 1 1 0 5 
Koo 2016129 0 0 1 0 1 1 0 3 
Kroenke 200588 1 0 1 0 1 1 0 4 
Kumar 199797 1 1 1 0 1 1 0 5 
Kwan 201282 1 1 1 0 1 1 0 5 
Lankester 2002130 1 1 1 0 1 0 0 4 
Littman 201098 1 1 1 0 1 1 0 5 
Liu 201499 1 1 1 0 1 1 0 5 
Makari-Judson 200763 1 1 1 0 1 1 0 5 
Mason 201383 1 1 1 1 1 1 0 6 
Maunsell 200253 1 1 1 0 1 0 0 4 
Nichols 200989 1 0 1 0 1 1 0 4 
Nissen 2011131 1 1 1 0 1 0 0 4 
Nyrop 201767 1 1 1 1 1 1 0 6 
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data? Total Score 
Phillips 2016121 1 0 1 0 1 0 0 3 
Rabin 2006100 1 1 1 0 1 0 0 4 
Saquib 2007171 1 1 1 0 1 1 0 5 
Sedjo 2013116 1 1 1 1 1 1 0 6 
Sheppard 201364 1 1 1 0 1 1 0 5 
Skeie 2009101 1 0 1 0 1 1 0 4 
Steinhilper 201378 1 1 1 0 1 0 0 4 
Thivat 2010132 1 1 1 0 1 0 0 4 
Trédan 201075 1 0 1 0 1 0 0 3 
Vagenas 2015133 1 1 1 0 1 0 0 4 
Vargas-Meza 2016172 1 1 1 0 1 0 0 4 
Velentzis 201084 1 1 1 0 1 1 0 5 
Wanders 2015134 1 1 1 0 1 0 0 4 
Wang 2014173 1 1 1 0 1 0 0 4 
Wayne 200485 1 1 1 0 1 1 0 5 
Yaw 2010118 1 1 1 0 1 0 0 4 
Young 2014135 1 1 1 0 1 0 0 4 
 
Note: Each criterion is assessed as satisfied (1) or not satisfied (0). The scores were summed to give each study a composite score ranging from 0 to 7, with 







Table 2. Summary of studies on dietary change after a breast cancer diagnosis 
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Table 3. Summary of studies on physical activity change after a breast cancer diagnosis 
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Table 4. Summary of studies on cigarette smoking and alcohol intake after a breast cancer diagnosis 
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Table 5. Summary of studies on weight change after a breast cancer diagnosis 
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Background: There is a growing interest in understanding the effect of lifestyle behaviors following a 
breast cancer (BC) diagnosis on BC clinical outcomes.  Previous studies that examined the change in 
health behaviors after a BC diagnosis reported mixed results in patterns of change. This study aimed to 
identify distinct trajectories of change in diet, physical activity and alcohol intake following a BC diagnosis.  
Methods: Data on diet [fruit/vegetable (F/V) and dietary fat intake], physical activity [moderate to vigorous 
physical activity (MVPA) and sedentary behavior], and alcohol intake were prospectively collected by the 
Pathways Study, a population-based cohort study of 4505 women newly diagnosed with a BC within the 
Kaiser Permanente Northern California network. The trajectory groups of health behaviors from baseline 
to 6 and 24 months follow-up were analyzed using a combination of a semi-parametric, group-based 
trajectory modeling and a non-parametric K-means for longitudinal data analysis. Predictors of behavior 
trajectories were tested using multinomial logistic regression. 
Results: In the first 24 months following a BC diagnosis, this analysis identified three distinct trajectories 
of F/V intake (11% high increase-stable, 41% medium increase-stable, 48% low increase-stable), MVPA 
(7% high decrease-temporary, 35% medium decrease-temporary, 58% low stable) and alcohol intake 
(5% high decrease-stable, 16% medium decrease-temporary, and 79% low-stable), and four trajectories 
of dietary fat intake (14% high-stable, 35% medium high-stable, 35% medium low-stable, 17% low-stable) 
and sedentary behaviors (18% high-stable, 24% medium increase-stable, 27% medium decrease-stable, 
31% low stable). Compared to the low increase-stable F/V group, women who were in the high or 
medium increase-stable F/V group had higher education and income, higher dispositional optimism and 
perceived social support. Compared to the low-stable group, women who were in the medium high-stable 
dietary fat group were more likely to experience chemotherapy-induced peripheral neuropathy at 6 
months after a BC diagnosis. For MVPA, women who followed the high or medium decrease-temporary 
trajectory had higher education and income, higher dispositional optimism and perceived social support.  




higher education, lower income, and reported higher perceived social support. Finally, women who follow 
the high or medium decrease-temporary trajectory of alcohol intake had higher education and income.  
Conclusion: Overall, participants in the Pathways Study maintained their lifestyle behaviors during the 
first 24 months after a BC diagnosis. Socioeconomic status, dispositional optimism, perceived social 
support, and the severity of CIPN during active treatment may predict the post-diagnosis trajectories of 






The overall prognosis of early stage breast cancer (BC) is good, with nearly 90% of BC survivors 
living beyond five years after diagnosis.41,43,44 The reduction in BC mortality is primarily due to 
advancement in cancer screening and treatment. Population screening with mammography has led to the 
early detection of breast cancer and reduced BC mortality by approximately 15-20%.174 Chemotherapy 
combined with hormonal therapy may reduce the BC mortality by an additional 45%-57%.175 However, for 
long-term BC survivors, data from the US Surveillance, Epidemiology and End Results (SEER) program 
and the national Swedish Cancer Database have shown that 54-70% of deaths are due to non-cancer 
chronic conditions, such as cardiovascular diseases, diseases of pulmonary circulation and 
gastrointestinal disease.176-178  
Recommendations for healthy lifestyles have been made for cancer survivors to further reduce 
mortality due to a second cancer and non-cancer conditions among BC survivors, such as meeting 
certain thresholds for physical activity and dietary intake.37,48 These health behaviors may offer promising 
survival benefits for cancer survivors. For example, an observational study (n=1,490) reported that 
consuming 5 servings of fruit and vegetables and walking 30 minutes a day after diagnosis reduced 50% 
of BC mortality.179 The After Breast Cancer Pooling Project, a consortium of four cohorts of 13,302 breast 
cancer survivors from the United States and China, suggested that engagement in at least 150 minutes of 
moderate to vigorous physical activities (MVPA) may reduce the all-cause mortality by 27%.180 However, 
large population-based surveys in the US have shown that the majority of BC survivors are not meeting 
lifestyle behavior recommendations.50,51 It is unclear how women change their lifestyle in response to a 
BC diagnosis, and how these changes may affect overall survival. 
To date, only a limited number of observational studies have examined spontaneous changes in 
health behaviors following a BC diagnosis. These studies suggest that women may reduce alcohol intake 
and reduce time spent on MVPA after a BC diagnosis.10,12,14,52 53 However, what aspects of diet, 
particularly fruit/vegetable (F/V) and dietary fat, and other health behaviors are most affected by a cancer 
diagnosis remain inconclusive. Furthermore, very few studies examined predictors of behavior change 
after a BC diagnosis. In order to improve interventions to promote adherence to lifestyle guidelines, it is 




behavior change will enhance the effectiveness of targeted interventions. Previous studies have reported 
inconsistent associations between pre-diagnosis characteristics, such as demographic and clinical 
factors, and lifestyles changes after a BC diagnosis.60,63,93,96,97,114 Some studies have shown that receipt 
of chemotherapy is most consistently associated with a decrease in MVPA.82,110 Additionally, the 
decrease in MVPA is more commonly seen among women who experience treatment complications.81  
There are important methodological limitations with prior studies of post-diagnosis behavior 
change.  Previous studies of post-diagnosis change in health behavior often examined the mean change 
in health behaviors within the study population and therefore ignored the possibility that BC survivors 
follow a mixture of behavior change trajectories. The existence of latent behavior change trajectories, 
where individuals are captured by trajectories that are unobserved (latent), has rarely been evaluated in 
BC survivors. To my knowledge, only one study has examined the latent trajectory of changes in MVPA 
over the first year after a BC diagnosis, and identified five distinct trajectories of change in MVPA.119 
However, the study is limited by its small sample size (n=199) and a short period of follow-up (12 months 
post-diagnosis). To my knowledge, no prior study has assessed the trajectory of changes in MVPA 
beyond the first year of BC diagnosis, or changes in other health behaviors, including diet, sedentary 
behavior, and alcohol intake.   
This analysis fills in these research gaps by identifying distinct trajectories of changes in diet (F/V 
and dietary fat intake), physical activity (MVPA and sedentary behavior), and alcohol intake among BC 
survivors over the first 24 months after diagnosis. Based on previously reported behavior change 
patterns, I hypothesized that women will follow one of six trajectories after a BC diagnosis, including 1) 
maintain a healthy lifestyle, 2) make a persistently positive change, 3) make a temporarily positive 
change, 4) make a persistently negative change, 5) make a temporarily negative change, and 6) maintain 
an unhealthy lifestyle.. Given that lower socioeconomic status is frequently associated with unhealthy 
lifestyle behaviors in the general population,181-185 and that higher stress and cancer treatment-related 
side effects may disrupt normal health behaviors in cancer survivors,35,145,150,151 I also evaluated the 
associations between behavior change trajectories with socioeconomic status (SES), psychosocial 




regression, after controlling for baseline behavior level and demographic and clinical characteristics. 
Ultimately, the analysis will identify subgroups of women who may be good targets for behavior 
interventions following a breast cancer diagnosis. 
 
3.3 METHODS 
3.3.1 Study participants 
The study used data from the Pathways Study,36 a population-based prospective cohort of 
women newly diagnosed with invasive breast cancer within the Kaiser Permanente Northern California 
(KPNC) network from January 2006 to April 2013. Women who were at least 21 years of age at diagnosis 
and a current KP member, had a recent diagnosis of invasive breast cancer, had no previous history of 
malignant cancer, spoke English, Spanish, Cantonese, or Mandarin, and lived within a 65-mile radius of a 
field interviewer were eligible for recruitment. The Pathways Study recruited women using rapid case 
ascertainment methods. Most participants were recruited within two months (mean time = 1.8 months, 
range = 0.3-7.2 months) post-diagnosis. Baseline demographic and lifestyle information were collected 
during an in-person interview. During the follow-up, lifestyle data were collected at 6 and 24 months via 
mailed questionnaires, and breast cancer outcomes were identified via telephone interviews every 12 
months after baseline and confirmed using KPNC electronic databases. The study protocol was approved 
by the institutional review board of all collaborating institutions [Kaiser Permanente Division of Research 
(Oakland, CA); Kaiser Permanente of Northern California; University of California at San Francisco; 
Georgetown University (Washington, DC); Roswell Park Cancer Institute (Buffalo, NY); the Cancer 
Prevention Institute of California (Fremont, CA); and Zero Breast Cancer (San Rafael, CA)]. Written 
informed consent was obtained from all participating subjects.  
A total of 11,233 potentially eligible women were invited to participate in the study, and 4,505 
enrolled. As of August 16, 2016, 416 recurrences and 549 deaths have been confirmed, with 898 
experiencing either recurrence and/or death. Among the 3,579 active participants, 2,712 participants 
completed their 24 months behavior data collection as of August 2016, while the 72 month data collection 




3.3.2 Baseline and follow-up data collection 
Interviewers administered detailed questionnaires on diet, exercise, and psychosocial and quality-
of-life measures during the baseline interview. Clinical and tumor characteristics were obtained from the 
KPNC Cancer Registry approximately four months post-diagnosis. At 6 and 24 months, follow-up 
questionnaires, phone interview, and web surveys were used to update the lifestyle information, with 
interviewer assistance offered if needed.  
3.3.3 Measurement of health behaviors 
Physical activity 
Baseline physical activity data were collected using the Arizona Activity Frequency 
Questionnaire,186 which assesses frequency and duration of daily household, recreational, transportation, 
and sedentary behaviors. The questionnaire is divided into four main sections: job or work-related 
activities, activities not related to paid or volunteer work, recreational activities, and transportation. The 
activities not related to paid or volunteer work are further subdivided into household chores (6 items), 
caregiving (5 items), and home maintenance and repairs (7 items). Recreational activities are sub-divided 
into sports, exercise, and dance (23 items) and sedentary recreational activities, such as reading or 
socializing (6 items). Four items are included under transportation. Respondents reported the frequency, 
duration, and intensity of each activity they engaged in at least once a month during the previous six 
months. Next, each activity is assigned a standard metabolic equivalent value (MET).187 One MET is 
defined as the energy it takes to sit quietly. For the average adult, one MET is approximately one calorie 
per every 2.2 pounds of body weight per hour; an individual who weighs 160 pounds burns approximately 
70 calories an hour while sitting or sleeping.  
This analysis used data on time spent engaged in moderate-to-vigorous physical activities 
(MVPA) and sedentary behaviors.  Moderate physical activity refers to activities equivalent in intensity to 
brisk walking or bicycling (3-6 METs). Vigorous physical activity produces large increases in breathing or 
heart rate, such as jogging, aerobic dance or bicycling uphill (>6 METs). Therefore, MVPA was defined as 




workplace, in the domestic environment, and during leisure time. Typical sedentary behaviors include TV 
viewing, computer use, or sitting in an automobile (1-1.5 METs).  
Diet 
Dietary history was collected using a 139-item modified version of the Block 2005 food frequency 
questionnaire (FFQ) (NutritionQuest, Berkeley, CA).188-190 The FFQ included food items selected by 
identifying the top population contributors of each nutrient among Whites, African Americans and 
Hispanics in the National Health and Nutrition Examination Survey (1999–2002). The 139 food items and 
additional questions were selected to be representative of a wide range of dietary factors, as well as to 
capture foods that are popular in Hispanic and Asian populations. Completed questionnaires were sent to 
NutritionQuest for scanning using a nutrient database developed primarily from the USDA Food and 
Nutrient Database for Dietary Studies.191 Nutrient intakes were then calculated via computerized software 
programs that multiply the reported frequency of each food by the amount of nutrient in a serving of that 
food according to the USA nutrition database. Total nutrient intakes were then calculated by summing all 
foods containing that nutrient. 
The primary dietary variables include daily intakes of fruit/vegetable (F/V), percent of energy from 
dietary fat, dietary fibers, meat, total calories, and alcohol. The FFQ assessed a number of vegetable 
groups, including daily intake of dark-green vegetables, deep-yellow vegetables, tomatoes, white 
potatoes, fried potatoes, legumes, other starchy vegetables, avocado and similar, and other vegetables 
(in cups).  Fruit groups included citrus fruit and fruit excluding citrus fruit (in cups). Dietary fat intakes 
included daily intake of total fat, saturated fat, monounsaturated fatty acids, polyunsaturated fatty acids, 
and trans-fats (in grams). The percent energy from fat was used as the analytical variable for trajectory 
analysis, which was calculated as: 
100% × (Dietary fat intake (grams) × 9)/ Total energy intake (kcal) 
Daily alcohol intake was measured by the FFQ and converted into daily ethanol intake (in grams). 
3.3.4 Key variables 




Baseline and follow-up questionnaires assessed sociodemographic characteristics, including age 
at diagnosis (<50 years, 50-59 years, and 60+ years), race/ethnicity (non-Hispanic white, non-Hispanic 
black, Hispanic, and Asian), education (high school or less, some college, and college and above), and 
household income (<$50,000.00, $50,000-$89,999, and >$90,000.00 per year).  
Clinical characteristics  
Breast cancer and other clinical characteristics were obtained from the KPNC cancer registry and 
the EHR, including family history of breast cancer (yes, no), menopausal status (pre- and post-
menopause), American Joint Committee on Cancer (AJCC) stage (I-IV) 192, number of positive lymph 
nodes (0, 1, and 2+), tumor estrogen/progesterone receptor (ER/PR) positivity (positive, negative), human 
epidermal growth factor receptor 2 (HER2) positivity (positive, negative), breast cancer surgery type, and 
adjuvant treatment received (chemotherapy, hormonal therapy, radiation therapy).193  
Psychosocial measures 
Depression. Depression during the past seven days was measured by the Center for 
Epidemiological Studies Depression Scale (CES-D).194 The CES-D is a 20-item measure that asks 
caregivers to rate how often over the past week they experienced symptoms associated with depression, 
such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each 
item (0 = rarely or none of the time, 1 = some or little of the time, 2 = moderately or much of the time, 3 = 
most or almost all the time). Scores range from 0 to 60, with high scores indicating greater depressive 
symptoms. A CES-D score of 16 or greater is considered at risk for clinical depression.  
Dispositional optimism. Dispositional optimism was measured by the 12-question Life Orientation 
Test (LOT) scale.195 Of the 12 LOT scale items, 4 items measure optimism, 4 items measure pessimism, 
and 4 items serve as fillers. Respondents rate each item on a 4-point scale (0 = strongly disagree, 1 = 
disagree, 2 = neutral, 3 = agree, and 4 = strongly agree). Scores range from 0 to 32, with high scores 
indicating greater optimism. A score of 24 or higher suggests optimism. 
Social support. Perceived social support was measured using the Medical Outcome Study (MOS) 
Social Support Survey Instrument.196 The 19-item MOS social support survey consists of four separate 




and affection) and an overall functional social support index. Each of the 19 items is rated on a five-point 
scale ranging from “none of the time” to “all of the time”, with a high subscale and/or overall score 
indicating a high level of perceived social support. The overall support index ranges from 19 to 95. An 
MOS social support score of 57 or less has been considered as lack of support. 
Cancer treatment side effects 
Physical well-being (PWB). The Functional Assessment of Cancer Therapy-General (FACT-G) 
assessed PWB using a 7-item subscale at baseline and 6 months.197 This subscale asks participants to 
rate themselves for symptoms related to breast cancer treatment side effect in the past 7 days, such as 
lack of energy, nausea, and pain. For each item, self-reported symptoms were assessed on a 0-4 scale 
(0, very much; 1, quite a bit; 2, somewhat; 3, a little bit; 4, not at all). The total FACT-G PWB score sums 
responses for each item (range 0-28), with lower scores indicating worse PWB. In these analyses, a ≥3 
decrease in the FACT-G PWB score from baseline to 6 months will be considered a clinically meaningful 
decrease in PWB.197  
Chemotherapy-induced peripheral neuropathy (CIPN). CIPN was assessed at baseline and 6 
months using the Functional Assessment of Cancer Therapy-Taxane Neurotoxicity (FACT-NTX).198 For 
each item, self-reported symptoms were assessed in the prior 7 days using a 0-4 scale (0, very much; 1, 
quite a bit; 2, somewhat; 3, a little bit; 4, not at all). The total FACT-NTX score sums responses for each 
item (range 0-44), with lower scores indicating worse neuropathy. In previous studies, a ≥10% decrease 
in the FACT-NTX score was considered a clinically meaningful increase in CIPN.199,200 
3.3.5 Statistical analysis 
  The primary goal of this study was to identify latent groups of health behavior trajectories (diet, 
physical activity, alcohol intake) after a breast cancer diagnosis and to identify predictors of these specific 
trajectories. To identify trajectory groups, the study used semi-parametric, group-based trajectory 
modeling (GBTM) procedures as proposed by Nagin39 to identify latent classes of trajectories and 
estimate the parameters of trajectories. GBTM uses a single outcome variable measured at multiple time 
points to define a latent class model in which the latent classes correspond to different growth curve 




generally assume a uniform trajectory underlying a group of people. In contrast, GBTM assumes that the 
population is composed of a mixture of distinct groups defined by their shapes of developmental 
trajectory. As such, this method will estimate the shape parameters and the probability of group 
membership, which allows further examination of the predictors of group membership. To evaluate the 
influence of loss to follow-up on the identification of trajectory groups, a sensitivity analysis was 
performed by applying the inverse probability weight (IPW)206 at 24 months to GBTM. In addition, a 
validation analysis was conducted to identify behavior change trajectory groups using a fully non-
parametric method, K-means for longitudinal data (KmL).40 Using the best trajectory group membership 
derived from the three models, this analysis further evaluated the predictors of each behavior change 
trajectory using the multinomial logistic regression. To evaluate the impact of missing data in both 
predictors and behavior change trajectories, a sensitivity analysis was conducted to fill in the missing data 
using multiple imputations,207 and then evaluate the deviations between associations that are observed 
under the complete-case analysis and those under the multiple imputations. The analytical workflow is 
summarized in Figure 2 and 3, and described in detail below. 
Main GBTM analysis. In this study, GBTM was used as the primary method to identify the optimal 
number of behavior change trajectories. The outcome variables were F/V intake, percent of energy from 
dietary fat, time spent on MVPA and sedentary behaviors, and alcohol intake from baseline to 6 and 24 
months follow-up. For each behavior change outcome, assuming the outcome variable followed a normal 
distribution, a single-group model saturated with quadratic parameters was tested initially, and then one 
additional group was included in each successive model. The study hypothesized that six distinct 
trajectories would be identified, and therefore tested models composed of one to six trajectory groups to 
find the optimal number of trajectories. Model fit was assessed based on the Bayesian Information 
Criterion (BIC), whereby the model with the lower BIC was favored as lower BIC indicates better model fit. 
Once the number of groups was determined, participants were assigned to the trajectory group that best 
corresponded to their observed behavior according to the maximum posterior probability of group 
membership. The final model was selected based on parsimony, interpretability and prior knowledge of 
common behavior patterns in BC survivors.208 209 In analyzing F/V trajectories, total calories were used as 




Bill No. 97) may influence the dietary fat intake trajectory for participants who were followed before and 
after the passage of this bill, sensitivity analyses of dietary fat change trajectories were additionally 
adjusted for a time varying covariate indicating whether the trans-fat ban was passed at each follow-up.  
Weighted GBTM analysis. More than 30% of women were lost to follow-up at 6 months and 40% 
were lost to follow-up at 24 months in the Pathways Study. To evaluate the influence of loss to follow-up 
on the identification of trajectory groups, a sensitivity analysis was performed by applying the inverse 
probability weight (IPW)206 at 24 months to GBTM. The IPW has been shown to be more effective in 
correcting for selection bias than adjustment for variables that predict loss to follow-up.210 To calculate the 
IPW, the probability of loss to follow-up at the 24-month wave was estimated in a logistic regression with 
baseline demographic and clinical characteristics as independent variables. Women who missed the 6 
month follow-up but completed the 24 month follow-up were not considered as lost to follow-up at 24 
months. Baseline demographic characteristics (age, race, education, and household income), tumor 
characteristics (tumor stage, size, grade, hormonal receptor status, and number of positive nodes), and 
treatment received (surgery, chemotherapy, hormonal therapy, and radiation) that were empirically 
associated with loss to follow-up at 24 months were included to impute the IPW. The IPW was calculated 
as the reciprocal of the probability of remaining in follow-up at 24 months.  
Validation analysis. To verify the efficiency and success of GBTM, the study performed a 
validation analysis to identify behavior change trajectory groups using a fully non-parametric method, K-
means for longitudinal data (KmL).40 The KmL is a robust classification algorithm based on the 
Expectation-Maximization (EM) method.211 The KmL starts by assigning each observation to a random 
cluster, then uses the EM algorithm to alternate between 1) computing the center of each cluster (the 
Expectation phase), and 2) assigning each observation to its nearest cluster based on its distance to the 
cluster center (the Maximization phase). The EM algorithm repeats these two phases till cluster 
assignments become stable. By definition, KmL is not a model-based approach, and therefore is less 
restricted by the normality assumption required for GBTM. However, because there are no absolute 
criteria for an optimal number of clusters in KmL, the optimal number of cluster identified through GBTM 




does not allow adjustment of total energy as a time-varying covariate. Thus the KmL was not considered 
as an alternative to the GBTM when analyzing F/V trajectories. 
Selection of final trajectory groups. For each health behavior (F/V, % energy from fat, MVPA, 
sedentary behavior, and alcohol intake), the best trajectory group membership was identified through a 
series of pairwise comparisons among the above trajectory analyses. First, when the main GBTM and the 
IPW-weighted sensitivity analysis generated identical categories of trajectory groups, agreement between 
the two sets of group membership was measured using the Cohen’s kappa, 212 which is a common 
measure of agreement between two classifications of category a finite number of subjects belong to while 
accounting for agreement due to chance. A Cohen’s kappa >0.8 indicates good agreement between the 
two sets of group membership. If the two trajectory groups were of good agreement, the unweighted 
GBTM result was retained. On the other hand, if the two trajectory groups identified different trajectory 
groups or were of poor agreement (Cohen’s kappa ≤0.8), results from the IPW-weighted GBTM were 
favored. In the second step, the optimal group memberships derived from GBTM were then compared 
with that identified via KmL using Cohen’s kappa. If the two trajectory analyses produced concordant 
group memberships (Cohen’s kappa >0.8), results from the GBTM were retained; otherwise, results from 
the KmL were considered a better fit. The model selection process is shown in Figure 4. 
Analysis of predictors of behavior change trajectory. To investigate the predictors of behavior 
change trajectories, Chi-squared tests and logistic regression were used to examine if baseline 
socioeconomic, cancer treatment side effect and psychosocial variables were associated with behavior 
change trajectory group membership. Baseline demographic (age, race, menopausal status) and clinical 
factors (tumor stage, number of positive nodes, HER2 status, ER/PR status, receipt of surgery, 
chemotherapy, hormonal therapy, and radiation) associated with 1) socioeconomic status, psychosocial 
factors, and treatment side effects and 2) behavior change trajectories, and modified any beta coefficients 
for the association of predictors and behavior change trajectory by ≥10% were considered as potential 
confounders. Confounders were entered simultaneously into a multivariable multinomial logistic 
regression model with all predictors to assess their associations with the behavior change trajectory 
group membership. An omnibus test of the associations between predictors and outcomes were also 




Handling of missing data. Missing data in health behavior variables and covariates were 
addressed in multiple steps throughout the analyses. In the trajectory identification stage, participants 
who completed at least two assessments of health behavior were included in the GBTM and KmL 
analyses. GBTM used Full Information Maximum Likelihood (FIML) method to fill in missing behavior data 
under the assumption that data were missing at random. The KmL analysis used an innovative imputation 
method known as “copy mean”, which estimated the intermittent missing value of longitudinal data by 
treating the last observed value before each missing data as a starting value, and refined the imputation 
by finding the value that gives the imputed trajectory the same shape as the population mean 
trajectory.213 The “copy mean” method has been shown to be robust under various missing data 
mechanisms and is considered superior to traditional imputation methods.213 In analyses of the 
association of hypothesized predictors with behavior change trajectory, only participants with complete 
covariate data and known group membership were included in the main analysis. However, I performed a 
sensitivity analysis to examine how missing data influenced the observed association by filling missing 
covariate and outcome data using multiple imputations.207 Logistic regression based on ten imputed 
datasets were then pooled to estimate the beta coefficients and 95% confidence interval using Rubin’s 
methods.207 Briefly, beta coefficients estimated in each of the ten data sets were averaged to calculate 
the pooled beta coefficient; the pooled confidence interval was estimated as a function of variance within 
each imputed dataset and between-imputation variance. 
The GBTM was performed using the PROC TRAJ command in SAS.214 The KmL was 
implemented in R using the ‘’kml” package.215 Multiple imputations of missing data in baseline 
characteristics and trajectory group membership was conducted using the R “mi” package.216 
 
3.4 RESULTS 
3.4.1 Participant characteristics 
Demographic, clinical and psychosocial characteristics of the 4,505 Pathways Study participants 
are summarized in Table 6. On average, participants were diagnosed with BC at the age of 59 years 




baseline, the majority of participants were white (64%), had completed at least some college education 
(35% some college, 49% college or above), earned more than $50,000 a year (67%), and were 
postmenopausal (70%). Most women were diagnosed with stage I-III breast cancer (54% stage I, 35% 
stage II, and 10% stage III), negative for human epidermal growth factor receptor 2 (HER2) (86%) and 
positive for estrogen receptor (ER) and/or progesterone receptor (PR) (83%). Almost all women 
underwent surgery, with 54% receiving a mastectomy and 45% receiving a lumpectomy. Approximately 
48% women were treated with chemotherapy, 75% with hormonal therapy, and 44% with radiation. 
Approximately 26% of women reported high depressive symptoms and only 31% felt optimistic at 
baseline, although the majority (67%) reported high perceived social support.  
A total of 2,874 (63.7%) participants responded to 6-month follow-up questionnaires, and 2,666 
(59.1%) responded to the 24-month follow-up (Table 6).  Compared to the full cohort at baseline, 
participants who remained in the follow-up at 6 and 24 months were older, more likely to be white, 
received higher education, postmenopausal, diagnosed with early stage, ER/PR positive tumor, received 
chemotherapy and radiation therapy, and had low depressive symptom at baseline. By six months, 23% 
of participants reported clinically worse physical well-being, and 34% reported clinically meaningful 
chemotherapy-induced peripheral neuropathy. Among factors associated with loss to follow-up, 
multivariable logistic regression analysis identified younger age, non-white race, lower education, higher 
income, higher tumor stage, receipt of breast surgery and chemotherapy at baseline as significant 
indicators of loss to follow-up, which were used to estimate the inverse probability weight for remaining in 
follow-up (data not shown). 
3.4.2 Identification of behavior change trajectory groups 
 The GBTM tested models with one to six trajectories to find the best fit for each health behavior. 
The distribution of F/V, % energy from fat, MVPA, and sedentary time at each assessment approximated 
a normal distribution, while the distribution of alcohol intake was slightly skewed to the left. The trajectory 
groups and their distributions are summarized in Table 7. Trajectory groups were labeled by the relative 
level of baseline behavior (high, medium, low), direction of change (increase or decrease), and the 




three dietary assessments from baseline to 6 and 24 months follow-up were included to identify F/V, 
dietary fat, and alcohol intake trajectory groups; 2,995 women who completed at least two out of three 
physical activity questionnaires were included to identify trajectory groups of MVPA and sedentary 
behavior. For each health behavior, the optimal model was identified if the model 1) had the lowest BIC 
value (sedentary behavior), or 2) yielded trajectory groups that were parsimonious and had adequate 
group size (F/V intake, dietary fat intake, MVPA, and alcohol intake). A three-group model was 
considered optimal for F/V intake, MVPA, and alcohol intake, while a four-group model was considered 
optimal for dietary fat intake and sedentary behavior.  
 The group memberships derived from the main GBTM analysis were then compared against 
those identified through GBTM analysis with IPW and the validation analysis using KmL to determine the 
final group assignment. Trajectory groups from the three sets of analyses, as well as the final model 
choices, are shown in Table 8.  The unweighted and IPW-weighted GBTM identified highly concordant 
trajectory groups (Cohen’s kappa ranged from 0.96-0.99). Therefore, trajectory derived from unweighted 
GBTM was not likely affected by loss to follow-up, and therefore was retained. Using the number of 
trajectory groups identified through GBTM, the KmL analysis identified trajectory groups with similar 
shape as those derived from GBTM. The KmL-based trajectory groups were preferred if 1) they had 
different groups than the GBTM-based trajectories (sedentary behavior), or 2) the KmL- and GBTM-based 
trajectories identified the same groups but the two sets of group membership were discordant, as 
evidenced by a Cohen’s kappa<0.8 (dietary fat intake and MVPA). Because the KmL analysis of F/V was 
unable to adjust for energy intake as a time-varying covariate, the F/V trajectory groups identified via 
unweighted GBTM was retained.   
Figure 4 illustrates the individual behavior trajectories color-coded by the trajectory groups 
(Figure 4 Column A), and the mean trajectories for each group (Figure 4 Column B). Visual assessment 
of the final group assignments suggested that the final models successfully isolated groups with 
apparently distinct behavior trajectories.  Examination of change in each subcategory of F/V, dietary fat, 
MVPA and sedentary behaviors suggested that the F/V trajectories were largely driven by the intake of 
fruits, dark green vegetables, and non-legume vegetables (Appendix 12A); the dietary fat trajectories 




(Appendix 12B).  The change in overall MVPA during the 24 months after a BC diagnosis was largely 
determined by changes in household chores and recreational activities (Appendix 13A); change in 
sedentary behavior was primarily due to changes in driving, reading, socializing and watching TV 
(Appendix 13B).  
3.4.3 Mean health behavior by behavior trajectory groups  
Mean baseline behavior levels and mean behavior changes were summarized for each behavior 
trajectory group (Table 9).  Trajectory groups were labeled by the relative level of baseline behavior (high, 
medium, low), direction of change (increase or decrease), and the persistence of change (temporary or 
stable). Across behaviors, baseline behavior level differed significantly by trajectory group (all P for 
ANOVA <0.001, not shown in Table 9). Groups that were characterized by a stable trend over time 
generally had a small change at 6 and 24 months, although there were statistically significant but small 
changes in the medium high-stable and medium low-stable groups of dietary fat intake, and the low-
stable MVPA group at 6 and 24 months.  For groups that were classified as a temporary decrease, the 
mean change in health behaviors were statistically significantly different from zero at 6 months but 
reverted back to baseline values at 24 months, although some groups continued to report a statistically 
significant change at 24 months (e.g. the medium decrease-temporary MVPA group and alcohol). The 
groups with stable increase or decrease reported statistically significant change at both 6 and 24 months. 
The specific changes in each behavior trajectory are summarized below. 
F/V: For F/V intake, the mean baseline F/V intake was 9.17 servings/day for the high increase-
stable group (11% of women), 6.16 servings/day for the medium increase-stable group (41%), and 3.31 
servings/day for the low increase-stable group (48%). The marginal change in F/V after adjusting for total 
energy intake suggested that there were statistically significant increases in all three groups at 6 and 24 
months.  However, the increases in F/V intake were relatively small; for example, the high increase-stable 
group reported a mean increase of 0.54 servings/day of F/V at 6 months, and an increase of 0.39 
servings/day at 24 months. 
Dietary fat: For dietary fat intake, the baseline mean percent energy from dietary fat was 46.5% 




low increase-stable group (35%), and 28.4% for the low-stable group (17%).  Although the dietary fat 
level remained largely unchanged for these groups, the medium high-stable group reported a decrease of 
0.83% energy from fat at 6 months (P<0.001), while the medium low-stable group reported an increase of 
0.67% energy from fat at 6 months (P<0.01) and 0.72% at 24 months (P=0.01).  
MVPA: At baseline, the mean time spent on MVPA was 18.09 hours/week for the high decrease-
temporary group (7% of women), 9.05 hours/week for the medium decrease-temporary group (35%), and 
2.73 hours/week for the low -stable group (48%). Most women temporarily decreased engagement in 
MVPA at 6 months. The high decrease-temporary group reported a decrease of 3.03 hours/week of 
MVPA at 6 months (P<0.001); the medium decrease-temporary group decreased 2.37 hours/week of 
MVPA at 6 months (P<0.001) and decreased 0.74 hours/week at 24 months (P<0.001).  The low-stable 
group also reported a slight decrease of 0.49 hours/week MVPA at 6 months (P<0.001).  
Sedentary behavior: At baseline, the mean time spent on sedentary behavior was 27.94 
hours/week for the high-stable group (18% of women), 15.41 hours/week for the medium increase-stable 
group (24%), 22.55 hours/week for the medium decrease-stable group (27%), and 11.29 hours/week for 
the low-stable group (31%). The medium increase-stable group spent 4.66 more hours/week on 
sedentary behaviors at 6 months and 4.64 hours/week more at 24 months (both P<0.001). The medium 
decrease-stable group decreased 6.85 hours/week of sedentary behaviors at 6 months and decreased 
5.31 hours/week at the 24 months (both P<0.001). Moreover, the high-stable and low-stable groups also 
decreased a small but statistically significant amount of time spent on sedentary behavior. 
Alcohol: The mean baseline alcohol intake as measured by ethanol was 41.43 grams/day for the 
high decrease-temporary group (5% of women), 18.81 grams/day for the medium decrease-temporary 
group (16% of women), and 1.95 grams/day for the low-stable group (79% of women). The high 
decrease-temporary group decreased ethanol intake by 6.85 grams/day at 6 months (P<0.001), but the 
decrease was not statistically significant at 24 months.  The medium decrease-temporary group 
decreased 4.88 grams/day of ethanol at 6 months (P<0.001) and 2.74 grams/day at 24 months 





3.4.4 Characteristics of behavior trajectory groups 
Women who followed different trajectories of behavior change differed in a number of 
demographic and clinical characteristics (Appendix 3-7). Factors associated with specific behavior 
change trajectories in univariable analyses are described below. 
Age: In univariable analyses, women diagnosed at older age were more likely to be in the high 
F/V intake, high sedentary behavior and high alcohol intake groups, but were less likely to be in the high 
MVPA group.  
Race/ethnicity: Race/ethnicity was generally associated with trajectory of F/V, MVPA, sedentary 
behavior, and alcohol intake, with white women being more likely to be in the high F/V intake, high MVPA, 
high sedentary behavior, and high alcohol intake groups, compared to other race/ethnicity groups.  
Education: Women with higher education were more likely to be in the high F/V, high MVPA, high 
sedentary behavior, and the low alcohol intake trajectory groups.  
Income: Women with a household income of $50,000 or above were more likely to be in the high 
F/V, high MVPA, high sedentary behavior, and the high alcohol intake trajectory groups.  
Menopausal status: Postmenopausal women were less likely to be in the high MVPA trajectory 
group, but more likely to be in the high sedentary behavior and alcohol intake trajectory groups. 
Tumor characteristics:  Among tumor characteristics, higher tumor stage was associated with the 
low MVPA trajectory groups, and women who were positive for ER/PR were less likely to be in the low 
alcohol intake trajectory group.  
Cancer treatment: Women who received mastectomy were more likely to be in the low F/V, low 
sedentary behavior, and the low alcohol trajectory groups compared to women who received 
lumpectomy. Women treated with chemotherapy were likely to be in the low F/V, high sedentary behavior, 
and low alcohol intake trajectory groups. Receipt of hormonal therapy was also associated with the low 
F/V trajectory group. Finally, women who received radiation were more likely to be in the high F/V, high 




Psychosocial factors related to stress coping: Women who had higher depressive symptom at 
baseline were more likely in the low F/V trajectory group. Women who were more optimistic and reported 
receiving higher social support at baseline were more likely to be in the high F/V, high MVPA, high 
sedentary behavior, and high alcohol intake trajectory group. Women who reported experiencing worse 
CIPN at 6 months were more likely in the high dietary fat trajectory group.  
3.4.5 Predictors of behavior change trajectory groups 
 Multinomial logistic regression analysis examined the associations of baseline behavior level, 
socioeconomic status, stress coping ability, and cancer treatment side effects with group membership of 
behavior change trajectories. The overall associations between behavior trajectory group membership 
and each predictor were tested first using the omnibus likelihood ratio test. Associations between each 
group of behavior trajectory and the predictors were tested using multinomial logistic regression analysis. 
Women who were in the lowest level of each health behavior were used as the referent level. Specifically, 
the analysis of F/V trajectory used the “low increase-stable” group as the referent group; analysis of 
dietary fat, MVPA, sedentary behavior, and alcohol intake used the “low-stable” group as the referent, as 
the “low increase-stable” group was not identified for these behaviors. The results of the regression 
analyses are summarized in Tables 10-12. The study screened and tested for confounding from 
demographic and clinical characteristics, and identified age at diagnosis, race/ethnicity, menopausal 
status, tumor stage, number of positive node removed, ER/PR positivity, and receipt of surgery, 
chemotherapy, hormonal therapy, and radiation as potential confounders. Therefore, an unadjusted 
model and a fully adjusted model with all confounders were fitted to examine the adjusted odds ratio of 
being in each of the behavior trajectory groups.  
Socioeconomic status. Table 10 shows the results for association of education and household 
income with behavior trajectory groups. In fully adjusted analyses, women who completed college 
education or above had higher odds of being in the F/V high increase-stable trajectory group (OR=2.74, 
95% CI: 1.64-4.57) and the medium increase-stable trajectory of F/V (OR=2.33, 95% CI: 1.67-3.26) 
compared to those with a high school degree or less. Higher education was also associated with higher 




less: OR=3.48, 95% CI: 1.45-8.38; college or above vs. high school or less: OR=4.36, 95% CI: 1.83, 
10.35) and the MVPA medium decrease-temporary trajectory group (some college vs. high school or less: 
OR=1.63, 95% CI: 1.16-2.30; college or above vs. high school or less: OR=2.04, 95% CI: 1.46-2.84).  
However, women with a college degree or above were also more likely to be in the high-stable sedentary 
behavior group (OR=1.63, 95% CI: 1.16-2.30) and the medium increase-stable alcohol intake group 
(OR=2.21, 95% CI: 1.35-3.60).  
In fully adjusted analysis, compared to women with an annual household income of less than 
$50,000, women with a household income of $50,000-$89,000 were more likely to be in the F/V medium 
increase-stable trajectory group (OR=1.36, 95% CI: 1.07-1.72) and the MVPA medium decrease-
temporary trajectory group (OR=1.37, 95% CI: 1.09-1.71), and were less likely to be in the sedentary 
behavior high-stable trajectory group (OR=0.66, 95% CI: 0.48-0.91). However, women with a household 
income of $50,000-$89,000 were more likely to be in the high decrease-temporary group (OR=2.54, 95% 
CI: 1.49-4.34) and the high decrease-temporary alcohol intake group (OR=1.64, 95% CI: 1.21-2.21). 
Stress coping. Table 11 shows the results for association of stress coping with behavior trajectory 
groups. In fully adjusted analyses, higher baseline dispositional optimism was associated with greater 
odds of being in the F/V high increase-stable (OR=1.83, 95% CI: 1.31-2.54) and the medium increase-
stable trajectory groups (OR=1.50, 95% CI: 1.19-1.89), and greater odds of being in the MVPA high 
decrease-stable (OR=1.85, 95% CI: 1.25-2.75) and the medium decrease-stable trajectory group 
(OR=1.61, 95% CI: 1.29-2.00). The omnibus test showed that higher optimism was also associated with 
dietary fat intake trajectory groups (P<0.01, not shown in table), although there was no statistically 
significant association between optimism and individual groups of dietary fat trajectory. Women who 
reported receiving higher social support at baseline were more likely to be in the F/V high increase-stable 
(OR=1.82, 95% CI: 1.25-2.65) and the medium decrease-temporary trajectory group (OR=1.33, 95% CI: 
1.06-1.67), but also more likely to be in the sedentary behavior high-stable (OR=1.86, 95% CI: 1.34-2.57) 
and medium decrease-stable (OR=1.42, 95% CI: 1.08-1.87) trajectory groups. 
Cancer treatment side effect. Table 12 shows the results for association of cancer treatment side 




was associated with higher odds of following the medium high-stable trajectory of dietary fat intake 
(OR=1.48, 95% CI: 1.06-2.06).  
Tumor characteristics and cancer treatment received: Appendix 8 shows the associations 
between tumor characteristics and cancer treatment received and behavior trajectories. In fully adjusted 
analyses, higher number of positive lymph nodes removed was associated with higher odds of being in 
the F/V high increase-stable trajectory group. Women who received surgery were less likely to maintain a 
high level of alcohol intake; women who received chemotherapy were more likely to be in the high 
decrease-stable MVPA group; women who received hormonal therapy were more likely to be in the 
medium low-stable dietary fat group and the medium decrease-stable MVPA group. 
3.4.6 Sensitivity analyses 
Sensitivity analysis with multiple imputations  
Appendix 14 shows the pattern of missing data in key analytical variables. Although the baseline 
demographic and clinical data were almost complete for all participants, a large number of data were 
missing for change in PWB (40%) and CIPN (56%). Missing data was more common for behavior data, 
with 17% baseline dietary data and 1% baseline physical activity data were missing. Because the 
trajectory analyses excluded participants with less than two non-missing data points, approximately 34%-
38% participants were excluded from the trajectory analyses, thus their behavior change trajectory group 
memberships were missing. Using the multiple imputations (MI) method under the assumption that these 
data were missing at random, the study imputed ten separate datasets to fill in missing data in the key 
analytical variables and behavior trajectory group membership. Pooled results of fully adjusted 
multinomial logistic regression analyses from the ten imputed datasets were compared with results based 
on the complete case analysis (Figure 6). Briefly, the missing data have a minor influence on the 
observed associations of socioeconomic status, stress coping, and cancer treatment side effects with 
behavior trajectories. After MI, higher education was statistically significantly associated with the medium 
increase-stable trajectory of F/V intake (some college vs. high school or less: OR=1.59, 95% CI: 1.21-




stable dietary fat group (OR= OR=0.57, 95% CI: 0.36-0.92), but women with some college education 
were more likely to be in the high-stable sedentary behavior group (OR= OR=1.55, 95% CI: 1.10-2.19). 
Sensitivity analysis examining exact time since diagnosis as time scale 
Because participants may enter into the study at different time points after diagnosis, I examined 
the distribution of time since diagnosis at each data collection point and used exact time since diagnosis 
as the underlying time scale to perform another trajectory analysis.  The results suggested that women 
enter the study at the median time of 8 weeks (approximately 2 months) after diagnosis, while the 6 and 
24 month data were collected, respectively, at the median time of 34 weeks (8.5 months) and 111 weeks 
(28 months) after diagnosis. Although the exact times of data collection closely matched the scheduled 
data collection time, there were great variations in time since diagnosis at each wave of data collection. 
Comparison among participants who enrolled within 2 months, between 2-3 months, and more than 3 
months after diagnosis suggested that there were no differences in demographic and clinical factors 
among early and late enrollees (Appendix 9). However, later enrollment appeared to be associated with 
lower chemotherapy initiation and fewer cancer treatment-related side effects. Trajectory analyses based 
on exact time since diagnosis at each data collection point identified similar trajectory groups as those 
identified under approximate time (i.e., baseline as an approximate for time of diagnosis, 6-month follow-
up as an approximate for 6 months post diagnosis, etc.; data not shown). These results suggest that the 
use of approximate time instead of exact time did not affect the trajectory analyses. 
Sensitivity analysis examining the influence of extreme dietary data 
My initial analysis used all available dietary data from the Pathways Study. However, the 
complete data set may include extreme dietary recall data, which were not removed by the Pathways 
Study or NutritionQuest during data collection and cleaning. To examine the influence of extreme dietary 
data on the identification of dietary trajectory groups, I performed a sensitivity analyses by excluding all 
extreme dietary data from women whose daily energy intake were greater than three standard deviations 
above the mean energy intake at each data collection. Appendix 10 shows the cutoff values to define 
extreme dietary data and number of women excluded at each wave (cutoff values are: 3398.3 kcal/day at 
baseline, 3084.6 kcal/day at 6 months and 3175.2 kcal/day at 24 months). After exclusion of extreme diet 




had at least two alcohol intake data. Trajectory analyses after the exclusion of extreme dietary data 
generated almost identical trajectory groups (Appendix 11). Therefore, extreme dietary data were unlikely 




 This analysis showed that the majority of breast cancer survivors in the Pathways Study 
maintained their lifestyles over the 24 months following a diagnosis of BC, although women generally 
reported slight increases in F/V intake and temporary decrease in MVPA and alcohol intake during this 
period. Specifically, 52% of women reported medium to high level of F/V intake at baseline, and slightly 
increased F/V intake by no more than 0.5 serving/day over the 24 months following a BC diagnosis. 
Approximately 42% women reported medium to high level MVPA at baseline, but temporarily decreased 
engagement in MVPA by 2-3 hours/week at 6 months after diagnosis.  Approximately 24% of women 
increased and 27% of women decreased time spent on sedentary behaviors by 5 hours/week over the 24 
months after a BC diagnosis. Finally, 21% of women reported medium to high alcohol intake at baseline 
and temporarily decreased alcohol intake by 5-7 grams/day at 6 months after diagnosis.  This analysis 
also identified characteristics that were predictors of health behavior trajectories, including socioeconomic 
status, dispositional optimism, perceived social support, and the severity of CIPN during active treatment. 
Specifically, higher education and income was commonly associated with higher odds of the high/medium 
increase-stable groups of F/V, high/medium decease-temporary groups of MVPA, and high/medium 
decrease-temporary groups of alcohol intake. However, women with higher education were more likely to 
be in the high-stable sedentary behavior group, while women with higher income were at lower odds of 
maintaining high level of sedentary behavior. Higher dispositional optimism and perceived social support 
were associated with higher odds of the high/medium increase-stable F/V group and the high/medium 
decrease-temporary of MVPA, while higher social support was also associated with higher odds of the 
high-stable and medium decrease-stable groups of sedentary behavior. Finally, worse CIPN at 6 months 




 This analysis proposed new ways to identify target populations for behavior interventions. By 
depicting latent trajectories of health behaviors, future studies can potentially identify and directly target 
patients who are at high likelihood of following unfavorable health behavior trajectories.  This analysis 
revealed that the level of health behavior at time of diagnosis is highly predictive of subsequent health 
behaviors during treatment and early survivorship after a BC diagnosis. Therefore, screening for health 
behavior at the time of cancer diagnosis could effectively identify targets to deliver behavior interventions. 
When direct measure of health behavior is unavailable, the high-risk group could be identified based on a 
patient’s demographic characteristics, such as education and household income, or based on the 
psychosocial response to stress due to cancer, such as depressive symptom and dispositional optimism. 
 Few studies have examined the longitudinal trajectories of diet, physical activity and alcohol 
intake among BC survivors.  Traditionally, studies have reported the average population change at certain 
time points over the course of follow-up. Based on analyses of mean change, previous studies reported 
relatively small and inconsistent changes in F/V, dietary fat, MVPA and sedentary behavior after a BC 
diagnosis. For instance, in a German cohort study (n=229), Steinhilper et al.78 reported that BC survivors 
increased fruit intake by only 0.4 serving/day at one year post-surgery, and increased the frequency of 
fruit and vegetable intake by 0.9 and 0.7 times/week, respectively. Similarly, the British DietCompLyf 
cohort study (n=1,560)84 reported that BC survivors increased approximately 0.5 serving/1000 kcal/day of 
fruit and 0.5 serving/1000 kcal/day of vegetable at 1 year after diagnosis after adjusting for total energy 
intake. The reported changes in dietary fat intake were also small. The HEAL study (n=260)85 reported 
that BC survivors on average reduced 3.6 g/day of fat intake and 1% of energy from fat at 2 years post-
diagnosis. Similarly, the DietCompLyf study (n=1,560)84 reported a decrease of 4 g/1000 kcal/day in total 
fat intake at 1 year after diagnosis. Reports of change in MVPA were inconclusive; however, the 
fluctuation of MVPA after a BC diagnosis was within 2 hours/week.14,81,98 In the Pathways Study 
(n=1,696), Kwan et al. reported that MVPA decreased by 1.28 hour/week from 2 to 8 months after BC 
diagnosis.14 A population-based cohort study of 287 Australian BC survivors reported that participants 
spent 17 more minutes/week on vigorous PA but 55 fewer minutes/week on moderate PA from 6 to 18 
months after diagnosis.81 However, a population-based cohort study of BC survivors in the US (n=315) 




at 12 months post-diagnosis.98 Only one study reported a mean change in sedentary behavior among BC 
survivors. In the Pathways Study (n=1,696), Kwan et al. reported that BC survivors on average spent 0.83 
fewer hours/week in sedentary behavior at 6 months after diagnosis.82  
 The current analysis suggests that most women maintained their health behaviors in the 24 
months after diagnosis, and among women who did make changes, the changes were very modest. 
Among women who fell into the “increase” groups of F/V, the energy-adjusted increase in F/V was less 
than one serving/day. For instance, although women in the high and medium increase-stable F/V group 
reported a statistically significant increase in F/V intake at 6 and 24 months, the average change was less 
than 1 serving/day of F/V. Similarly, changes in alcohol intake was also small, with the high and medium 
decrease-temporary group reporting a decrease of less than 1 standard drink of alcohol, which is 
equivalent to 16 grams of ethanol. However, the changes in physical activity were relatively larger. For 
instance, women in the high decrease-temporary MVPA group reported a decrease of 3 hours/week 
MVPA by 6 months, and women in the medium decrease-temporary group reported a decrease of 2.47 
hours/week by 6 months after diagnosis. Considering that the lifestyle guidelines recommend a minimum 
of 2.5 hours/week of MVPA, these decreases are worthy of attention. Based on the magnitude of change, 
these results suggest that a BC diagnosis may encourage women to make relatively small dietary 
changes, but it may also prevent women from engaging in exercise. 
 Very few studies reported the distribution of behavior change patterns in BC survivors. Only two 
studies reported the prevalence of MVPA change patterns after a BC diagnosis. The HEAL study (n=545) 
reported that at 30 months after a BC diagnosis, 35% of women decreased time engagement in MVPA, 
while 26% maintained and 39% increased engagement in MVPA.79 The current study reported a similar 
distribution, with approximately 42% women reporting decreased MVPA. To my knowledge, only one 
previous study has examined the trajectory of change in MVPA after a BC diagnosis. Using a hospital 
sample of 199 BC patients in Montreal, Canada, Brunet et al. analyzed data on MVPA collected every 
three months during the first year after a BC diagnosis. Using GBTM analysis, they demonstrated that 
women may follow five distinct trajectories of change in MVPA during the first year after diagnosis: 5.5% 




MVPA, 25% were somewhat inactive over time, and 49% were consistently active.119 In comparison, my 
analysis did not identify a group of women who followed an increasing trajectory of MVPA. In fact, my 
analysis indicates that the majority of women (58%) maintained a low level of MVPA, and only 7% were 
constantly active. The differences in the discovery and distribution of MVPA trajectories could be due to 
the differences in the underlying source population and the method of assessing of MVPA. The current 
analysis defined MVPA as the total time spent on household chores, recreational activities and 
transportation. In contrast, Brunet et al. only assessed leisure time MVPA, which primarily included 
recreational activities. As such, the amount of MVPA reported in Brunet et al.’s study was considerably 
lower that what as reported in this analysis. In the current analysis, the majority of women were inactive, 
which suggests the need for increasing physical activity after a BC diagnosis.  
The trajectory analyses of four health behaviors revealed that most women in the Pathways 
Study maintained a stable level of health behaviors in the 24 months after diagnosis. These findings raise 
the question as whether a cancer diagnosis elicits a true “teachable moment” where patients take action. 
A “teachable moment” refers to the period immediately following a major health event that may lead 
patients to be receptive to uptake of health promotion information. For example, a teachable moment is 
thought to occur after a smoker receives a diagnosis of lung disease or suffers a heart attack.217,218 The 
worries associated with these major health events motivate patients to adopt healthy behaviors, such as 
smoking cessation. Previous studies have suggested that cancer diagnosis would be followed by such a 
teachable moment, as cancer survivors are likely to feel that their lives are threatened and may 
experience strong emotional distress and social withdrawal.219-221 However, since a cancer patient 
typically goes through surgery and systematic therapy that may spans over as long as 24 months, a 
patient’s readiness to adopt healthier behavior may vary depending on the duration of cancer treatment. 
Therefore, the timing when a “teachable moment” occurs remains unclear. A “teachable moment” could 
occur immediately after the cancer diagnosis, during active cancer treatment, or during recovery phase 
after treatment has been completed. Previous studies suggest that cancer survivors may be more ready 
to adopt dietary changes at a later time after diagnosis. A systematic review of health behavior 
interventions reported that studies targeting at cancer survivors diagnosed within four months had higher 




retention rates.222 The evidence for uptake of physical activity is mixed. For example, a study asked about 
the most preferred period for receiving exercise counseling and beginning an exercise program among 
more than 300 breast, prostate, colorectal, and lung cancer survivors. Approximately 39% of these cancer 
survivors said they preferred a time before treatment, 19% said during treatment, and 21% said 
immediately after treatment.223 This study suggested that the promotion of physical activity may not be 
dependent on timing of cancer treatment among cancer survivors. Although my analysis did not have 
data to examine the trajectory of readiness of behavior change, data suggest that BC survivors may start 
to increase F/V intake and reduce MVPA at baseline, which was approximately two months after 
diagnosis, suggesting that BC survivors may be most motivated to improve diet and face the biggest 
challenges to maintain regular physical activity shortly after diagnosis.  
The study also highlighted several predictors of changes in F/V and MVPA in BC survivors. 
Higher education and higher income strongly predicted healthier lifestyles choices in BC survivors 
enrolled in the Pathways Study, which is consistent with previous studies in the general population. 
Numerous studies suggest that the low SES groups tend to adopt unhealthy behaviors, which explains a 
substantial proportion of the excess mortality associated with low SES.181-185 The disparity in health 
behaviors between high and low SES groups is explained by a number of mechanisms: 1) chronic stress 
associated with economic disadvantage may limit an individual’s capacity to adopt healthy behaviors and 
may drive them to seek unhealthy behaviors that are low-cost and stress-reducing;224-227 2) the lower 
wealth of low SES groups give them less reason to invest in future longevity and more reason to focus on 
the present in making decisions about healthy behaviors; 228-232 3) the low SES group may lack 
knowledge of the harm of unhealthy behaviors and therefore have less motivation to adopt healthy 
behaviors; 233-238 4) low SES group may lack of education, which decreases their problem-solving skills, 
ability to process information, and locus of control needed to overcome obstacles to achieving healthy 
behaviors; 231,239-242 5) the low SES group lacks economic resources to overcome low education, efficacy, 
and agency in adopting healthy behaviors; 241-244 and 6) the low SES group may share poorer community 
resources and less social capital that facilitate adoption of healthy behavior, such as neighborhood built 
environment,245-250 networks of health-oriented family and friends, 251-254 and social cohesion.245,255-257 The 




resources should be provided to the low-income, low-education group of BC survivors. This is particularly 
important for BC survivors, as many women may face financial burden caused by high out-of-pocket costs 
associated with cancer treatment.258 With the financial toxicity, women may have fewer resources to 
support the choice of a healthier lifestyle and therefore need material assistance to help make a positive 
change in diet and physical activity. This finding also suggests that future behavior interventions of health 
behaviors targeting at BC survivors should prioritize low SES populations.  
Psychosocial factors relating to stress coping may influence the lifestyle choices after a BC 
diagnosis, but have not been formally tested in previous studies. Specifically, higher dispositional 
optimism and greater social support at the time of BC diagnosis may be promoters of a healthier lifestyle, 
especially for F/V intake and engagement in MVPA. This finding is in line with previous studies that 
explained the individual differences in lifestyle choices after a breast cancer diagnosis using the stress 
and coping model.152,153 The diagnosis and treatment of cancer is a significant stressor in itself that could 
contribute to changes in appetite and sleep and may disrupt health behaviors and potentially increase 
unhealthy behaviors.150,151 The stress and coping model posits that the ways that cancer survivors 
manage stressful feelings may influence their ability to make and sustain health behavior changes.154 In 
particular, this model proposes that the use of adaptive coping to deal with cancer diagnosis stressors will 
be related to positive health behavior change. In breast cancer survivors, depressive symptoms are the 
most common stress-related symptoms.151,155-157 Depressive symptoms are associated with smoking and 
physical inactivity in the general population 158,159 and breast and testis cancer survivors.119,160 In contrast, 
greater dispositional optimism has been associated with not smoking, moderate alcohol consumption, 
brisk walking, and vigorous physical activities in older women. In addition, higher perceived social support 
may facilitate stress coping and is linked to increased health behavior, specifically exercise, in cancer 
survivors.162,163 However, the study only observed a marginally significant association between higher 
depressive symptom and greater risk of decreasing F/V intake after a BC diagnosis (OR=1.86, 95% CI: 
0.98-3.54). The protective effect of social support was not observed in this study. 
Cancer treatments may also disrupt health behaviors. For example, cancer patients report 




induced by chemotherapy may alter food preferences and nutritional intake.146-149  Although cancer 
treatment may present barriers to the adoption of healthy behaviors, few studies formally investigated the 
impact of cancer treatment and treatment-related side effects on changes in health behaviors in breast 
cancer survivors.  However, the association between cancer treatment side effects and trajectories of 
health behaviors was weak in this population.  Of particular note, women who experienced worse CIPN 
during treatment period were more likely to follow a relatively high level of dietary fat intake. However, 
because the dietary fat pattern and the onset of CIPN were defined in overlapping time periods, this 
association does not indicate that women began to follow a high-fat diet after experiencing CIPN 
symptoms. It is also possible that women who had a high-fat diet were at greater risk of developing CIPN 
during active treatment, which is worthy of further investigation.  
Changing lifestyle behaviors is a complex process and previous analyses of the mean change of 
these behaviors within a specific population are not sufficient to understand the complexity of behavior 
change among BC survivors. Therefore, more advanced analytical methods that distinguish the pattern of 
change are required. A major advantage of these analyses is the novel use of GBTM and KmL to identify 
subpopulations of BC survivors with distinct behavior change trajectories. These methods are person-
centered analyses, which focuses on the similarities among the participants’ longitudinal data, and differ 
from the variable-centered cluster analysis, such as the latent class analysis or latent transition analysis 
that focuses on understanding relationships among variables.259 The goal of the variable-centered 
analysis is to find commonality among a number of variables. In contrast, the person-centered analysis 
aims to identify similarities among individuals. Unlike other members of the finite mixture model family, 
such as the growth mixture modeling (GMM),260 which identifies latent classes of growth pattern based on 
individual characteristics, the GBTM identifies latent classes of growth patterns based on the shape 
parameters of growth curves. In addition, GBTM will handle missing data using Full Information Maximum 
Likelihood (FIML) estimation, which is unbiased and more efficient than methods that delete observations 
with incomplete data.261 As such, the GBTM is a more appropriate method to identify behavior change 
trajectories. The use of KmL provides another robust method to validate the trajectory found in GBTM, 
adding confidence to the reproducibility of our findings. Because the KmL uses the EM algorithm to find 




distributed, or group size is small. Additionally, KmL imputes missing data using an innovative method 
that provides reliable imputations even when the MAR assumption is violated. 
The analysis also suffers from a number of limitations. An important limitation of this analysis is 
the lack of an ideal comparison group which represents the health behaviors before a BC diagnosis. In 
this analysis, baseline behavior data, which were captured at an average of 2 months post-diagnosis, 
were used as a measure of pre-diagnosis behavior. As such, the analysis only estimated a surrogate of 
change in health behaviors before and after breast cancer diagnosis. However, since the baseline 
behaviors were captured within approximately two months after diagnosis, one can reasonably assume 
that the baseline values well approximate behaviors pre-diagnosis, although no study has specifically 
examined the change in health behaviors immediately after a BC diagnosis. Studies that have collected 
both pre- and post-diagnosis behavior data are scarce. In my search of published articles, only one study 
examined the changes in health behaviors before and after a cancer diagnosis.262  The study by Newsom 
et al. used data from the Canadian National Population Health Survey (NPHS) which followed 17,276 
individuals aged 12 or older in 1994-1995. Follow-ups were conducted every 24 months. The study 
included 5,404 participants aged 50 or older at the first cycle who initially reported no chronic condition, 
but who reported a new diagnosis of one of five chronic conditions in a subsequent cycle during cycles 1 
to 7 (1994-1995 to 2006-2007) of study follow-up. These chronic conditions included “heart disease,” 
“cancer” (skin cancer excluded), “effects of stroke,” “chronic bronchitis or emphysema” (asthma 
excluded), and “diabetes”. The study by Newsom et al. reported significant reduction in alcohol intake and 
smoking following a cancer diagnosis. However, because the study was only able to compare the change 
in health behaviors during a two-year period around the time of diagnosis, it is difficult to ascertain the 
exact timing of behavior change after diagnosis. Therefore, it remains unclear whether BC survivors in the 
Pathways Study began to make lifestyle changes before the baseline interview and whether baseline 
behavior approximated pre-diagnosis behavior. Collecting timely behavior data prior to the diagnosis of 
cancer is difficult. For large population-based cohort study, it is not feasible to prospectively collect 
behavior data close to a cancer diagnosis because data collection schedules are not determined by 
timing of cancer diagnosis. Thus, in studies of cancer survivors, recall of health behaviors before 




include a comparison population without breast cancer whose behaviors were not affected by a breast 
cancer diagnosis (the “unexposed”). However, because breast cancer may be caused by unhealthy diet 
and physical inactivity, breast cancer survivors may be more likely to engage unhealthy behaviors pre-
diagnosis than the general population. Therefore, the use of healthy controls may introduce selection 
bias, leading to overestimation of behavior changes following a breast cancer diagnosis.  
Another important limitation is the self-reported behavior data, which are subject to measurement 
error comprised of bias and random error. Social desirability bias is a common measurement error, which 
refers to the tendency to over- or under-report particular behaviors in order to avoid being viewed 
negatively.263 Increased media coverage of the potential benefits of healthy eating and physical activity 
may have changed people’s awareness of their diet and accuracy of self-report. If the relationship 
between self-report and actual health behavior changes, trend estimates or comparisons of self-reported 
data across different time points will conflate true changes in health behavior with changes in reporting 
accuracy. As such, my findings of the general increasing trend in fruit/vegetable intake raise the question 
of whether the self-reported diet reflect the actual diet, or merely the increased desire to present oneself 
as a health-conscious individual. Social desirability bias could also occur if the response rate to 
fruit/vegetables items on the food frequency questionnaire increased over time, leading to differential non-
response bias in estimates over time. Therefore, social desirability bias may lead to erroneous 
conclusions regarding the observed trend estimates in fruit/vegetable and relationships with other 
variables of interest. In contrast, social desirability may have lower impact on physical activity and BMI, 
which showed either flat or decreasing trends. Due to the lack of objective behavior data in this analysis, 
future studies can assess the magnitude of the social desirability on reporting accuracy by comparing 
trajectories derived from self-reported and objective data. Previous studies of large national surveys 
suggest that the increases in BMI and leisure time physical activity over the past few decades were likely 
to reflect the actual behavior change instead of changes in reporting accuracy.264,265 However, social 
desirability may be associated with a downward bias in reporting food intake, especially total energy and 




Although the self-reported data were unlikely to bias the trend estimate for MVPA, almost all 
women reported engaging in sufficient amount of MVPA as recommended by the ACS, suggesting the 
self-reported physical activity data may overestimate the actual MVPA level. The Pathways Study 
assessed physical activity using the Arizona Activity Frequency Questionnaire (AAFQ), which has been 
shown to be an effective and accurate tool for prediction of physical activity energy expenditure based on 
validation studies using doubly labeled water.186,267  However, based on data from two large population-
based studies, LACE (Life After Cancer Epidemiology) and CMH (California Men’s Health Study), 
respondents typically misunderstood the definitions of activity intensity in the AAFQ, which may result in 
over-reporting work-related physical activities.268   In particular, sedentary office workers may over-report 
the time they spent walking or standing as they tend to report any walking instead of walking that lasted 
longer than 10 minutes. Although MVPA at work was not counted towards the overall MVPA in this 
analysis, the majority of women in the Pathways Study were older than 60 years old and spent most of 
their time sitting, who may also over-report MVPA due in part because of the tendency to recall any 
MVPA at home, which may explain the overestimation of overall MVPA.  
In addition, this analysis may also suffer from selection bias. Because more than 50% of eligible 
women who were diagnosed with a breast cancer within the KPNC network refused to participate in the 
Pathways Study, women enrolled in this study might represent a subgroup of the source population that 
are more interested in lifestyle information after breast cancer diagnosis, or who are more motivated to 
seek healthier behavior change. Therefore, a selection bias may lead to a higher proportion of women 
who made a positive change in health-related behaviors after breast cancer diagnosis. However, in this 
analysis, the shape of behavior trajectory groups and the assignment of trajectory group membership 
were highly concordant under the analysis with and without adjustment for loss to follow-up, suggesting 
the impact of loss to follow-up was unlikely to have biased the identification of behavior trajectories.  
Lack of generalizability is also a limitation of this analysis.  The Pathways Study recruited 
participants within the KPNC healthcare system, which provides passive access to diagnoses and 
procedures for millions of patients. However, the participants may not be representative sample of a 




employed, and may exclude women who were diagnosed outside the health plan.269  In addition, 
members of the KPNC plan may change insurers over time. Furthermore, because members of the KPNC 
plan are employed, they may be systematically younger and healthier than the cancer survivors who are 
unemployed. Due to these reasons, the results regarding health behaviors of Pathways Study participants 
may not be generalized to breast cancer survivors living in northern California but outside of KPNC, or 
survivors living in other areas of the US. In addition, since the Pathways Study did not include women 
diagnosed with stage IV or higher stage breast cancer, these results may have limited applicability that 
extends only to populations with early stage (I-III) breast cancer. Finally, although a “teachable moment” 
may be common among survivors of various cancers, my analysis was only among BC survivors, and 
may not be generalizable to all cancer survivors.219-221 
Furthermore, the statistical method used to identify behavior change trajectories is also limited by 
a few factors. The group-based modeling of trajectory groups is a data driven rather than a hypothesis-
driven approach. As such, the model will define trajectories groups based on their shapes, rather than a 
set of a priori cutoff point to define the high and low level of healthy behaviors. However, given the limited 
literature on this topic, it could be used as a first step to building hypotheses for subsequent analyses. 
Another limitation of the group-based model is its assumption of a uniform shape of trajectory within the 
same group. Because the group-based model estimates a mean growth curve for each group, no 
individual variation around the mean group curves is allowed; the variation in the shape of trajectories 
within a group is assumed to be zero. A further complication of this limitation is that it may over simplify 
the trajectories of behavior change and regress behavior data to the mean. In this analysis, trajectories of 
absolute behavior were generally clustered by the mean baseline level and were not reflective of the 
change. The relatively small magnitude of change, the short period of data collection, and the limited 
number of repeated measures may explain the clustering by the baseline behavior. Future studies can 
explore the methodology to capture trajectory clusters by the slope of individual trajectories. 
In summary, this analysis indicates that most women maintained their lifestyles after a BC 
diagnosis. There are a few notable patterns of behavior change. Half of women reported medium to high 




diagnosis. Approximately 42% of women reported medium to high level MVPA at baseline, but 
temporarily decreased engagement in MVPA at 6 months after diagnosis.  A quarter of women increased 
and another quarter decreased time spent on sedentary behaviors over the 24 months after a BC 
diagnosis. Finally, 21% of women reported medium to high alcohol intake at baseline and temporarily 
decreased alcohol intake at 6 months after diagnosis.  The predictors of health behavior trajectories 
included socioeconomic status, dispositional optimism, perceived social support, and the severity of CIPN 
during active treatment. Although higher socioeconomic status was generally associated with better 
health behaviors, women with higher education were more likely to stay inactive after a BC diagnosis.  
Given the potential benefit of healthy lifestyles on the overall survival of BC, it is important to prioritize 
health promotion in BC survivors who are at high risk of maintaining or adopting unhealthy behaviors post 
diagnosis. Moreover, these findings highlight important risk factors for maintaining unhealthy behaviors 
following a BC diagnosis, including lower education and income, lower dispositional optimism and social 
support, and the onset of CIPN during cancer treatment, suggesting a need for more efforts to promote 




3.6 TABLES AND FIGURES 





6 months  
(n=2874)  
24 months  
(n=2666) 
Variable n %   n % P1   n % P1 
Age           
<50 996 22%  536 19% <0.01  481 18% <0.01 
50-59 1316 29%  755 26%   690 26%  
60-70 1297 29%  926 32%   870 33%  
70+ 896 20%  657 23%   625 23%  
Race/ethnicity           
White 2894 64%  1996 69% <0.01  1818 68% <0.01 
Black 358 8%  173 6%   172 6%  
Asian 578 13%  337 12%   328 12%  
Hispanic 557 12%  301 10%   285 11%  
Other 118 3%  67 2%   63 2%  
Education           
HS or less 707 16%  410 14% <0.01  389 15% <0.01 
Some college 1568 35%  970 34%   886 33%  
College or above 2222 49%  1491 52%   1388 52%  
Household income          
<$50K 1949 43%  1259 44% <0.01  1166 44% 0.05 
$50K-$89K 2020 45%  1315 46%   1209 45%  
$90K+ 536 12%  300 10%   291 11%  
Menopausal status          
Premenopausal 1352 30%  755 26% <0.01  670 25% <0.01 
Postmenopausal 3153 70%  2119 74%   1996 75%  
Tumor stage           
I 2432 54%  1597 56% <0.01  1504 56% <0.01 
II 1561 35%  972 34%   904 34%  
III 439 10%  273 9%   238 9%  
IV 73 2%  32 1%   20 1%  
Number of positive nodes         
0 202 4%  125 4% 0.57  105 4% 0.09 
1 978 22%  613 21%   589 22%  
2+ 3325 74%  2136 74%   1972 74%  
HER2 positivity           
Negative 3726 86%  2382 86% 0.71  2225 87% 0.09 
Positive 590 14%  372 14%   330 13%  
ER/PR positivity           
Negative 751 17%  455 16% 0.05  404 15% <0.01 
Positive 3749 83%  2414 84%   2258 85%  
Surgery type           
Lumpectomy 2017 45%  1320 46% <0.01  1258 47% <0.01 
Mastectomy 2437 54%  1532 53%   1396 52%  
None 51 1%  22 1%   12 0%  
Received chemotherapy          
Yes 2145 48%  1323 46% <0.01  1199 45% <0.01 
No 2347 52%  1544 54%   1459 55%  
Received hormonal therapy         
Yes 3337 75%  2151 75% 0.14  2013 76% 0.01 
No 1135 25%  703 25%   637 24%  
Received radiation          




No 2531 56%  1579 55%   1444 54%  
Depressive symptom          
Low 3149 74%  2154 77% <0.01  1999 77% <0.01 
High 1127 26%  661 23%   590 23%  
Dispositional optimism          
Low 2945 69%  1908 68% 0.04  1766 68% 0.29 
High 1340 31%  912 32%   827 32%  
Perceived social support          
Low 1394 33%  914 32% 0.83  821 32% 0.14 
High 2890 67%  1906 68%   1771 68%  
Worse PWB at 6 months          
No - -  2101 77% -  1638 79% <0.01 
Yes - -  613 23%   438 21%  
Worse CIPN at 6 months          
No  - -  1350 66% -  1084 67% 0.06 
Yes - -   691 34%     529 33%   
Note           
Abbreviations: HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, progesterone receptor  
1. Chi-squared test compared the distribution of demographic, clinical and psychosocial characteristics between participants 
at baseline and follow-up 




Table 7. Results for group-based trajectory modelling 
       
Number of 
groups BIC AIC 
 Estimated probability for trajectory group (%) 
  1.0 2.0 3.0 4.0 5.0 6.0 
Change in fruit/vegetable intake       
1 -17759.5 -17744.6  100.0               
2 -16594.9 -16565.1  71.6 28.4            
3 (selected) -16211.8 -16167.1   46.6 41.2 12.2         
4 -16040.5 -15980.9  42.1 35.3 19.8 2.8      
5 -16013.8 -15939.3  17.6 34.7 41.4 3.8 2.5   
6 -15991.7 -15902.3  19.5 33.8 3.9 41.0 1.6 0.2 
Change in dietary fat intake        
1 -25501.4 -25489.5  100.0               
2 -24864.6 -24840.7  51.2 48.8            
3 -24631.4 -24595.6  27.3 60.2 12.5         
4 (selected) -24562.3 -24514.6   10.3 44.7 39.8 5.2      
5 -24554.3 -24494.7  2.2 23.2 45.9 25.1 3.5   
6 -24549.7 -24478.2  1.8 21.1 44.4 28.2 4.3 0.2 
Change in moderate to vigorous physical activity     
1 -23572.4 -23560.4  100.0               
2 -22551.3 -22527.3  85.8 14.2            
3 (selected) -22161.1 -22125.0   70.2 26.1 3.7         
4 -21968.5 -21920.5  66.3 28.2 5.1 0.4      
5 -21870.2 -21810.1  64.1 29.0 4.6 1.9 0.4   
6 -21827.9 -21755.9  27.4 60.4 5.1 5.4 1.4 0.3 
Change in sedentary behavior        
1 -26622.1 -26610.1  100.0               
2 -25892.3 -25868.3  62.6 37.4            
3 -25658.5 -25622.5  38.9 51.0 10.2         
4 (selected) -25612.6 -25564.6   27.8 46.9 22.0 3.2      
5 -25622.2 -25562.2  17.7 30.5 34.5 14.7 2.5   
6 -25615.9 -25543.9  17.3 30.6 0.2 34.7 14.8 2.5 
Change in alcohol intake        
1 -23153.0 -23141.0  100.0               
2 -21558.4 -21534.5  88.9 11.1            
3 (selected) -21026.9 -20991.2   78.8 16.4 4.8         
4 -20918.8 -20871.2  16.0 66.5 13.8 3.7      
5 -20668.7 -20609.1  15.0 63.4 14.7 6.0 0.9   
6 -20494.6 -20423.0   15.3 5.0 62.1 14.9 1.8 0.9 
Note          










Model 1: Unweighted GBTM  Model 2: Weighted GBTM  Model 3: KML  Cohen's kappa
1 
 











Change in fruit/vegetable intake 
High increase-stable 320 11.2%  High increase-stable 312 10.9%  High-stable 403 14.1%  0.99 - - 
Unweig
hted 
GBTM Medium increase-stable 1180 41.2%  Medium increase-stable 1171 41.0%  Medium-stable 1175 41.0%     
Low increase-stable 1365 47.6%  Low increase-stable 1372 48.1%  Low-stable 1287 44.9%     
Change in dietary fat 
High-stable 131 4.6%  High-stable 130 4.6%  High-stable 392 13.7%  0.99 0.69 0.69 
KML 
Medium high-stable 1142 39.9%  Medium high-stable 1153 40.4%  Medium high-stable 1002 35.0%     
Medium low-stable 1336 46.6%  Medium low-stable 1326 46.4%  Medium low-stable 992 34.6%     
Low-stable 256 8.9%  Low-stable 246 8.6%  Low-stable 479 16.7%     
Change in moderate to vigorous physical activity 
High decrease-temporary 111 3.7%  High decrease-temporary 111 3.7%  High decrease-temporary 219 7.3%  0.99 0.66 0.65 
KML 
Medium decrease-
temporary 753 25.1%  
Medium decrease-
temporary 739 24.7%  Medium decrease-temporary 1045 34.8%     
Low-stable 2131 71.2%  Low-stable 2136 71.5%  Low-stable 1736 57.9%     
Change in sedentary time 
High-stable 77 2.6%  High-stable 84 2.8%  High-stable 536 17.9%  0.98 - - 
KML 
Medium high-stable 635 21.2%  Medium high-stable 645 21.6%  Medium increase-stable 728 24.3%     
Medium low-stable 1495 50.0%  Medium low-stable 1481 49.7%  Medium decrease-stable 816 27.2%     
Low-stable 783 26.2%  Low-stable 771 25.9%  Low-stable 917 30.6%     
Change in alcohol intake 





temporary 459 16.0%  
Medium decrease-
temporary 461 16.1%  Medium decrease-temporary 527 18.4%     
Low-stable 2269 79.2%   Low-stable 2255 79.0%   Low-stable 2149 75.0%         
Note               
 
Abbreviations: GBTM, Group based trajectory modelling; KML, K-means for longitudinal data analysis       
 
1. Cohen's kappa measured agreement between group memberships identified from different analyses. A Cohen's kappa greater than 0.8 indicates concordance between two analyses. The Cohen's 
kappa was not computed when groups were not identical. 






Table 9. Mean changes in health behaviors by trajectory groups 
     
    Baseline    6 months  24 months 
Group n %   Mean (SD)   Mean (SD) Mean change (SD) P2   Mean (SD) Mean change (SD) P2 
Fruit/vegetable (servings/day)            
High increase-stable 320 11%  9.17 (3.13)  9.32 (3.17) 0.54 (0.17) <0.01  9.07 (3.19) 0.39 (0.18) 0.03 
Medium increase-stable 1180 41%  6.16 (2.23)  6.04 (2.13) 0.32 (0.07) <0.001  6.14 (2.37) 0.17 (0.06) 0.01 
Low increase-stable 1365 48%  3.31 (1.66)  3.23 (1.66) 0.33 (0.05) <0.001  3.48 (1.83) 0.15 (0.05) <0.01 
Dietary fat (grams/day)1             
High-stable 392 14%  46.52 (5.47)  46.6 (5.14) 0.03 (7.57) 1.00  46.56 (5.61) -0.09 (7.43) 1.00 
Medium high-stable 1002 35%  40.19 (3.94)  39.38 (4.03) -0.83 (6.46) <0.001  40.1 (4.09) 0.04 (6.5) 1.00 
Medium low-stable 992 35%  34.07 (3.65)  34.72 (3.77) 0.67 (5.98) <0.01  34.77 (4.14) 0.72 (6.08) 0.01 
Low-stable 479 17%  28.36 (4.34)  27.85 (4.17) -0.58 (5.74) 0.13  28.71 (4.66) 0.21 (6.32) 1.00 
Moderate to vigorous physical activity (hours/week)       
High decrease-temporary 219 7%  18.09 (7.18)  15 (6.4) -3.03 (8.99) <0.001  16.57 (6.41) -1.45 (8.56) 0.10 
Medium decrease-temporary 1045 35%  9.05 (3.58)  6.69 (3.54) -2.37 (5.4) <0.001  8.21 (3.55) -0.74 (5.49) <0.001 
Low-stable 1736 58%  2.73 (2.12)  2.26 (2.11) -0.49 (2.73) <0.001  2.85 (2.3) 0.04 (2.89) 1.00 
Sedentary behavior (hours/week)1            
High-stable 536 18%  27.94 (5.27)  26.58 (5.13) -1.36 (7.03) <0.001  26.46 (5.6) -1.55 (7.24) <0.001 
Medium increase-stable 728 24%  15.41 (3.47)  20.1 (4.05) 4.66 (4.55) <0.001  20.02 (4.46) 4.64 (5.34) <0.001 
Medium decrease-stable 816 27%  22.55 (3.64)  15.7 (4.14) -6.85 (5.23) <0.001  17.18 (4.31) -5.31 (5.6) <0.001 
Low-stable 917 31%  11.29 (4.2)  10.63 (3.94) -0.67 (5.46) <0.001  10.56 (4.03) -0.85 (5.85) <0.001 
Alcohol (grams/day)1             
High decrease-temporary 137 5%  41.43 (16.44)  34.36 (15.86) -6.95 (21.48) <0.001  39.18 (12.74) -1.23 (17.18) 1.00 
Medium decrease-temporary 459 16%  18.81 (8.86)  14.02 (8.72) -4.88 (12.86) <0.001  15.82 (8.43) -2.74 (12.85) <0.001 
Low-stable 2269 79%   1.95 (3.39)   1.38 (2.79) -0.57 (3.43) <0.001   1.68 (2.94) -0.36 (3.43) <0.001 
Note             
1. Changes in dietary fat, time spent on sedentary activities, and ethanol intake are reverse-coded so that higher value indicates positive change 
2. T-test examined whether the mean changes were statistically significantly different from 0 at 6 and 24 months.  For F/V, a linear regression tested the marginal change in F/V after adjusting for total 
energy intake. P-values were adjusted using Bonferroni correction to account for comparisons among multiple group within each behavior trajectory variable. 
3. Trajectory groups were labeled by the relative level of baseline behavior (high, medium, low), direction of change (increase or decrease), and the persistence of change (temporary or stable). 
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Table 10.  Multinomial logistic regression of socioeconomic status and health behavior change 
trajectory 
 
Predictors OR (95% CI) P   OR (95% CI) P   OR (95% CI) P 
 Fruit/vegetable intake trajectory groups (referent group=low increase-stable) 
 High increase-stable   Medium increase-stable     
Unadjusted         
Education  
(ref=high school or less)        
Some college 1.39 (0.88, 2.20) 0.16  1.73 (1.34, 2.24) <0.001    
College and above 3.49 (2.29, 5.31) <0.001  2.86 (2.23, 3.67) <0.001    
Income (ref=<$50K)         
$50K-$89K 1.57 (1.21, 2.04) <0.001  1.49 (1.26, 1.75) <0.001    
$90K+ 1.30 (0.86, 1.96) 0.22  0.94 (0.71, 1.24) 0.65    
Fully adjusted1         
Education  
(ref=high school or less)         
Some college 0.95 (0.55, 1.65) 0.87  1.24 (0.88, 1.75) 0.22    
College and above 2.74 (1.64, 4.57) <0.001  2.33 (1.67, 3.26) <0.001    
Income (ref=<$50K)         
$50K-$89K 1.07 (0.75, 1.53) 0.71  1.36 (1.07, 1.72) 0.01    
$90K+ 1.29 (0.76, 2.18) 0.34   0.80 (0.54, 1.18) 0.26       
 Dietary fat intake trajectory groups (referent group=low-stable) 
 High-stable   Medium high-stable   Medium low-stable 
Unadjusted         
Education  
(ref=high school or less)         
Some college 0.88 (0.58, 1.34) 0.55  0.84 (0.59, 1.19) 0.33  0.95 (0.66, 1.36) 0.78 
College and above 0.72 (0.48, 1.08) 0.11  0.80 (0.58, 1.12) 0.20  0.94 (0.67, 1.32) 0.73 
Income (ref=<$50K)         
$50K-$89K 1.28 (0.97, 1.69) 0.09  1.12 (0.89, 1.41) 0.33  1.16 (0.92, 1.46) 0.21 
$90K+ 0.91 (0.55, 1.48) 0.69  0.89 (0.61, 1.31) 0.56  1.36 (0.94, 1.96) 0.11 
Fully adjusted1         
Education  
(ref=high school or less)         
Some college 1.13 (0.65, 1.98) 0.66  1.01 (0.64, 1.61) 0.95  1.29 (0.80, 2.08) 0.30 
College and above 0.68 (0.39, 1.17) 0.17  0.75 (0.48, 1.17) 0.21  1.12 (0.71, 1.78) 0.62 
Income (ref=<$50K)         
$50K-$89K 1.31 (0.88, 1.94) 0.18  1.05 (0.76, 1.45) 0.77  1.10 (0.80, 1.52) 0.56 
$90K+ 0.91 (0.47, 1.77) 0.79   0.81 (0.48, 1.38) 0.45   1.36 (0.82, 2.25) 0.23 
 Moderate to vigorous physical activity trajectory groups (referent group=low-stable) 
 High decrease-temporary   Medium decrease-temporary     
Unadjusted         
Education  
(ref=high school or less)        
Some college 1.64 (0.99, 2.72) 0.06  1.59 (1.22, 2.07) <0.001    
College and above 2.28 (1.41, 3.69) <0.001  2.29 (1.78, 2.93) <0.001    
Income (ref=<$50K)         
$50K-$89K 1.92 (1.43, 2.59) <0.001  1.65 (1.40, 1.95) <0.001    
$90K+ 0.56 (0.29, 1.08) 0.08  0.94 (0.72, 1.24) 0.66    
Fully adjusted1         
Education  
(ref=high school or less)         
Some college 3.48 (1.45, 8.38) 0.01  1.63 (1.16, 2.3) <0.001    
College and above 4.36 (1.83, 10.35) <0.001  2.04 (1.46, 2.84) <0.001    
Income (ref=<$50K)         
$50K-$89K 1.48 (0.97, 2.25) 0.07  1.37 (1.09, 1.71) 0.01    
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$90K+ 0.97 (0.45, 2.09) 0.94   1.03 (0.71, 1.5) 0.87       
  Sedentary time trajectory groups (referent group=low-stable) 
 High-stable   Medium increase-stable   Medium decrease-stable 
Unadjusted         
Education  
(ref=high school or less)        
Some college 1.53 (1.07, 2.20) 0.02  1.08 (0.80, 1.47) 0.61  1.21 (0.90, 1.61) 0.20 
College and above 1.69 (1.20, 2.38) <0.001  1.20 (0.90, 1.60) 0.21  0.98 (0.75, 1.30) 0.91 
Income (ref=<$50K)         
$50K-$89K 0.70 (0.56, 0.88) <0.001  0.83 (0.68, 1.02) 0.07  0.84 (0.69, 1.03) 0.10 
$90K+ 0.75 (0.52, 1.10) 0.14  0.80 (0.57, 1.14) 0.22  1.09 (0.79, 1.50) 0.58 
Fully adjusted1         
Education  
(ref=high school or less)         
Some college 1.41 (0.87, 2.29) 0.17  1.13 (0.75, 1.71) 0.55  1.22 (0.82, 1.81) 0.33 
College and above 1.83 (1.15, 2.93) 0.01  1.04 (0.70, 1.56) 0.85  1.02 (0.70, 1.51) 0.90 
Income (ref=<$50K)         
$50K-$89K 0.66 (0.48, 0.91) 0.01  0.85 (0.64, 1.14) 0.28  1.02 (0.76, 1.35) 0.92 
$90K+ 0.64 (0.38, 1.09) 0.10   0.93 (0.58, 1.48) 0.76   1.14 (0.73, 1.78) 0.56 
 Alcohol intake trajectory groups (referent group=low-stable) 
 High decrease-temporary   Medium decrease-temporary     
Unadjusted         
Education  
(ref=high school or less)         
Some college 1.76 (0.92, 3.36) 0.09  1.60 (1.09, 2.34) 0.02    
College and above 2.02 (1.09, 3.75) 0.03  2.33 (1.63, 3.34) <0.001    
Income (ref=<$50K)         
$50K-$89K 2.23 (1.53, 3.26) <0.001  1.66 (1.34, 2.05) <0.001    
$90K+ 0.81 (0.38, 1.76) 0.60  0.90 (0.61, 1.33) 0.59    
Fully adjusted1         
Education  
(ref=high school or less)         
Some college     0.63 (0.30, 1.32) 0.22      1.51 (0.91, 2.5) 0.11    
College and above     0.79 (0.40, 1.6) 0.52      2.21 (1.35, 3.6) <0.001    
Income (ref=<$50K)         
$50K-$89K     2.54 (1.49, 4.34) <0.001      1.64 (1.21, 2.21) <0.001    
$90K+     0.18 (0.02, 1.33) 0.09       0.84 (0.50, 1.43) 0.53       
Note         
Abbreviations: OR, odds ratio; CI, confidence interval 
1. Fully adjusted model controlled for age, race, menopausal status, tumor stage, number of positive nodes, receipt of surgery, 
chemotherapy, hormonal therapy, and radiation therapy 
2. Trajectory groups were labeled by the relative level of baseline behavior (high, medium, low), direction of change (increase or 
decrease), and the persistence of change (temporary or stable). 
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Table 11.  Multinomial logistic regression of stress coping and health behavior change trajectory 
   
Predictors OR (95% CI) P   OR (95% CI) P   OR (95% CI) P 
 Fruit/vegetable intake trajectory groups (referent group=low increase-stable) 
 High increase-stable   Medium increase-stable     
Unadjusted         
Depressive symptoms (high vs. low) 0.55 (0.40, 0.75) <0.001  0.68 (0.56, 0.81) <0.001    
Optimism (high vs. low) 2.01 (1.56, 2.58) <0.001  1.30 (1.10, 1.54) <0.01    
Social support (high vs. low) 2.13 (1.59, 2.86) <0.001  1.24 (1.05, 1.46) 0.01    
Fully adjusted1         
Depressive symptoms (high vs. low) 0.78 (0.51, 1.18) 0.24  0.84 (0.65, 1.09) 0.18    
Optimism (high vs. low) 1.83 (1.31, 2.54) <0.001  1.50 (1.19, 1.89) <0.001    
Social support (high vs. low) 1.82 (1.25, 2.65) <0.01   1.08 (0.86, 1.36) 0.51       
 Dietary fat intake trajectory groups (referent group=low-stable) 
 High-stable   Medium high-stable   Medium low-stable 
Unadjusted         
Depressive symptoms (high vs. low) 0.99 (0.71, 1.38) 0.96  1.23 (0.94, 1.60) 0.13  1.28 (0.98, 1.67) 0.07 
Optimism (high vs. low) 1.18 (0.89, 1.56) 0.26  0.92 (0.73, 1.17) 0.50  1.08 (0.86, 1.37) 0.51 
Social support (high vs. low) 0.84 (0.63, 1.12) 0.23  0.91 (0.72, 1.15) 0.43  0.90 (0.71, 1.14) 0.39 
Fully adjusted1         
Depressive symptoms (high vs. low) 1.09 (0.69, 1.70) 0.72  1.08 (0.75, 1.56) 0.67  1.20 (0.83, 1.73) 0.33 
Optimism (high vs. low) 1.36 (0.93, 1.98) 0.11  0.79 (0.58, 1.08) 0.14  1.22 (0.89, 1.66) 0.22 
Social support (high vs. low) 0.80 (0.54, 1.18) 0.26   1.01 (0.74, 1.39) 0.94   0.95 (0.69, 1.31) 0.75 
 Moderate to vigorous physical activity trajectory groups (referent group=low-stable) 
 High decrease-temporary   Medium decrease-temporary     
Unadjusted         
Depressive symptoms (high vs. low) 0.99 (0.71, 1.38) 0.95  0.82 (0.68, 0.98) 0.03    
Optimism (high vs. low) 1.96 (1.47, 2.62) <0.001  1.59 (1.35, 1.88) <0.001    
Social support (high vs. low) 1.56 (1.13, 2.15) 0.01  1.46 (1.23, 1.72) <0.001    
Fully adjusted1         
Depressive symptoms (high vs. low) 1.24 (0.79, 1.95) 0.34  0.95 (0.74, 1.23) 0.71    
Optimism (high vs. low) 1.85 (1.25, 2.75) <0.001  1.61 (1.29, 2.00) <0.001    
Social support (high vs. low) 1.23 (0.80, 1.89) 0.34   1.33 (1.06, 1.67) 0.02    
  Sedentary time trajectory groups (referent group=low-stable) 
 High-stable   Medium increase-stable   Medium decrease-stable 
Unadjusted         
Depressive symptoms (high vs. low) 0.73 (0.56, 0.96) 0.02  1.07 (0.85, 1.34) 0.56  0.97 (0.77, 1.21) 0.78 
Optimism (high vs. low) 1.57 (1.25, 1.97) <0.001  1.20 (0.97, 1.48) 0.09  1.16 (0.94, 1.42) 0.17 
Social support (high vs. low) 1.68 (1.32, 2.13) <0.001  1.16 (0.94, 1.42) 0.16  1.29 (1.05, 1.58) 0.01 
Fully adjusted1         
Depressive symptoms (high vs. low) 1.00 (0.69, 1.45) 0.99  1.19 (0.86, 1.63) 0.29  1.23 (0.91, 1.68) 0.18 
Optimism (high vs. low) 1.31 (0.96, 1.78) 0.09  1.09 (0.81, 1.45) 0.57  1.16 (0.88, 1.52) 0.30 
Social support (high vs. low) 1.86 (1.34, 2.57) <0.001   1.25 (0.94, 1.66) 0.12   1.42 (1.08, 1.87) 0.01 
 Alcohol intake trajectory groups (referent group=low-stable) 
 High decrease-temporary   Medium decrease-temporary     
Unadjusted         
Depressive symptoms (high vs. low) 0.81 (0.53, 1.25) 0.35  0.81 (0.63, 1.04) 0.10    
Optimism (high vs. low) 1.58 (1.12, 2.25) 0.01  1.17 (0.95, 1.45) 0.14    
Social support (high vs. low) 1.44 (0.97, 2.13) 0.07  1.26 (1.00, 1.57) 0.05    
Fully adjusted1         
Depressive symptoms (high vs. low)     1.26 (0.72, 2.21) 0.41      0.90 (0.64, 1.28) 0.57    
Optimism (high vs. low)     1.17 (0.71, 1.91) 0.54      1.04 (0.78, 1.38) 0.79    
Social support (high vs. low)     1.07 (0.64, 1.79) 0.80       1.26 (0.93, 1.71) 0.14       
Note         
Abbreviations: F/V, fruit/vegetable; CIPN, chemotherapy-induced peripheral neuropathy; OR, odds ratio; CI, confidence interval 
1. Fully adjusted model controlled for age, race, menopausal status, tumor stage, number of positive nodes, receipt of surgery,  
chemotherapy, hormonal therapy, and radiation therapy 
2. Trajectory groups were labeled by the relative level of baseline behavior (high, medium, low), direction of change (increase or decrease),  
and the persistence of change (temporary or stable) 
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Table 12.  Multinomial logistic regression of cancer treatment side effect and health behavior 
change trajectory 
 
Predictors OR (95% CI) P   OR (95% CI) P   OR (95% CI) P 
 Fruit/vegetable intake trajectory groups (referent group=low increase-stable) 
 High increase-stable   Medium increase-stable     
Unadjusted         
Worse PWB at 6 months (yes vs. no) 0.84 (0.61, 1.14) 0.26  0.82 (0.67, 1.00) 0.04    
Worse CIPN at 6 months (yes vs. no) 0.73 (0.53, 1.01) 0.06  1.06 (0.87, 1.30) 0.55    
Fully adjusted1         
Worse PWB at 6 months (yes vs. no) 1.00 (0.68, 1.49) 0.99  0.82 (0.63, 1.06) 0.13    
Worse CIPN at 6 months (yes vs. no) 0.82 (0.56, 1.19) 0.30   1.27 (1.00, 1.61) 0.05       
 Dietary fat intake trajectory groups (referent group=low-stable) 
 High-stable   Medium high-stable   Medium low-stable 
Unadjusted         
Worse PWB at 6 months (yes vs. no) 1.18 (0.84, 1.66) 0.34  1.22 (0.92, 1.62) 0.16  1.10 (0.83, 1.47) 0.50 
Worse CIPN at 6 months(yes vs. no) 1.46 (1.03, 2.08) 0.04  1.57 (1.17, 2.10) <0.01  1.36 (1.01, 1.82) 0.04 
Fully adjusted1         
Worse PWB at 6 months (yes vs. no) 0.88 (0.57, 1.37) 0.58  1.01 (0.71, 1.44) 0.96  0.86 (0.60, 1.24) 0.42 
Worse CIPN at 6 months(yes vs. no) 1.46 (0.97, 2.18) 0.07   1.48 (1.06, 2.06) 0.02   1.39 (1.00, 1.95) 0.05 
 Moderate to vigorous physical activity trajectory groups (referent group=low-stable) 
 High decrease-temporary   Medium decrease-temporary     
Unadjusted         
Worse PWB at 6 months (yes vs. no) 0.86 (0.59, 1.24) 0.42  0.95 (0.78, 1.15) 0.60    
Worse CIPN at 6 months(yes vs. no) 0.78 (0.54, 1.12) 0.18  0.80 (0.66, 0.98) 0.03    
Fully adjusted1         
Worse PWB at 6 months (yes vs. no) 0.97 (0.61, 1.56) 0.91  1.03 (0.80, 1.32) 0.83    
Worse CIPN at 6 months(yes vs. no) 0.92 (0.60, 1.4) 0.69   0.84 (0.67, 1.06) 0.14       
  Sedentary time trajectory groups (referent group=low-stable) 
 High-stable   Medium increase-stable   Medium decrease-stable 
Unadjusted         
Worse PWB at 6 months (yes vs. no) 0.99 (0.75, 1.30) 0.93  1.09 (0.86, 1.40) 0.48  0.98 (0.77, 1.24) 0.84 
Worse CIPN at 6 months(yes vs. no) 1.14 (0.86, 1.50) 0.36  1.42 (1.10, 1.83) 0.01  1.24 (0.97, 1.59) 0.09 
Fully adjusted1         
Worse PWB at 6 months (yes vs. no) 1.13 (0.79, 1.61) 0.52  1.13 (0.82, 1.56) 0.45  1.08 (0.79, 1.47) 0.63 
Worse CIPN at 6 months(yes vs. no) 1.21 (0.87, 1.67) 0.26   1.30 (0.97, 1.74) 0.08   1.15 (0.87, 1.53) 0.32 
 Alcohol intake trajectory groups (referent group=low-stable) 
 High decrease-temporary   Medium decrease-temporary     
Unadjusted         
Worse PWB at 6 months (yes vs. no) 0.73 (0.46, 1.15) 0.18  0.74 (0.56, 0.96) 0.02    
Worse CIPN at 6 months(yes vs. no) 0.94 (0.60, 1.46) 0.77  0.72 (0.55, 0.94) 0.01    
Fully adjusted1         
Worse PWB at 6 months (yes vs. no) 1.03 (0.58, 1.86) 0.91  0.85 (0.60, 1.20) 0.36    
Worse CIPN at 6 months(yes vs. no) 1.13 (0.67, 1.88) 0.65  0.91 (0.68, 1.24) 0.56       
Note         
Abbreviations: PWB, physical wellbeing; CIPN, chemotherapy-induced peripheral neuropathy; OR, odds ratio; CI, confidence interval 
1. Fully adjusted model controlled for age, race, menopausal status, tumor stage, number of positive nodes, receipt of surgery, chemotherapy, 
hormonal therapy, and radiation therapy 
2. Trajectory groups were labeled by the relative level of baseline behavior (high, medium, low), direction of change (increase or decrease), and the 
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Figure 65. Trajectories of health behavior after a breast cancer diagnosis among the Pathways 
Study participants. This figure shows the individual trajectories (left panel) and group mean 
trajetories (right panel) of behavioral change during the first 24 months  following a BC diagnosis.   
 
 
Figure 66. Trajectories of health behavior after a breast cancer diagnosis among the Pathways 
Study participants. This figure shows the individual trajectories (left panel) and group mean 







Figure 81. Trajectories of health behavior after a breast cancer diagnosis among the Pathways 
Study participants. This figure displays the fully adjusted odds ratios of following each trajectory of 
post-diagnosis behavioral change under the complete case analysis (solid line) and that under the 
multiple imputations (dash lines). The two analyses yielded similar associations of behavioral change 
trajectories with socioeconomic status, stress and coping, and cancer treatment related side effects. 
 
 
Figure 82. Trajectories of health behavior after a breast cancer diagnosis among the Pathways 
Study participants. This figure displays the fully adjusted odds ratios of following each trajectory of 
post-diagnosis behavioral change under the complete case analysis (solid line) and that under the 
multiple imputations (dash lines). The two analyses yielded similar associations of behavioral change 





CHAPTER 4: IDENTIFYING DISTINCT TRAJECTORIES AND PREDICTORS OF BMI AFTER A 
BREAST CANCER DIAGNOSIS 
 
4.1 ABSTRACT 
Background: Body mass index (BMI) has been associated with breast cancer outcomes, yet the 
distribution of BMI change patterns and predictors of BMI trajectories have not been assessed in breast 
cancer (BC) survivors. This analysis aimed to 1) identify distinct trajectories of BMI in a population-based 
cohort study of female BC survivors over the first 24 months after diagnosis, and 2) identify specific health 
behavior trajectories that were associated with BMI trajectories. 
Methods: Data on self-reported body weight and height were collected from the 4,505 women enrolled in 
the Pathways Study at baseline (n with BMI data=4,479), 6 months (n=2,773) and 24 months (n=2,058) 
follow-up. BMI at baseline and each follow-up were analyzed using two methods, including semi-
parametric, group-based trajectory modeling and non-parametric K-means for longitudinal data analysis. 
Multinomial logistic regression was used to examine predictors of BMI trajectories. 
Results: Trajectory analyses identified three distinct BMI trajectories over the 24 month period: the 
majority (56%) of women maintained a healthy weight [baseline mean±SD=23.5±2.5 kg/m2, median=23.5 
kg/m2, inter-quartile range (IQR)=3.7 kg/m2], 36% of women remained overweight/obese (baseline 
mean±SD=31.3±3.0 kg/m2, median=30.8 kg/m2, IQR=4.3 kg/m2), and 8% women were severely obese 
(baseline mean±SD=42.4±5.0 kg/m2, median=40.8 kg/m2, IQR=5.9 kg/m2). There was very little change in 
BMI over the two-year period.  Women who maintain a high level of F/V (high increase-stable: OR=0.41, 
95% CI: 0.19-0.89; medium increase-stable group: OR=0.61, 95% CI: 0.40-0.94), high level of MVPA 
(high decrease-temporary group: OR=0.26, 95% CI: 0.10-0.63; medium decrease-temporary group: 
OR=0.24, 95% CI: 0.15-0.39), and high level of alcohol intake (high decrease-temporary group: OR=0.16, 
95% CI: 0.04-0.70; medium decrease-temporary group: OR=0.36, 95% CI: 0.19-0.68) were less likely to 
remained overweight/obese as compared to maintaining a healthy weight. Conversely, maintaining a high 
dietary fat intake (high-stable group: OR=2.24, 95% CI: 1.09-4.58) and high level of sedentary behavior 
(high-stable group: OR=2.43, 95% CI: 1.39-4.26) were associated with membership in the severely obese 
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trajectory group.  Similarly, higher level of F/V, MVPA, and alcohol intake, but lower dietary fat intake and 
sedentary behavior were associated with the membership in the overweight/obese trajectory group.  
Conclusion: Three distinct BMI trajectories were identified over the 24 months following a breast cancer 
diagnosis.  BMI trajectories were stable over time and were based upon BMI at baseline.  Trajectories of 
diet, physical activity and alcohol intake were strongly associated with memberships in the 
overweight/obese and severely obese trajectory group, independent of clinical factors and cancer 
treatment.  These data suggest that women who kept an unhealthy lifestyle after a BC diagnosis are 




Overweight and obesity at the time of breast cancer diagnosis have been associated with worse 
survival.2,111,270,271 A growing number of studies have also observed an association of weight gain 
following a breast cancer diagnosis with a higher risk of recurrence and mortality,2,113,272 while other 
studies have reported that weight loss after breast cancer diagnosis is associated with the greatest 
mortality risk.111,273  Weight gain is a common and persistent problem for many BC survivors, both during 
treatment and in the months and years after diagnosis.27 Weight gain is also known to impact negatively 
on the quality of life and to increase the risk of developing comorbid conditions.28-30 Furthermore, 
unfavorable changes in body composition including fat gain and loss of lean tissue , which is known as 
sarcopenic obesity,31,32 may further exacerbate the problem of weight gain and combined with gains in 
adipose tissue, may lead to metabolic disturbance, treatment complications, and poor survival 
outcomes.31-34 Despite these findings, the typical trajectories and predictors of post-diagnosis BMI have 
not been described. 
Although data are accumulating on the adverse prognostic effects of weight gain and sarcopenic 
obesity, the underlying behavior determinants of these changes in the post-diagnosis period are not well 
understood. Previous studies have evaluated diet and exercise patterns after diagnosis and possible 
treatment-related reductions in resting energy expenditure.31,32,35 However, the extent to which these 
individual components of energy balance contribute to weight change is not yet clear. Poorer diet has 
been implicated in weight gain among breast cancer survivors, but there are significant gaps in 
knowledge, and the limited reports on this issue have important methodological limitations.  
The majority of previous studies have considered weight gain as a result of breast cancer 
treatment regimens, most notably chemotherapy and hormonal therapy.26,27,164,165 Behavior changes that 
cause energy imbalance may also contribute to the weight change after a breast cancer diagnosis. 
However, whether post-diagnosis weight change is caused by changes in behavior change after 
diagnosis has not been tested. To date, most studies of weight change in BC survivors defined weight 
gain and weight loss based on the percent change in body weight between two time points, thus ignoring 
the fluctuation in body weight over multiple assessments. Therefore, fluctuation of body weight and its 
associations with changes in energy balance-related behaviors after diagnosis remain largely 
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unexamined. For instance, weight cycling, also known as “yo-yo” dieting, refers to the repeated periods of 
weight loss followed by regaining.274,275 Weight cycling occurs as a result of initial success in weight loss 
through modified diet and physical activity, and subsequent weight regain after reversion into prior 
behavior patterns. Approximately 20-55% women experience weight cycling,276-278 and some 
observational studies have linked weight cycling with increased all-cause mortality and mortality from 
cardiovascular disease.275,279-281 As a result, weight cycling may explain the increased risk of mortality in 
breast cancer survivors.271 However, the prevalence of weight cycling and its relationship with changes in 
health behaviors have not been studied in breast cancer survivors. 
In this chapter, my goals are to identify the distinctive trajectories of BMI after a breast cancer 
diagnosis and identify the specific changes in health behaviors that are associated with each type of BMI 
trajectory. Based on previous studies, I hypothesize that women will follow five different trajectories of 
BMI after a breast cancer diagnosis, which include: 1) maintaining a high weight, 2) losing weight 
persistently, 3) losing weight temporarily, also known as weight cycling, 4) gaining weight persistently, 5) 
gaining weight temporarily (weight cycling), and 6) maintaining a low weight. The analysis also tests the 
hypotheses that stable improvement in health behaviors is associated with persistent weight loss, and 
that stable decline in health behaviors is associated with weight gain, and temporary improvement in 
health behavior is associated with weight cycling. 
 
4.3 METHODS 
4.3.1 Study participants 
The study used data from the Pathways Study,36 a population-based prospective cohort of 
women newly diagnosed with invasive breast cancer within the Kaiser Permanente Northern California 
(KPNC) network from January 2006 to April 2013. Women who were at least 21 years of age at diagnosis 
and a current KP member, had a recent diagnosis of invasive breast cancer, had no previous history of 
malignant cancer, spoke English, Spanish, Cantonese, or Mandarin, and lived within a 65-mile radius of a 
field interviewer were eligible for recruitment. The Pathways Study recruited women from the KPNC 
patient population immediately after a breast cancer diagnosis though rapid case ascertainment. Most 
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participants were recruited within two months (mean time = 1.8 months, range = 0.3-7.2 months) post-
diagnosis. Baseline demographic and lifestyle data were collected during an in-person interview. During 
the follow-up period, lifestyle data were collected at 6, 24, and 72 months via mailed questionnaires, and 
breast cancer outcomes were identified via telephone interviews every 12 months after baseline and 
confirmed using KPNC electronic databases. The study protocol was approved by the institutional review 
board of all collaborating institutions. Written informed consent was obtained from all participating 
subjects.  A total of 11,233 potentially eligible women were invited to participate in the study, and 4,505 
enrolled.  
4.3.2 Baseline and follow-up data collection 
Interviewers administered detailed questionnaires on diet, exercise, and psychosocial and quality-
of-life measures during the baseline interview. The interviewers also collected anthropometric measures, 
including arm, waist, and hip measurements, and a saliva sample. Blood samples were collected during 
the baseline interview by the interviewer, at KPNC, or at home by an outside vendor (Examination 
Management Services, Inc. Irving, TX). Clinical and tumor characteristics were obtained from the KPNC 
Cancer Registry approximately four months post-diagnosis. At 6 and 24 months, follow-up 
questionnaires, phone interview, and web survey were used to update the lifestyle information, with 
interviewer assistance offered if needed.  
4.3.3 Measurement of health behaviors 
Physical activity 
Baseline physical activity data were collected using the Arizona Activity Frequency 
Questionnaire,186 which assesses frequency and duration of daily household, recreational, transportation, 
and sedentary activities. This set of analyses use data specific to time spent on moderate-to-vigorous 
physical activities (MVPA) and sedentary activities.  Moderate physical activity refers to activities 
equivalent in intensity to brisk walking or bicycling (3-6 METs). Vigorous physical activity produces large 
increases in breathing or heart rate, such as jogging, aerobic dance or bicycling uphill (>6 METs). For the 
purposes of this analysis, MVPA was defined as time spent on activities of ≥3 METs. Sedentary activity 
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included sitting during commuting, in the workplace, in the domestic environment, and during leisure time. 
Typical sedentary behaviors include TV viewing, computer use, or sitting in an automobile (1-1.5 METs).  
Diet 
Dietary history was collected using a 139-item modified version of the Block 2005 FFQ 
(NutritionQuest, Berkeley, CA). The FFQ included food items selected by identifying the top population 
contributors of each nutrient among whites, African Americans and Hispanics in the National Health and 
Nutrition Examination Survey (1999–2002). The 139 food items and additional questions were selected to 
be representative of a wide range of dietary factors, as well as to capture foods that are popular in 
Hispanic and Asian populations. The primary dietary variables include intakes of fruit/vegetable (F/V), 
dietary fat, dietary fibers, meat, total calories, and alcohol intakes. The FFQ assessed a number of 
vegetable groups, including daily intake of dark-green vegetables, deep-yellow vegetables, tomatoes, 
white potatoes, fried potatoes, legumes, other starchy vegetables, avocado and similar, and other 
vegetables (in cups). Fruit groups included citrus fruit and fruit excluding citrus fruit (in cups). Dietary fat 
intakes included daily intake of total fat, saturated fat, monounsaturated fatty acids, polyunsaturated fatty 
acids, and trans-fats (in grams). The percent energy from fat was used as the analytical variable for 
trajectory analysis. Alcohol intake was measured by the FFQ and converted into daily ethanol intake (in 
grams). 
4.3.4 Key variables 
Body weight 
Body weight (kg) and height (m) were assessed at baseline and each follow-up via self-reported 
weight and height data from the Pathways Study participants. Weight and height were used to calculate 
body mass index (BMI) using the formula:  
BMI = Weight (kg) / Height (m) 2 
Other variables 
The sociodemographic, clinical, psychosocial characteristics and cancer treatment side effect 
variables were described in Chapter 3. Briefly, the Pathways Study collected data on sociodemographic 
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factors included age at diagnosis, race/ethnicity, education, and household income at interview. Data on 
clinical and breast cancer characteristics were collected from the KPNC cancer registry and EHR. The 
analysis also included measures of stress and coping and measures of cancer treatment side effects, 
such as physical well-being (PWB) and chemotherapy-induced peripheral neuropathy (CIPN).197  
4.3.5 Statistical analysis 
  The primary goal of this study was to identify latent groups of BMI trajectories after a breast 
cancer diagnosis and to examine the associations between specific behaviors (F/V, dietary fat, MVPA, 
sedentary behavior, and alcohol intake) and weight change trajectories. BMI trajectory groups were 
identified using the same methodology as described in Chapter 3. Briefly, the study started with the main 
analysis using group-based trajectory modeling (GBTM) procedure,39 and then performed a sensitivity 
analysis by applying the inverse probability weight (IPW)206 of remaining at 24 months to the main GBTM. 
The selected model was then validated using the K-means for longitudinal data (KmL)40  method. These 
analytical steps are described below and shown in Figure 7. 
Analytical variables: The outcome variable was BMI at baseline, 6 and 24 month follow-up.  
Main analyses: The study first used the GBTM procedure proposed by Nagin 39 to identify the 
optimal number of BMI trajectories that best fit the observed data. The analysis was restricted to 
participants with at least two out of three non-missing BMI data from baseline to the 24 months follow-up. 
Under the assumption that the outcome variable followed a normal distribution, a single-group model 
saturated with quadratic parameters was tested initially, and then one additional group was included in 
successive models. The study hypothesized that five distinct trajectories would be identified, and 
therefore tested models composed of one to six trajectory groups to find the optimal number of 
trajectories. Model fit was assessed based on the Bayesian Information Criterion (BIC), whereby the 
model with the lower BIC was favored. Once the number of groups was determined, participants were 
assigned to the trajectory group that best corresponded to their observed weight change according to the 
maximum posterior probability of group membership. The final model was selected based on parsimony, 
interpretability and prior knowledge of common behavior patterns in BC survivors.208,209  
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Sensitivity analysis: To evaluate the influence of loss to follow-up on the identification of trajectory 
groups, a sensitivity analysis was performed by applying the IPW at 24 months to the main GBTM. To 
calculate the IPW, the probability of loss to follow-up at the 24-month wave was estimated in a logistic 
regression with baseline demographic and clinical characteristics as independent variables. Women who 
had interim missing data at 6 months but not 24 months (n=467) were not considered lost to follow-up 
and therefore were included in the analysis. Baseline demographic characteristics (age, race, education, 
and household income), tumor characteristics (tumor stage, size, grade, hormonal receptor status, and 
number of positive nodes), and treatment received (surgery, chemotherapy, hormonal therapy, and 
radiation) that were empirically associated with loss to follow-up at 24 months were included to impute 
IPW. The IPW was calculated as the reciprocal of the probability of remaining in follow-up at 24 months.  
Validation analysis: To verify the efficiency and success of the GBTM, the study performed a 
validation analysis to identify the BMI trajectory groups using the KmL, which is a fully non-parametric 
method.40 The KmL is a robust classification algorithm based on the Expectation-Maximization (EM) 
method.211 The KmL starts by assigning each observation to a random cluster, then uses the EM 
algorithm to alternate between 1) computing the center of each cluster (the Expectation phase), and 2) 
assigning each observation to its nearest cluster based on its distance to the cluster center (the 
Maximization phase). The EM algorithm repeats these two phases until cluster assignments become 
stable. Because there are no absolute criteria for an optimal number of clusters in KmL, the optimal 
number of cluster identified through GBTM will be used to verify if KmL produces similar trajectory groups.  
Final model selection: The best trajectory group membership was identified through a series of 
pairwise comparisons among the above trajectory analyses. First, when the main GBTM and the IPW-
weighted sensitivity analysis generated identical categories of trajectory groups, agreement between the 
two sets of group membership was measured using the Cohen’s kappa,212 which is a common measure 
of agreement between two classifications of category a finite number of subjects belong to while 
accounting for agreement due to chance. A Cohen’s kappa >0.8 indicates good agreement between the 
two sets of group membership. If the two trajectory groups were of good agreement, the unweighted 
GBTM result was retained since the loss to follow-up had little impact on the identification of trajectory of 
BMI. Otherwise, if the two trajectory groups identified different trajectory groups or were of poor 
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agreement (Cohen’s kappa ≤0.8), results from the IPW-weighted GBTM were favored. In the second step, 
the optimal group memberships derived from GBTM were then compared with that identified via KmL 
using Cohen’s kappa. If the two trajectory analyses produced concordant group memberships (Cohen’s 
kappa >0.8), results from the GBTM were retained; otherwise, results from the KmL were considered a 
better fit. 
To investigate the associations of behavior trajectory and BMI trajectory, we first tested the 
difference in percent weight change between different behavior trajectory groups using the Z-test and 
linear regression and then tested if group membership of BMI was associated with behavior trajectory 
group membership using the chi-squared test and logistic regression. Baseline demographic (age, 
race/ethnicity, education, household income), clinical (menopausal status, tumor stage, number of 
positive nodes, HER2 status, EP/PR status, CIPN), cancer treatment received (surgery, chemotherapy, 
hormonal therapy, and radiation, physical wellbeing), and psychosocial factors (depressive symptom, 
dispositional optimism, and perceived social support) associated with 1) any health behavior change 
trajectories, 2) BMI trajectory and 3) modified any beta coefficients for the association of behavior and 
BMI trajectory by ≥10% were considered as potential confounders. Confounders were entered 
simultaneously into a multivariable multinomial logistic regression model with all behavior trajectory 
variables to assess their associations with the BMI trajectory group membership.  
Cancer treatments, such as chemotherapy and hormonal therapy, that are known to influence 
body weight changes among BC survivors26,27,164,165 but did not met the criteria as a potential confounder 
based on the above criteria were additionally adjusted in a sensitivity analysis. In analyzing the 
association of F/V and BMI trajectories, sensitivity analyses were conducted to evaluate the influence of 
total energy intake and change in total energy intake by additionally adjusting for total energy intake at 
baseline and 24 months, and change in total energy intake from baseline to 24 months, respectively.  
Additionally, a sensitivity analysis was conducted to compare the association of F/V intake and BMI 
trajectories with and without adjustment of dietary fat intake trajectory, as changes in percent energy from 
dietary fat may be determined by changes in F/V intake. Similarly, a sensitivity analysis tested the 
association of dietary fat trajectory and BMI trajectory without adjustment of F/V trajectory to evaluate the 
potential mediation effect of F/V. Because the “low-stable” or “low increase-stable” groups of 
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behavior/BMI trajectories was commonly observed for all health behaviors, it was used as the referent 
group in multinomial logistic regression analyses for consistency in reporting results. 
Missing data in health behavior and covariates were addressed in multiple steps throughout the 
analyses. In the trajectory identification stage, participants who had at least two assessments of body 
weight. GBTM used Full Information Maximum Likelihood (FIML) method to fill in missing behavior data 
under the assumption that data were missing at random. The KmL analysis used an innovative imputation 
method known as “copy mean”, which estimated the intermittent missing value of longitudinal data by 
treating the last observed value before each missing data as a starting value, and refined the imputation 
by finding the value that gives the imputed trajectory the same shape as the population mean 
trajectory.213 The “copy mean” method has been shown to be robust under various missing data 
mechanisms and is considered superior over traditional imputation methods.213 In analyses of the 
association of hypothesized predictors with behavior trajectory, only participants with complete covariate 
data and known group membership were included in the main analysis. However, the study performed a 
sensitivity analysis to examine how missing data influenced the observed association by filling missing 
covariate and outcome data using multiple imputations.207 Logistic regression based on 10 imputed 
datasets were then pooled to estimate the beta coefficients and 95% confidence interval using Rubin’s 
methods.207 Briefly, beta coefficients estimated in each of the ten data sets were averaged to calculate 
the pooled beta coefficient; the pooled confidence interval was estimated as a function of variance within 
each imputed dataset and between-imputation variance. The analytical workflow is shown in Figure 8. 
The GBTM was performed using the PROC TRAJ command in SAS.214 The KmL was 
implemented in R using the ‘’kml” package.215 Multiple imputations of missing data in baseline 
characteristics and trajectory group membership was conducted using the R “mi” package.216 
 
4.4 RESULTS 
4.4.1 Participant characteristics 
The demographic, clinical and psychosocial characteristics of the 4,505 Pathways Study 
participants were reported in Chapter 3 (Table 6).  Briefly, participants were diagnosed with BC at the age 
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of 59 years (standard deviation (SD) =12) and were enrolled within 2 months post-diagnosis (SD=0.8 
months). The majority of women were white, received at least some college education, earned more than 
$50,000 a year, and were postmenopausal. Most women were diagnosed with stage I-III breast cancer 
with tumors that were negative for human epidermal growth factor receptor 2 (HER2) and positive for 
estrogen receptor (ER) and/or progesterone receptor (PR). Almost all women underwent surgery, and 
48% women were treated with chemotherapy, 75% with hormonal therapy, and 44% with radiation. A total 
of 2,874 (63.8%) participants responded to 6-month follow-up questionnaires, and 2666 (59.2%) 
responded to the 24-month follow-up. Factors associated with loss to follow-up included age, race, 
education, income, tumor stage, receipt of breast surgery and chemotherapy at baseline as significant 
indicators of loss to follow-up, which were used to estimate the inverse probability weight for providing 
follow up data. 
4.4.2 Identification of BMI trajectory groups 
 The analysis used GBTM to test models with one to six trajectories of BMI using data from 
baseline (n with BMI data=4479), 6 months (n=2773) and 24 months (n=2058). A total of 2,955 (65.6%) 
women who had at least two non-missing BMI data points over the first three waves of follow-up were 
included to identify weight trajectory groups. The distributions of BMI at each assessment were close to 
following a normal distribution. Table 13 shows the model fit statistics and estimated group distribution for 
models with one to six trajectories. Although the model with six trajectories yielded the lowest BIC value, 
the trajectory group solutions did not identify unique trajectory groups with unique change patterns or 
adequate group sizes. A three-group model that clearly distinguished women who maintained high, 
medium, and low BMI over the observation period was selected over the model with four or more 
trajectories. The rationale for this section is that the four-trajectory model only separated the medium-
stable group into two smaller groups with stable trends and therefore did not provide more insights into 
the BMI change trajectories. The trajectory groups and their distributions are summarized in Table 14. 
Trajectory groups were labeled according to the clinical classification of BMI, including women who 
maintained a mean BMI less than 25 kg/m2 (“healthy weight”), who maintained a BMI between 25-35 
kg/m2 (“overweight/obese”), and who remained Class II-III obesity (BMI >35 kg/m2, “severely obese”).  
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 Next, the group memberships derived from the main GBTM analysis were compared against 
group membership identified through GBTM analysis with IPW and the validation analysis using KmL to 
determine the final group assignment. The unweighted, IPW-weighted GBTM, and KmL analyses 
identified the same trajectory groups. The three sets of group membership assignments were highly 
concordant (all Cohen’s kappa > 0.8), suggesting the influence of loss to follow-up is minimal. Therefore, 
trajectory groups derived from unweighted GBTM was selected as the final group membership: 8% of 
women maintained a healthy weight [baseline mean±SD=23.5±2.5 kg/m2, median=23.5 kg/m2, inter-
quartile range (IQR)=3.7 kg/m2], 36% of women remained overweight/obese (baseline 
mean±SD=31.3±3.0 kg/m2, median=30.8 kg/m2, IQR=4.3 kg/m2), and 8% women were severely obese 
(baseline mean±SD=42.4±5.0 kg/m2, median=40.8 kg/m2, IQR=5.9 kg/m2).  
Trajectory groups from the three sets of analyses, as well as the final model choices, are shown 
in Table 14. Figure 9 illustrates the individual weight change trajectories color-coded by the trajectory 
groups (Figure 9 column A) and the mean weight change trajectories for each group (Figure 9 column B). 
Visual assessment of the final group assignments suggested that the final models successfully isolated 
three groups with distinct BMI trajectories.   
4.4.3 Characteristics of trajectory groups 
Table 15 summarizes the demographic, clinical, and psychosocial characteristics of the BMI 
trajectory groups. Compared to the healthy weight group, women who were in the severely obese group 
were more likely to be older at diagnosis, black or Hispanic, received lower education, had lower annual 
household income, and were more likely to be postmenopausal. The severely obese group was also 
more likely to receive a lumpectomy compared to a mastectomy and more likely to initiate radiation 
therapy. There were no differences in chemotherapy and hormonal therapy initiation across BMI 
trajectory groups. Women who reported high baseline depressive symptoms, worsening of physical well-
being and CIPN at 6 months were also more likely to be in the severely obese group of BMI.  
4.4.4 Mean baseline weight and mean weight change by trajectory groups 
Table 16 describes the mean baseline weight and mean weight changes for each BMI trajectory 
group.  Baseline weight differed significantly by trajectory group (P for ANOVA <0.001, not shown in 
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Table 16). The mean weight was 113.2 kg for the severely obese group, 82.8 kg for the overweight/obese 
group, and 62.4 kg for the healthy weight group.  Although the mean change and percent change in body 
weight at 6 and 24 months were generally not statistically significantly different from zero, women in the 
severely obese group experienced a mean weight loss of 2.9 kg (2.2%) at 24 months (P<0.01), and the 
overweight/obese group lost a mean of 0.5 kg (0.3%) body weight at 6 months (P=0.01).  
4.4.5 Associations of health behaviors with mean weight change  
 Figure 10 shows the mean weight change by behavior trajectory groups that were identified in 
Chapter 2. Based on the t-test of mean percent changes, women who were in the low-stable dietary fat 
group and the low-stable MVPA group had statistically significantly decreased body weight at 6 months 
and 24 months after a BC diagnosis. 
 In multivariable analysis of all behavior trajectories and controlled for age, race/ethnicity, 
education, income, menopausal status, tumor stage, receipt of surgery, chemotherapy, hormonal therapy, 
radiation, baseline depressive symptom, worsening of physical well-being, and worsening of CIPN at 6 
months, women who were in the high decrease-temporary MVPA group gained more weight than women 
in the healthy weight MVPA group (difference in percent weight change =1.16%, 95% CI: 0.12-2.19%) at 
6 months (Table 5). Analysis of the mean weight change further showed that women who were in the  
high-stable dietary fat trajectory group gained more weight than women in the low-stable dietary fat group 
(difference in mean weight change =1.12 kg, 95% CI: 0.06-2.17 kg), and women in the high-stable 
sedentary behavior group also gained more weight than women in the low-stable sedentary behavior 
group (difference in mean weight change =0.89 kg, 95% CI: 0.03-1.75 kg) (Appendix 15). 
4.4.6 Associations of health behaviors with BMI trajectory 
 Figure 11 provides a visual representation of the distribution of BMI trajectory groups by behavior 
trajectory groups. Across behavior trajectory groups, the majority of women were in the healthy weight 
group of BMI. There is a trend towards lower proportion of women who maintained a low BMI in the low-
stable F/V group, high-stable dietary fat group, low-stable MVPA group, high-stable sedentary behavior 




Multinomial logistic regression analysis examined the associations of behavior trajectories with 
group membership of BMI trajectories. An omnibus test was performed first to examine the overall 
association between BMI and behavior trajectory groups. To examine the adjusted odds ratio of being in 
each BMI group relative to the “healthy weight” group, unadjusted and fully adjusted models that included 
all confounders and all behavior trajectories were fit. The results of the regression analyses are 
summarized in Tables 18-22. The analysis screened and tested for confounding from demographic and 
clinical characteristics, and identified age, race/ethnicity, education, income, menopausal status, tumor 
stage, receipt of surgery, chemotherapy, hormonal therapy, radiation, baseline dispositional optimism, 
worsening of physical well-being, and worsening of CIPN as potential confounders. The results of the fully 
adjusted model are summarized below. Because the omnibus test and tests specific to each BMI 
trajectory group showed the same associations with behavior trajectories, the omnibus test results are not 
reported here. 
F/V and BMI trajectories: Compared to women who were in the low increase-stable F/V trajectory 
group, women who were in the high-stable F/V group were less likely to be in the severely obese group 
(OR=0.41, 95% CI: 0.19-0.89; Table 18), and women in the medium increase-stable FV group were less 
likely to be in the severely obese (OR=0.61, 95% CI: 0.40-0.94; Table 18) and overweight/obese group 
(OR=0.73, 95% CI: 0.57-0.93; Table 18). Associations were similar when dietary fat intake trajectory was 
not adjusted for in the model, or when we included total energy intake and change in total energy as a 
covariate in the model (Table 18). 
Dietary fat and BMI trajectories: Compared to women in the low-stable dietary fat group, women 
in the high-stable dietary fat group were more likely to follow the severely obese (OR=2.24, 95% CI: 1.09-
4.58; Table 19) and overweight/obese trajectory (OR=2.34, 95% CI: 1.55-3.54; Table 19). Additionally, 
women in the medium high-stable dietary fat group (OR=1.62, 95% CI: 1.16-2.27; Table 19) and medium 
low-stable group (OR=1.47, 95% CI: 1.05-2.06; Table 19) were also more likely to follow the 
overweight/obese trajectory. In a sensitivity analysis without adjusting for F/V trajectory, the above 
associations were not changed. 
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MVPA and BMI trajectories: Compared to women in the low-stable MVPA group, women in the 
high decrease-temporary MVPA group were less likely to follow the severely obese (OR=0.26, 95% CI: 
0.10-0.63; Table 20) and overweight/obese trajectory (OR=0.46, 95% CI: 0.29-0.72; Table 20). Women in 
the medium decrease-temporary MVPA group were also less likely to follow the severely obese 
(OR=0.24, 95% CI: 0.15-0.39; Table 20) and overweight/obese trajectory (OR=0.58, 95% CI: 0.45-0.74; 
Table 20). 
Sedentary behavior and BMI trajectories: Compared to women in the low-stable sedentary 
behavior group, women in the high-stable sedentary behavior group were more likely to follow the 
severely obese (OR=2.43, 95% CI: 1.39-4.26; Table 21) and overweight/obese trajectory (OR=2.27, 95% 
CI: 1.62-3.18; Table 21).  
Alcohol and BMI trajectories: Compared to women in the low-stable alcohol intake group, women 
in the high decrease-temporary alcohol intake group were less likely to follow the severely obese 
trajectory (OR=0.16, 95% CI: 0.04-0.70; Table 22). Similarly, women in the medium-stable alcohol intake 
group were also less likely to follow the severely obese (OR=0.36, 95% CI: 0.19-0.68; Table 22) and 
overweight/obese trajectory of BMI (OR=0.64, 95% CI: 0.47-0.87; Table 22). 
4.4.7 Sensitivity analysis with multiple imputations 
Using the multiple imputations (MI) method under the assumption that data were missing at 
random, the study imputed ten separate datasets to fill in missing data in the key analytical variables and 
BMI trajectories. Pooled results of fully adjusted multinomial logistic regression analyses from the ten 
imputed datasets were compared with results based on the complete case analysis (Figure 12). In 
general, the missing data have a minor influence on the observed associations of behavior change 
trajectories with weight change trajectories. However, after imputing the missing data, women in the 
medium increase-stable (OR=1.38, 95% CI: 1.08-1.76; data not shown) and medium decrease-stable 
groups (OR=1.29, 95% CI: 1.02-1.63; data not shown) of sedentary behavior were more likely to follow 
the overweight/obese trajectory, and women in the high-stable alcohol intake group were less likely to 
follow the overweight/obese trajectory (OR=0.63, 95% CI: 0.43-0.93; data not shown). 
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4.4.8 Sensitivity analysis by excluding extreme dietary data 
 To test whether the association between high alcohol intake and low BMI was due to lower total 
energy intake in women who had higher alcohol intake, I first examined the distribution of energy intake 
by alcohol intake groups (Appendix 19).  The mean total energy intakes were higher in women who 
maintained high alcohol intake vs. non-drinkers. However, extremely high energy intake was more 
frequent in women in the low-stable alcohol intake group, as evidenced by the number of data points 
greater than the mean plus three standard deviations of total energy intake. Subsequent sensitivity 
analyses after the exclusion of extreme dietary data and adjusted for baseline energy intake showed 
similar association between alcohol intake trajectory and BMI trajectory (Appendix 16). These results 
suggested that the trajectory analyses of diet were minimally impacted by the extreme diet data, and that 
the conclusion about alcohol intake trajectory and BMI trajectory was not changed after exclusion of 
extreme dietary data. 
4.4.9 Sensitivity analysis by restricting to women with complete BMI data 
To examine the influence of missing BMI data, I performed a sensitivity analyses by restricting the 
trajectory analyses to women who had complete BMI data. A total of 1,862 women with three BMI 
measures were included in the sensitivity analysis. The trajectory analyses based on complete BMI data 
identified similar BMI trajectory groups as those identified with at least two data points. The results 
suggested that the trajectory analyses were robust against one missing data point and were not likely to 
be biased by missing BMI data. 
4.4.10 Correlation between clinical BMI classifications and BMI trajectory groups 
Appendix 17 showed the cross-tabulation of clinical classification of BMI and BMI trajectory 
groups. These two types of BMI classifications were highly correlated, indicating the healthy weight 
trajectory group mostly included women with a BMI <25 kg/m2, the overweight/obese group included 
women who had a BMI between 25-30 kg/m2, and the severely obese group mostly included women 
whose BMI were greater than 35 kg/m2. Therefore, the trajectory analyses showed that women in the 
overweight and obese categories followed similar trajectories, and identified a unique cluster of women 





This analysis identified three distinct trajectories of BMI during the first 24 months after a BC 
diagnosis: the majority (56%) of women maintained a low BMI during this period, 36% of women 
maintained a medium BMI, and 8% women maintained a high BMI. These trajectories of BMI were 
statistically significantly associated with the trajectory of diet, physical activity and alcohol intake over the 
same period of time, independent of demographic background, tumor characteristics and cancer 
treatment received. In particular, the severely obese group was negatively associated with the 
high/medium increase-stable F/V groups, the high/medium decrease-temporary MVPA groups and the 
high decrease-temporary alcohol intake group. The severely obese group was also positively associated 
with the high-stable dietary fat intake group and the high-stable sedentary behavior group.  Similarly, the 
overweight/obese group was negatively associated with the medium increase-stable F/V groups, the 
high/medium decrease-temporary MVPA group, and the high/medium decrease-temporary alcohol intake 
group. The overweight/obese group was also positively associated with the high/medium dietary fat intake 
group and the high-stable sedentary behavior group. 
 This analysis provides a novel application of trajectory analysis to measure and define weight 
change patterns after a BC diagnosis, which could be used in analyzing the effect of longitudinal pattern 
of health behaviors on BC survival. Currently, the association between post-diagnosis weight change and 
BC survival are considered as a U-shaped relationship, in which both weight gain and weight loss are 
associated with poorer overall survival.80,271,282 A recent meta-analysis of observational studies concluded 
that a gain of ≥5% body weight post-diagnosis is associated with increased all-cause mortality compared 
with maintaining weight.282  The hazard associated with weight gain was particularly pronounced in 
women who gained more than 10% weight, and among those who were not obese at the time of 
diagnosis.282 Two recent observational studies in the US further suggested that post-diagnosis weight 
gain may only increase all-cause mortality at 3-5 years after diagnosis.80,283 However, other observational 
studies have reported a strong association between weight loss and increased BC recurrence and all-
cause mortality during the early period (18–54 months post diagnosis) after BC diagnosis, irrespective of 
initial body weight.80,271,284 These studies, however, are limited by the way weight change was defined. 
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Weight change has been commonly defined as weight maintenance (< ± 5.0% body weight), weight gain 
(≥ 5% weight gain), or weight loss (≥ 5% weight loss).80,122,271,284,285 Some studies defined a large weight 
gain or loss as a change of ≥10% body weight.80,122,271,284 However, this measurement of weight change is 
based on weight data at two time points, which may span over a few years after diagnosis, and thus may 
ignore the weight fluctuations between measurement time points. The choices of 5% and 10% as the 
cutoff points to define low and high weight change in previous studies are largely arbitrary, which may 
introduce bias due to non-differential misclassification of weight change.   
This analysis showed that the majority of women maintained their body weight during the first 24 
months after diagnosis. In contrast, previous studies reported that approximately 19%-84% of women 
diagnosed with BC experience significant weight gain during the 1-2 years after diagnosis,77,80,91,92,112,122 
and the weight gain maintained in 30% of BC survivors long-term.93,95 Four population-based cohort 
studies in the US and China measured self-reported weight and height among BC survivors.80,91,113,116 
The After Breast Cancer Pooling Project (n=12,915 stage I-IV BC survivors) compared weight at 1 year 
prior to BC diagnosis and weight at 18-48 months post-diagnosis, and reported an average of 1.6 kg 
increase in body weight.91 Approximately 34.7% of women gained weight while 14.7% lost weight during 
this period. A recent study using data from the LACE and the Pathways Study (n=3,109 stage I-III BC 
survivors) reported similar findings, with 25% of women reporting weight gain and 14% reporting weight 
loss at 24 months after diagnosis.92 However, results from the Long Island Breast Cancer Study Project 
(n=1,436) suggested that weight gain (23%) and weight loss (22%) were equally common in BC survivors 
at 1 year after diagnosis.113 One study followed 345 early stage BC survivors who received chemotherapy 
after diagnosis and 305 healthy women over 6 years and reported that 42% of BC survivors and 32% of 
healthy women experienced a weight gain of ≥5% baseline weight.116  In contrast, the current analysis did 
not identify a subgroup of women who experienced significant weight gain after a BC diagnosis. The 
reported differences in the prevalence of weight gain may be due to the underlying differences in 
population characteristics, the timing of weight measurement, and type of treatment received. 
Additionally, previous studies may have misclassified women with a small amount of weight gain as true 
weight gain, who would have been classified as weight maintenance under the trajectory analysis. 
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However, it is unclear whether the trajectory analysis is capable of detecting weight change patterns than 
traditional methods.  
This analysis contributes to the literature that identified modifiable targets for weight management 
among BC survivors. While there is an established link between adjuvant chemotherapy and weight gain, 
especially for women on longer duration treatments26,27,164,165, potential changes in diet and physical 
activity in response to the stress of cancer and its treatment is an area of active research. Behavior 
changes affecting energy balance may play an important etiologic role underlying weight change after a 
BC diagnosis, because weight gain is evidenced among breast cancer patients who did not receive 
adjuvant treatment, and many breast cancer survivors reported progressive weight gain after initial 
treatment.26 Despite recent efforts to capture possible changes in dietary intake during and after 
treatment, empirical analyses supporting an association between increased energy intake after diagnosis 
and post-diagnosis weight gain is lacking.114 A study by Irwin et al.,96 however, reported a significant 
reduction in physical activity during and after treatment, which may play a role in post-diagnosis weight 
gain. This study by Irwin et al.96 reported results from the Health, Eating, Activity, and Lifestyle (HEAL) 
study of 514 women with stage 0-III breast cancer, almost half of whom used tamoxifen, but only 27% 
received chemotherapy. At two yeas post treatment, women increased their weight by a mean of 1.7 kg. 
Women who reported a decrease in their physical activity from diagnosis to up to 3 years after diagnosis 
reported greater weight gain than women who did not. The current analysis further demonstrated that, 
even for women who had high level of MVPA at time of diagnosis, a temporary decrease in engagement 
in MVPA was associated with a temporary weight gain after a BC diagnosis. Furthermore, maintaining a 
high MVPA was associated with a stable and low BMI during the first 24 months of BC survivorship. This 
analysis also suggested that physical inactivity may also play a role in weight management for BC 
survivors. In this population, women who reported high level of sedentary behavior throughout the 4 
months after a BC diagnosis gained 0.89 kg more weight than those who reported a persistently low level 
of sedentary behavior. Although these results offer limited inference regarding the effect of changing 
MVPA and sedentary behavior on post-diagnosis weight change, it confirms and highlights the strong 
association of physical activity with weight maintenance in BC survivors.  
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These results also demonstrated the importance of diet in weight management for BC survivors. 
Previous studies suggested that dietary change may be related to weight change in breast cancer 
patients and survivors,  but the evidence is not consistent.27,114 Goodwin et al. reported that caloric intake 
and physical activity did not explain weight gain during the first year after BC diagnosis among 535 
Canadian BC survivors.27 The WHEL study observed that higher energy intake after BC diagnosis was 
independently associated with increased risk for weight gain up to 4 years after cancer diagnosis.286 In 
this current analysis, instead of establishing a link between dietary change and weight change, the results 
indicated that maintaining a diet high in F/V and low in dietary fat was associated with a stable and low 
BMI after a BC diagnosis.  Furthermore, women who consumed a high-fat diet gained 1.12 kg more 
weight than women with a low-fat diet during the first 24 months after diagnosis.  However, it remains 
unclear whether increasing F/V intake and reducing dietary fat intake will protect against weight gain after 
a BC diagnosis. 
This analysis further showed that reduced alcohol intake post-diagnosis was associated with low 
and stable BMI after a BC diagnosis. This result is consistent with previous studies that reported the 
association between increase in alcohol intake and increased body weight.287,288 Alcohol is an energy-
dense yet nutritionally poor food source with an energy content of 7.1 kilocalories per gram.289 
Epidemiological studies showed that alcohol-derived calories added to food intake do not appreciably 
alter the average daily intake of other macronutrients.290 Therefore, alcohol seems to make an 
independent contribution to metabolic energy. Therefore, effects of alcohol consumption on body weight 
may be explained by the extra energy intake from alcohol. The results further suggested that, even for 
women reported higher alcohol intake at baseline, reducing alcohol intake may protect against 
maintaining a high BMI after diagnosis. However, the interpretation of the results of my analysis is 
complicated by the fact that BC survivors who reduced alcohol intake were the same women who 
maintained a higher alcohol intake at time of diagnosis. It is possible that higher alcohol intake at baseline 
may be associated with lower BMI. Although there is little evidence to justify this possible explanation, my 
analysis showed that extreme energy intake was more common among non-drinkers. Analysis after 
exclusion of the extreme energy intake did not change my results, suggesting other mechanisms may link 
high alcohol intake with low BMI among the Pathways Study participants. Therefore, the role of alcohol 
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intake in weight management among BC survivors is complicated and warrants further investigation, and 
alcohol reduction may be a potential target for weight loss interventions among BC survivors.  
This analysis has a number of limitations. Although the analysis failed to identify groups of weight 
gain and weight loss, it does not mean that BC survivors did gain weight or lose weight. In fact, the failure 
to detect a change in BMI trajectory may be due to the small magnitude of weight change relative to 
baseline weight. Instead of identifying changing trends in BMI, the trajectory analysis revealed that the 
BMI of Pathways Study participants were clustered into three levels. These levels correspond with the 
normal weight, overweight/obese and class II obesity defined by clinical classification of BMI, suggesting 
that the trajectory analysis offered similar classification of body fatness as that based on traditional BMI 
cutoffs. Therefore, the BMI category at time of BC diagnosis is a stable indicator of subsequent BMI 
within the 24 months after diagnosis.  Additionally, only three waves of BMI data were available for 
analysis, which further limited the ability to observe a steady change in BMI. Although the Pathways 
Study partially completed the 72 months data collection, this analysis did not include the 72 months 
primarily because it is difficult to determine the nature of incomplete follow-up while the 72 months follow-
up is ongoing.  Furthermore, because the exposure variable, behavior change trajectories, depends on 
the success of identifying behavior change trajectories in Chapter 3, the exposure status may be 
misclassified if the behavior change group membership is incorrect. If the misclassification of exposure is 
dependent on the outcome, that is, if women are misclassified as having a negative trend towards 
unhealthy behaviors, and if the misclassification is more likely to occur in women who gain weight, the 
association between behavior change and weight change will be overestimated. Another limitation is that 
weight may not reflect body composition. Unlike typical weight gain that characterized by increases in 
both lean body mass and adipose tissue, cancer treatment-induced weight gain may occur either in the 
absence of lean tissue gain or in the presence of lean tissue loss.31,32 However, the Pathways study does 
not currently have data on body composition to assess whether changes in health-related behaviors are 
associated with changes in body fat or lean mass specifically. A previous study suggests that the waist 
circumference might be a good indicator of visceral fat,291 which could be used as a separate outcome to 
examine the association between behavior changes and changes in body fat. In addition, there is strong 
emerging evidence that WHO cutoff values for BMI may not be appropriate in older populations.292,293 A 
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recent meta-analysis of 32 cohort studies (n=197,940) of community-dwelling elderly people aged ≥65 
years found a U-shaped association between all-cause mortality, with mortality risk lowest at BMI 24-31 
kg/m2. This relationship remained when adjusting for smoking status, early death, pre-existing disease 
and geographical location.293 Therefore, it may be inappropriate to consider BMI between 25-30 kg/m2 as 
overweight or obese for women aged ≥ 65 years. Additionally, the relationship between BMI, body fat and 
health risks differed by race and ethnicity. The BMI cutoff values are lower for the Asian population (23.0, 
27.5, 32.5, and 37.5 kg/m2 for overweight, obese I, obese II and obese III, respectively).294 Finally, 
although the analyses used longitudinal data for analyses, this analysis only examined the cross-sectional 
association between variables that measures change over the same time period. Analyses that evaluate 
the effect of behavior trajectory on future weight change will provide stronger evidence to elucidate the 
causal relationship. Other limitations include the lack of pre-diagnosis data, self-reported behavior data, 
and the data-driven nature of group-based modeling, which may all introduce bias or errors as discussed 
in Chapter 3. 
In summary, this analysis did not observe a latent trajectory of weight gain or weight loss in the 
first 24 months after a BC diagnosis in the Pathways Study. Instead, my analysis suggests that most 
women maintained their body weight following a BC diagnosis. The BMI trajectories were strongly 
associated with trajectory of F/V, dietary fat intake, MVPA, sedentary behavior, and alcohol intake over 
the same period, independent of demographic characteristics, tumor characteristics and receipt of cancer 
therapies. These results highlight the importance of health behaviors in maintaining a healthy body weight 
after a BC diagnosis. Future studies should also examine the associations of these BMI trajectories and 
BC prognosis to better understand the effect of post-diagnosis weight change on BC-specific and all-
cause mortality.  
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4.6 TABLES AND FIGURES  
Table 13. Results for group-based trajectory modelling of body mass index 
 
Number of groups BIC AIC 
 
Estimated probability for trajectory group 
(%) 
  1.0 2.0 3.0 4.0 5.0 6.0 
1 -25327.5 -25315.5  100.0               
2 -23307.0 -23283.0  76.6 23.4            
3 (selected) -22045.8 -22009.8   55.8 35.8 8.3         
4 -21329.8 -21281.8  46.8 35.9 14.4 2.9      
5 -20843.3 -20783.4  37.4 34.1 20.0 7.3 1.2   
6 -20468.0 -20396.1   25.8 31.4 24.1 12.0 5.6 1.1 
Note 
         








Table 14. Comparison of body mass index trajectory groups derived from group-based trajectory modelling (GBTM) and K-means for 
longitudinal data analysis (KML) 
 
Model 1. Unweighted GBTM  Model 2. Weighted GBTM  Model 3. KML  Cohen's kappa
1 
 




vs. 3  
Model 2 
vs. 3  Model choice 
Healthy weight 243 8%   Healthy weight 239 8%   Healthy weight 337 11%   0.99 0.87 0.86 Unweighted 
GBTM 
Overweight/obese 1058 36%  Overweight/obese 1047 36%  Overweight/obese 1102 37%     
Severely obese 1654 56%   Severely obese 1661 56%   Severely obese 1520 51%         
Note               
 
Abbreviations: GBTM, Group based trajectory modelling; KML, K-means for longitudinal data analysis 
1. Cohen's kappa measured agreement between group memberships identified from different analyses. A Cohen's kappa greater than 0.8 indicates concordance between two 
analyses. The Cohen's kappa was not computed when groups were not identical. 
2. Trajectory groups were labeled according to the clinical classification of BMI, including women who maintained a mean BMI less than 25 kg/m2 (“healthy weight”), who maintained 
a BMI between 25-35 kg/m2 (“overweight/obese”), and who remained Class II-III obesity (BMI >35 kg/m2, “severely obese”). 
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obese (n=243)  
Overweight/obese 




P1 Variable n %   n %   n % 
Age          
<50 40 16%  152 14%  360 22% <0.001 
50-59 71 29%  297 28%  427 26%  
60-70 98 40%  358 34%  490 30%  
70+ 34 14%  251 24%  377 23%  
Race/ethnicity          
White 152 63%  730 69%  1148 69% <0.001 
Black 46 19%  80 8%  51 3%  
Asian 6 2%  79 7%  279 17%  
Hispanic 31 13%  140 13%  143 9%  
Other 8 3%  29 3%  33 2%  
Education          
HS or less 47 19%  202 19%  173 10% <0.001 
Some college 111 46%  419 40%  468 28%  
College or above 85 35%  437 41%  1013 61%  
Household income          
<$50K 135 56%  526 50%  643 39% <0.001 
$50K-$89K 89 37%  417 39%  846 51%  
$90K+ 19 8%  115 11%  165 10%  
Menopausal status          
Premenopausal 57 23%  228 22%  502 30% <0.001 
Postmenopausal 186 77%  830 78%  1152 70%  
Tumor stage          
I 131 54%  586 55%  918 56% 0.21 
II 80 33%  359 34%  570 34%  
III 28 12%  108 10%  144 9%  
IV 4 2%  5 0%  22 1%  
Number of positive nodes         
0 11 5%  51 5%  65 4% 0.65 
1 45 19%  228 22%  356 22%  
2+ 187 77%  779 74%  1233 75%  
HER2 positivity          
Negative 203 87%  887 87%  1367 86% 0.83 
Positive 31 13%  131 13%  217 14%  
ER/PR positivity          
Negative 47 20%  152 14%  263 16% 0.12 
Positive 192 80%  905 86%  1391 84%  
Surgery type          
Lumpectomy 122 50%  518 49%  720 44% 0.01 
Mastectomy 117 48%  536 51%  919 56%  
None 4 2%  4 0%  15 1%  
Received chemotherapy         
Yes 120 50%  470 45%  778 47% 0.24 
No 121 50%  584 55%  874 53%  
Received hormonal therapy         
Yes 186 77%  811 77%  1224 74% 0.23 
No 56 23%  238 23%  419 26%  
Received radiation          
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Yes 117 48%  504 48%  710 43% 0.03 
No 126 52%  554 52%  943 57%  
Depressive symptom         
Low 166 72%  801 77%  1244 77% 0.22 
High 65 28%  238 23%  376 23%  
Dispositional optimism         
Low 162 70%  730 70%  1065 66% 0.05 
High 70 30%  312 30%  557 34%  
Perceived social support         
Low 74 32%  345 33%  518 32% 0.78 
High 158 68%  695 67%  1106 68%  
Worse physical well-being at 6 months       
No 147 71%  711 75%  1193 80% <0.001 
Yes 60 29%  242 25%  292 20%  
Worse CIPN at 6 months         
No 100 61%  428 62%  783 69% <0.01 
Yes 64 39%   257 38%   349 31%   
Note          
Abbreviations: HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, 
progesterone receptor; CIPN, chemotherapy-induced peripheral neuropathy  
1. Chi-squared test determined whether the distributions of demographic, clinical and psychosocial 
characteristics were independent of trajectory groups.  
2. Trajectory groups were labeled according to the clinical classification of BMI, including women who 
maintained a mean BMI less than 25 kg/m2 (“healthy weight”), who maintained a BMI between 25-35 







Table 16. Mean changes in body mass index by trajectory groups 
           
       6 months  24 months 
 Baseline     Absolute change (kg)  Percent change (%)   Absolute change (kg)  Percent change (%) 
Group n %   Mean (SD)   Mean (SD) Mean (SD) P-value1   Mean (SD) P-value1   Mean (SD) Mean (SD) P-value1   Mean (SD) P-value1 
Severely obese 243 8%  113.2 (16.8)  111.8 (17.3) -0.9 (8.1) 0.09  -0.6 (6.8) 0.16  110.8 (18.6) -2.9 (11) <0.01  -2.2 (9.2) <0.01 
Overweight/obese 1058 36%  82.8 (11)  82.1 (10.6) -0.5 (5.9) 0.01  -0.3 (6.4) 0.12  81.9 (10.8) -0.7 (7.1) 0.01  -0.5 (8.1) 0.07 
Healthy weight 1654 56%   62.4 (8.4)   62.4 (8.4) -0.1 (3.2) 0.30   0.0 (4.8) 0.85   62.4 (8.4) -0.1 (4.2) 0.25   -0.1 (6.3) 0.76 
Note                   
1. T-test examined whether the mean changes were statistically significantly different from 0. Bonferroni correction was used to account for multiple comparisons. 
2. Trajectory groups were labeled according to the clinical classification of BMI, including women who maintained a mean BMI less than 25 kg/m2 (“healthy weight”), who maintained a  







Table 17.  Linear regression analysis of difference in percent weight change at 6 and 24 months following a breast cancer diagnosis by 
behavior trajectories 
 
 6 months  24 months 
 Unadjusted  Fully adjusted
1  Unadjusted  Fully adjusted
1 
Behavior trajectory groups Difference (95% CI) P   Difference (95% CI) P   Difference (95% CI) P   Difference (95% CI) P 
Fruit/vegetable (ref=Low increase-stable)           
High increase-stable  0.52 (-0.16, 1.20) 0.14   0.84 (-0.03, 1.71) 0.06   0.07 (-0.93, 1.07) 0.89  -0.02 (-1.22, 1.19) 0.98 
Medium increase-stable  0.03 (-0.41, 0.47) 0.91   0.23 (-0.36, 0.82) 0.45  -0.17 (-0.83, 0.49) 0.62  -0.36 (-1.20, 0.48) 0.40 
Dietary fat (ref=Low-stable)            
High-stable  0.50 (-0.25, 1.26) 0.19   0.59 (-0.38, 1.56) 0.23   0.94 (-0.18, 2.07) 0.10   1.05 (-0.30, 2.41) 0.13 
Medium high-stable  0.40 (-0.22, 1.01) 0.21   0.16 (-0.62, 0.95) 0.69   0.55 (-0.37, 1.47) 0.24  -0.15 (-1.27, 0.97) 0.79 
Medium low-stable  0.51 (-0.11, 1.12) 0.10   0.23 (-0.55, 1.00) 0.57   0.36 (-0.56, 1.27) 0.44   0.34 (-0.77, 1.44) 0.55 
Moderate to vigorous physical activity (ref=Low-stable)          
High decrease-temporary  1.03 (0.21, 1.84) 0.01   1.16 (0.12, 2.19) 0.03   0.71 (-0.47, 1.90) 0.24   0.45 (-0.98, 1.89) 0.53 
Medium decrease-temporary  0.51 (0.06, 0.95) 0.02   0.41 (-0.17, 0.99) 0.17   0.93 (0.26, 1.60) 0.01   0.43 (-0.38, 1.24) 0.30 
Sedentary activity (ref=Low-stable)           
High-stable -0.22 (-0.84, 0.39) 0.48   0.07 (-0.73, 0.87) 0.86   0.16 (-0.77, 1.09) 0.73   0.70 (-0.41, 1.81) 0.21 
Medium high-stable  0.10 (-0.46, 0.66) 0.72   0.21 (-0.52, 0.93) 0.58  -0.11 (-0.97, 0.75) 0.80   0.11 (-0.94, 1.15) 0.84 
Medium low-stable -0.28 (-0.82, 0.26) 0.31  -0.14 (-0.83, 0.56) 0.69   0.38 (-0.44, 1.20) 0.36   0.29 (-0.69, 1.27) 0.56 
Alcohol (ref=Low-stable)            
High decrease-temporary  0.18 (-0.78, 1.14) 0.71  -0.10 (-1.37, 1.17) 0.87   0.06 (-1.39, 1.50) 0.94   0.42 (-1.40, 2.23) 0.65 
Medium decrease-temporary  0.01 (-0.55, 0.57) 0.97   -0.03 (-0.75, 0.68) 0.93    0.20 (-0.63, 1.03) 0.64    0.16 (-0.83, 1.16) 0.75 
Note            
Abbreviations: CI, confidence interval 
1. The fully adjusted analysis controlled for age, race/ethnicity, education, income, menopausal status, tumor stage, receipt of surgery, chemotherapy, hormonal therapy, radiation, 
baseline depressive symptom, worsening of physical well-being, and worsening of CIPN at 6 months 
2. The difference was calculated as the difference between two percentages. For instance, an unadjusted difference of 0.52 comparing the high increase-stable vs. the low 
increase-stable F/V groups means that women in the high increase-stable F/V group had 0.52 more percent weight change than women in the low increase-stable F/V group at 6 
months. 
3. Trajectory groups were labeled according to the clinical classification of BMI, including women who maintained a mean BMI less than 25 kg/m2 (“healthy weight”), who maintained 







Table 18.  Multinomial logistic regression fruit/vegetable trajectory and BMI trajectory 
 
 BMI trajectory groups (Referent= Healthy weight) 
Behavior change trajectory groups Severely obese   Overweight/obese 
(Referent=Low increase-stable) OR (95% CI) P   OR (95% CI) P 
Unadjusted      
High increase-stable 0.30 (0.17, 0.55) <0.001  0.62 (0.48, 0.81) <0.001 
Medium increase-stable 0.49 (0.36, 0.66) <0.001  0.59 (0.50, 0.70) <0.001 
Fully adjusted1      
High increase-stable 0.41 (0.19, 0.89) 0.02  0.79 (0.55, 1.13) 0.20 
Medium increase-stable 0.61 (0.40, 0.94) 0.02  0.73 (0.57, 0.93) 0.01 
Fully adjusted, without adjusting for dietary fat trajectory2     
High increase-stable 0.37 (0.17, 0.81) 0.01  0.73 (0.51, 1.05) 0.09 
Medium increase-stable 0.58 (0.38, 0.88) 0.01  0.69 (0.54, 0.88) <0.001 
Fully adjusted, additionally adjusted for total energy3     
High increase-stable  0.32 (0.31, 0.33) <0.001   0.74 (0.53, 1.05) 0.09 
Medium increase-stable  0.52 (0.44, 0.63) <0.001   0.72 (0.56, 0.92) 0.01 
Fully adjusted, additionally adjusted for change in total energy4    
High increase-stable  0.32 (0.13, 0.83) 0.02   0.77 (0.50, 1.17) 0.22 
Medium increase-stable  0.52 (0.30, 0.88) 0.02    0.73 (0.54, 0.98) 0.04 
Note      
Abbreviations: OR, odds ratio; CI, confidence interval 
1. Fully adjusted model simultaneously controlled for group membership of all other health behaviors (dietary fat intake, moderate to vigorous 
physical activity, sedentary time, and alcohol intake), age, race/ethnicity, education, income, menopausal status, tumor stage, receipt of surgery, 
chemotherapy, hormonal therapy, radiation, baseline dispositional optimism, worsening of physical well-being, and worsening of CIPN 
2. This model included all covariates in the fully adjusted model except for the group membership of dietary fat intake 
3. This model included all covariates in the fully adjusted model, and additionally adjusted for total energy intake at baseline and 6- and 24-
month follow-up 
4. This model included all covariates in the fully adjusted model, and additionally adjusted for change in total energy intake from baseline to 6- 
and 24-month follow-up 
5. Trajectory groups were labeled according to the clinical classification of BMI, including women who maintained a mean BMI less than 25 
kg/m2 (“healthy weight”), who maintained a BMI between 25-35 kg/m2 (“overweight/obese”), and who remained Class II-III obesity (BMI >35 







Table 19.  Multinomial logistic regression of dietary fat trajectory and BMI trajectory 
 
 BMI trajectory groups (Referent= Healthy weight) 
Behavior change trajectory groups Severely obese   Overweight/obese 
(Referent=Low-stable) OR (95% CI) P   OR (95% CI) P 
Unadjusted      
High-stable 3.73 (2.20, 6.32) <0.001  2.57 (1.91, 3.46) <0.001 
Medium high-stable 2.09 (1.30, 3.36) <0.001  1.68 (1.32, 2.15) <0.001 
Medium low-stable 1.63 (1.01, 2.64) 0.05  1.38 (1.08, 1.76) 0.01 
Fully adjusted1      
High-stable 2.24 (1.09, 4.58) 0.03  2.34 (1.55, 3.54) <0.001 
Medium high-stable 1.64 (0.87, 3.08) 0.13  1.62 (1.16, 2.27) 0.01 
Medium low-stable 1.39 (0.73, 2.64) 0.32  1.47 (1.05, 2.06) 0.02 
Fully adjusted, without adjusting for fruit/vegetable trajectory2    
High-stable 2.54 (1.25, 5.16) 0.01  2.48 (1.64, 3.73) <0.001 
Medium high-stable 1.79 (0.96, 3.35) 0.07  1.68 (1.20, 2.35) <0.001 
Medium low-stable 1.42 (0.75, 2.70) 0.28   1.49 (1.06, 2.08) 0.02 
Note      
Abbreviations: OR, odds ratio; CI, confidence interval 
1. Fully adjusted model simultaneously controlled for group membership of all other health behaviors (dietary fat intake, moderate to vigorous 
physical activity, sedentary time, and alcohol intake), age, race/ethnicity, education, income, menopausal status, tumor stage, receipt of surgery, 
chemotherapy, hormonal therapy, radiation, baseline dispositional optimism, worsening of physical well-being, and worsening of CIPN 
2. This model included all covariates in the fully adjusted model except for the group membership of fruit/vegetable intake 
3. Trajectory groups were labeled according to the clinical classification of BMI, including women who maintained a mean BMI less than 25 
kg/m2 (“healthy weight”), who maintained a BMI between 25-35 kg/m2 (“overweight/obese”), and who remained Class II-III obesity (BMI >35 







Table 20.  Multinomial logistic regression of change in moderate to vigorous physical activity and BMI trajectory 
 
 BMI trajectory groups (Referent= Healthy weight) 
Behavior change trajectory groups Severely obese   Overweight/obese 
(Referent=Low-stable) OR (95% CI) P   OR (95% CI) P 
Unadjusted      
High decrease-temporary 0.24 (0.12, 0.48) <0.001  0.38 (0.27, 0.52) <0.001 
Medium decrease-temporary 0.24 (0.17, 0.34) <0.001  0.52 (0.44, 0.61) <0.001 
Fully adjusted1      
High decrease-temporary 0.26 (0.10, 0.63) <0.001  0.46 (0.29, 0.72) <0.001 
Medium decrease-temporary 0.24 (0.15, 0.39) <0.001   0.58 (0.45, 0.74) <0.001 
Note      
Abbreviations: OR, odds ratio; CI, confidence interval 
1. Fully adjusted model simultaneously controlled for group membership of all other health behaviors (dietary fat intake, moderate to vigorous 
physical activity, sedentary time, and alcohol intake), age, race/ethnicity, education, income, menopausal status, tumor stage, receipt of surgery, 
chemotherapy, hormonal therapy, radiation, baseline dispositional optimism, worsening of physical well-being, and worsening of CIPN 
2. Trajectory groups were labeled according to the clinical classification of BMI, including women who maintained a mean BMI less than 25 
kg/m2 (“healthy weight”), who maintained a BMI between 25-35 kg/m2 (“overweight/obese”), and who remained Class II-III obesity (BMI >35 







Table 21.  Multinomial logistic regression of change in sedentary time trajectory and BMI trajectory 
 
 BMI trajectory groups (Referent=Healthy weight) 
Behavior change trajectory groups Severely obese   Overweight/obese 
(Referent=Low-stable) OR (95% CI) P   OR (95% CI) P 
Unadjusted      
High-stable 1.70 (1.16, 2.50) 0.01  1.94 (1.54, 2.45) <0.001 
Medium increase-stable 0.96 (0.66, 1.40) 0.84  1.23 (1.00, 1.53) 0.06 
Medium decrease-stable 1.02 (0.71, 1.46) 0.94  1.27 (1.03, 1.56) 0.02 
Fully adjusted1      
High-stable 2.43 (1.39, 4.26) <0.001  2.27 (1.62, 3.18) <0.001 
Medium increase-stable 0.90 (0.52, 1.56) 0.70  1.21 (0.89, 1.65) 0.22 
Medium decrease-stable 1.21 (0.73, 2.01) 0.46   1.26 (0.93, 1.69) 0.13 
Note      
Abbreviations: OR, odds ratio; CI, confidence interval 
1. Fully adjusted model simultaneously controlled for group membership of all other health behaviors (dietary fat intake, moderate to vigorous 
physical activity, sedentary time, and alcohol intake), age, race/ethnicity, education, income, menopausal status, tumor stage, receipt of surgery, 
chemotherapy, hormonal therapy, radiation, baseline dispositional optimism, worsening of physical well-being, and worsening of CIPN 
2. Trajectory groups were labeled according to the clinical classification of BMI, including women who maintained a mean BMI less than 25 
kg/m2 (“healthy weight”), who maintained a BMI between 25-35 kg/m2 (“overweight/obese”), and who remained Class II-III obesity (BMI >35 







Table 22.  Multinomial logistic regression of change in alcohol intake trajectory and BMI trajectory 
 
 BMI trajectory groups (Referent= Healthy weight) 
Behavior change trajectory groups Severely obese   Overweight/obese 
(Referent=Low-stable) OR (95% CI) P   OR (95% CI) P 
Unadjusted      
High decrease-temporary 0.12 (0.03, 0.51) <0.001  0.65 (0.45, 0.95) 0.02 
Medium decrease-temporary 0.29 (0.17, 0.48) <0.001  0.54 (0.43, 0.68) <0.001 
Fully adjusted1      
High decrease-temporary 0.16 (0.04, 0.70) 0.01  0.62 (0.36, 1.05) 0.07 
Medium decrease-temporary 0.36 (0.19, 0.68) <0.001   0.64 (0.47, 0.87) <0.001 
Note      
Abbreviations: OR, odds ratio; CI, confidence interval; NE, not estimable 
1. Fully adjusted model simultaneously controlled for group membership of all other health behaviors (dietary fat intake, moderate to vigorous 
physical activity, sedentary time, and alcohol intake), age, race/ethnicity, education, income, menopausal status, tumor stage, receipt of surgery, 
chemotherapy, hormonal therapy, radiation, baseline dispositional optimism, worsening of physical well-being, and worsening of CIPN 
2. Trajectory groups were labeled according to the clinical classification of BMI, including women who maintained a mean BMI less than 25 
kg/m2 (“healthy weight”), who maintained a BMI between 25-35 kg/m2 (“overweight/obese”), and who remained Class II-III obesity (BMI >35 
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Figure 129. Trajectories of body mass index (BMI) after a breast cancer diagnosis among the Pathways Study participants. This 
figure shows the individual trajectories (left panel) and group mean trajectories (right panel) of BMI during the first 24 months  following a 


























































Figure 145. Mean percent weight change by behavior trajectory groups. The bars represent the mean percent of weight change in each 
behavior trajectory group. The lines represent the 95% confidence interval of means. 
 
Figure 146. Mean percent weight change by behavior trajectory groups. The bars represent the mean percent of weight change in each 
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Figure 161. Distribution of BMI trajectory groups by behavior trajectory groups. The bars in the figure indicate the percent of women 
following each BMI trajectory, and color-coded according to the BMI group membership.   
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Figure 162. Multinomial logistic regression analyses under complete case analysis and multiple imputations. This figure displays the 
fully adjusted odds ratios of following each trajectory of BMI under the complete case analysis (solid line) and that under the multiple 




F/V: High increase-stable 
F/V: Medium increase-stable 
Dietary fat 
Fat: High-stable 
Fat: Medium high-stable 
Fat: Medium low-stable 
MVPA 
MVPA: High decrease-temporary 
MVPA: Medium decrease-temporary 
Sedentary behavior 
Sedentary: High-stable 
Sedentary: Medium high-stable 
Sedentary: Medium low-stable 
Alcohol 
Alcohol: High decrease-temporary 
Alcohol: Medium decrease-temporary 
 
Severely obese                                          Overweight/obese 
 
130 
CHAPTER 5: CONCLUSIONS 
  
The overall goals of my dissertation were to test the hypotheses that breast cancer (BC) survivors 
follow distinct trajectories of health behaviors during the first 24 months after diagnosis, and that their 
behavior trajectories will be associated with trajectories of body mass index (BMI). Using data from the 
Pathways Study, a large population-based cohort study of women newly diagnosed a BC within the 
Kaiser Permanente Northern California network, my dissertation identified latent trajectories of health 
behaviors and BMI during the first 24 months after a BC diagnosis using two novel methods, the group 
based trajectory modeling and the K-means for longitudinal data analysis. This chapter summarizes the 
results and implications of my dissertation. 
 In Chapter Two, I conducted a systematic review of literature related to changes in diet (F/V, 
dietary fat), physical activity (time spent on MVPA and sedentary behaviors), drinking, and body weight 
after a BC diagnosis. A total of 2,552 publications that reported a longitudinal change in health behaviors 
among BC survivors were screened and 66 observational studies were included in a systematic review. 
These studies reported change in health behaviors/body weight from BC diagnosis to 6 months or up to  
15 years after diagnosis, with the majority focusing on the first 1-2 years after diagnosis. There was 
strong evidence that women generally reduce alcohol intake and gain weight following a BC diagnosis. 
Furthermore, moderate evidence was found for a decrease in time spent on moderate to vigorous 
physical activities (MVPA) after a BC diagnosis. However, there was insufficient evidence to determine 
the change in fruit/vegetable (F/V) intake, dietary fat intake, and time spent on sedentary behaviors after 
a BC diagnosis. Moreover, most prior studies reported the mean changes in health behaviors; few studies 
have considered the heterogeneity of behavior changes among BC survivors. The understanding of the 
determinants of behavior change among BC survivors was also limited. This systematic review is one of 
the first to summarize and evaluate previous reports of changes in health behaviors after a BC diagnosis. 
The review suggested that there was relatively weak evidence to support the hypothesis that a cancer 
diagnosis would encourage women to engage in more health behaviors. Instead, most previous reports 
indicated that women made little to no change in diet and decreased engagement in exercise after a 
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diagnosis. The absence of spontaneous improvement in health behaviors suggests the importance of 
promoting health behaviors among BC survivors.  
 In Chapter Three, I analyzed the trajectory of diet (F/V and dietary fat intake), physical activity 
(MVPA and sedentary behavior), and alcohol intake from baseline to the 24-month follow-up in the 
Pathways Study. To identify the latent trajectory of health behaviors, I used a combination of semi-
parametric, group-based trajectory modeling and non-parametric K-means for longitudinal data analysis. 
These methods classified women into subgroups based on the similarity of their behavior and BMI 
trajectories. This analysis identified three distinct trajectories of F/V intake (11% high increase-stable, 
41% medium increase-stable, 48% low increase-stable), MVPA (7% high decrease-temporary, 35% 
medium decrease-temporary, 58% low stable) and alcohol intake (5% high decrease-stable, 16% medium 
decrease-temporary, and 79% low-stable), and four trajectories of dietary fat intake (14% high-stable, 
35% medium high-stable, 35% medium low-stable, 17% low-stable) and sedentary behaviors (18% high-
stable, 24% medium increase-stable, 27% medium decrease-stable, 31% low stable). However, this 
analysis did not identify the hypothesized weight gain or weight cycling groups. Compared to the low 
increase-stable F/V group, women who were in the high or medium increase-stable F/V group had higher 
education and income, higher dispositional optimism and perceived social support. Women who were in 
the medium high-stable dietary fat group were more likely to experience chemotherapy-induced 
peripheral neuropathy at 6 months after a BC diagnosis. For MVPA, women who were in the high or 
medium decrease-temporary trajectory groups had higher education and income, higher dispositional 
optimism and perceived social support.  Women who were in the high-stable and medium decrease-
stable sedentary behavior groups had higher education, lower income, and reported higher perceived 
social support. Finally, women who follow the high or medium decrease-temporary alcohol intake groups 
had higher education and income. These results identified subgroups of women who maintained 
unhealthy behaviors following a breast cancer diagnosis.  The findings suggest that there are subgroups 
of women who may benefit from targeted efforts in effective health behavior education and promotion 
programs. 
 Chapter Four further analyzed BMI trajectory groups during the first 24 months after a BC 
diagnosis. The trajectory analysis showed very little change in BMI over the two-year period: the majority 
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(56%) of women maintained a healthy weight, 36% of women remained overweight/obese, and 8% 
women were severely obese. Compared to the healthy weight group, women who remained severely 
obese were less likely to maintain a high-F/V diet, less likely to engage in high level of MVPA, and less 
likely to maintain a high intake of alcohol over the two-year period. Moreover, women who remained 
severely obese were more likely to have maintained a high-fat diet and sedentary behavior.  Similar to 
women who were in the high-stable group of BMI, membership in the overweight/obese trajectory group 
was also negatively associated with the maintenance of a high-F/V diet, high MVPA, and high alcohol 
intake, but positively associated with the maintenance of high-fat diet and high sedentary behavior. These 
associations were independent of demographic and clinical characteristics, psychosocial factors related 
to stress coping, cancer treatment received, and change in total energy intake. The results were robust to 
multiple imputations of missing data.   
 The results of my dissertation delineate the typical trajectories of health behaviors after a BC 
diagnosis, which may help identify women who could be classified as a high-risk group for maintaining an 
unfavorable lifestyle and thus would be particularly important targets for lifestyle counseling and 
interventions. Identifying the target population for health behavior promotion is an important first step to 
designing a successful behavior intervention among cancer survivors. A well-selected and implemented 
targeting method will maximize the health benefits from a diet and physical activity intervention by 
excluding patients who engage in sufficient health behaviors, while minimizing the cost by only including 
those who have the potential to benefit the most. In situations where educational and material resources 
to support a healthy lifestyle are not universally available to BC survivors in immediate need, targeted 
interventions can ensure optimal impact by directing limited resources to patients at the greatest risk of 
maintaining unhealthy lifestyles or losing healthy diet or exercise habit during and after cancer treatment. 
Currently, behavior interventions and programs of health behaviors cover a broad range of BC survivors 
and therefore are less specific to certain subgroups of women who engage in unhealthy behaviors. 
Improved targeting can lead to substantial reductions in cost associated with these interventions, without 
necessarily reducing their impact on those who could benefit the most. A previous behavior intervention 
tailored to Hispanic/Latina BC survivors, who have poor knowledge of and access to materials that 
sustain healthy lifestyle, proved highly effective in increasing intake of F/V.295-297  
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This analysis proposed new ways to identify the target population for behavior interventions. By 
depicting latent trajectories of health behaviors, future studies can potentially identify and directly target 
patients who are at high likelihood of following unfavorable trajectories of health behaviors.  This analysis 
revealed that the level of health behavior at time of diagnosis is highly predictive of subsequent health 
behaviors during treatment and early survivorship after a BC diagnosis. For instance, a woman who 
engages in unhealthy behaviors at the time of cancer diagnosis is most likely to maintain an unfavorable 
lifestyle in the first 24 months after a BC diagnosis. Therefore, screening for health behavior at the time of 
cancer diagnosis could effectively identify targets to deliver behavior interventions. When direct measures 
of health behaviors are unavailable, the high-risk group could be identified based on a patient’s 
demographic characteristics, such as education and household income, or based on the psychosocial 
response to stress due to cancer, such as depressive symptom and dispositional optimism. 
This dissertation also provides strong evidence to support the association of persistently 
unhealthy behavior with the maintenance of high BMI after a BC diagnosis. Furthermore, the analysis 
suggested that there was a small but increasing trend in F/V intake over the first 24 months after a BC 
diagnosis, for all women irrespective of pre-diagnosis F/V intake. On the other hand, women generally 
reduced engagement in MVPA and reduced alcohol intake after a BC diagnosis, especially for women 
who reported high MVPA and alcohol intake pre-diagnosis. Identifying the population of BC survivors who 
do not engage in health lifestyle behaviors after a BC diagnosis could help future lifestyle interventions 
focus on a more specific target population, which may improve the efficiency of lifestyle interventions. 
The results demonstrate that a high percentage of BC survivors did not adhere to the 
recommended level of health behaviors and patient-initiated behavior change was not evident during the 
first 24 months after diagnosis. Women who were of lower SES, had greater stress and fewer social 
support and experience cancer treatment side effect are most likely to maintain unhealthy behaviors. 
These findings provide strong evidence to support health behavior interventions among BC survivors. 
Interventions aimed at improvement of diet, physical activity levels and weight management have been 
implemented successfully among BC survivors.298,299 Dietary intervention studies utilizing face-to-face 
contact, print materials or telephone counseling reported an average increases of 0.6 servings per day of 
fruit and vegetable intake and an average of 7.3% decreases reduction in the percentage of calories from 
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fat.299,300  Supervised exercise as well as home-based exercise and telephone coaching have been 
successful in increasing physical activity levels, with increases seen up to 271 min/week.301-303 Weight 
loss interventions, utilizing in person or telephone coaching have also been successful in this population 
with weight loss of up to 12.5 kg achieved.304-306 These studies demonstrate the potential for health 
behavior intervention following a BC diagnosis. However, access to these successful interventions 
remains limited. The majority of these interventions require training and resources that are not readily 
available to patients and clinical care providers. Currently, most health intervention studies targeting 
cancer survivors were conducted in developed countries, partly due to the limited resources for cancer 
screening and treatment in developing countries. For cancer survivors in developing countries, they also 
face limited resources to allow health education delivery and exercise coaching. Future studies are 
needed to evaluate effectiveness of intervention strategies that require limited resources and training to 
make such interventions readily accessible to patients and providers, and interventions that help cancer 
survivors overcome physical and psychosocial burdens. 
My long-term research goal is to understand the effect of health behaviors on survival and cancer 
recurrence in Chinese cancer survivors. In China, the incidence of breast cancer has been increasing, 
with approximately 268,600 women diagnosed with breast cancer in 2015 alone.307 The five-year survival 
rate for breast cancer is approximately 73% in China, which is substantially lower than that in the US 
(90%).307 The increased BC risk among Chinese women may be partly due to the adoption of western 
dietary pattern, increased physical inactivity and higher obesity rate as a consequence of economic 
development. Therefore, promoting health behaviors among Chinese women diagnosed with breast 
cancer may reduce the risk of recurrence and other conditions related to unhealthy behaviors, and 
eventually improve overall survival.  
Health behavior interventions targeting Chinese populations could take advantage of the 
advancement in information technology in China. The increasing availability of smartphones and 
popularity of social media have opened up new channels and tools for health education delivery. Previous 
studies suggest that it is feasible to deliver eHealth interventions to improve health literacy in various 
populations 308, and social media may be an effective platform with promising applications in eHealth 
interventions 309. Researchers have tested delivering culturally tailored learning modules about healthy 
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eating and physical activity to adolescents on Facebook, which has led to favorable changes in health 
behaviors.310 In China, WeChat (Tencent Inc., Shenzhen, China) is the most popular social media 
platform, with more than 900 million active users worldwide. Like other social media platforms, WeChat 
offers a free instant multimedia messaging application for smartphone users. Researchers with a WeChat 
official account can deliver multimedia newsletters to WeChat users who subscribe to their accounts. 
Subscribers can read these newsletters, receive messages and interact with other subscribers via these 
official accounts. WeChat also has access to step count data if the users have pedometer-enabled 
smartphones, which allows researchers to collect physical activity data such as number of steps per day. 
However, it is unknown whether WeChat offers greater feasibility and effectiveness in promoting health 
behaviors in cancer survivors compared to traditional communication methods, such as print materials 
and telephone counseling.  
Since the majority of BC survivors reported decreasing MVPA after diagnosis, it is important to 
develop effective and acceptable ways to motivate BC survivors to engage in adequate MVPA. 
Traditional intervention strategies to increase MVPA, such as supervised exercise sessions and gym 
membership incentives, are costly and often inflexible. In addition, these forms of exercise do not 
integrate fitness and recreation, and do not concurrently promote participant’s physical and mental well-
being. Square dance is a form of aerobic physical activity that gained increasing popularity among 
middle-aged and elderly populations in China. It integrates the advantages of social participation, 
exercise and psychological recreation. Compared to traditional exercise such as running and swimming, 
square dance is characterized by simple movements, little to no training and minimum risk. Additionally, it 
is not restricted by space, time, theme, or rhythm. As previous interventional studies showed, square 
dance could effectively reduce the depression and anxiety symptoms of middle-aged and old women in 
China, suggesting women may find mental relief through participation in square dance.311 Therefore, 
square dance is a promising and suitable way to increase MVPA among BC survivors and is worthy of 
further investigation. 
Overall, based on the results of a trajectory analysis, my dissertation suggested that there is little 
change in lifestyle behaviors or BMI during the first 24 months following a BC diagnosis among early 
stage BC survivors enrolled in the Kaiser Permanente Northern California network – these behaviors 
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seem to be set based on pre-diagnosis behaviors.  Women who had lower SES, lower dispositional 
optimism, and experience greater cancer treatment side effect were more likely to maintain an unhealthy 
lifestyle. Nevertheless, the trajectory analysis did not effectively identify subgroups of women with 
meaningful change in any health behavior, likely due to the small magnitude of change relative to the 
baseline and the relatively short period of observation. This analysis was also limited by the high loss to 
follow-up rate, self-reported behavior and anthropometric data, and limited generalizability to the 
population other than women within the KPNC network.  
To validate the findings of this analysis and to gain better understanding of the variability of 
behavior change in BC survivors, future studies should examine the trajectory of health behaviors in other 
BC populations. The clinical implications of different trajectories of health behavior need to be 
investigated. As a new way to measure long-term health behavior pattern, behavior trajectories could be 
used to evaluate whether maintaining a healthy diet and engaging in exercise could reduce risk factors of 
mortality, including obesity, inflammation and metabolic disorders. Future studies should also evaluate 
the differences in BC prognosis and BC-specific and all-cause mortality among different behavior/BMI 
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Appendix 1. Search terms and results 
 
Pubmed = 1,682 records 
("diet"[Title/Abstract] OR "fruit"[Title/Abstract] OR "vegetable"[Title/Abstract] OR "dietary 
fat"[Title/Abstract] OR "total calories"[Title/Abstract] OR "caloric intake"[Title/Abstract] OR 
"alcohol"[Title/Abstract] OR "drinking"[Title/Abstract] OR "physical activity"[Title/Abstract] OR "moderate to 
vigorous activity"[Title/Abstract] OR "sedentary activity"[Title/Abstract] OR "exercise"[Title/Abstract] OR 
"smoking"[Title/Abstract] OR "cigarette"[Title/Abstract] OR "weight"[Title/Abstract] OR "body mass 
index"[Title/Abstract]) AND ("change"[Title/Abstract] OR "longitudinal change"[Title/Abstract] OR 
"difference"[Title/Abstract]) AND ("breast cancer"[Title/Abstract] OR "breast neoplasms"[Title/Abstract]) 
AND English[Language]  
 
Web of Science = 37 records 
(TI=(diet OR fruit OR vegetable OR dietary fat OR total calories OR caloric intake OR alcohol OR drinking 
OR physical activity OR moderate to vigorous activity OR sedentary activity OR exercise OR smoking OR 
cigarette OR weight OR body mass index) AND (change OR longitudinal change OR difference) AND 
(breast cancer survivors OR breast cancer diagnosis))) AND LANGUAGE: (English) AND DOCUMENT 
TYPES: (Article) 
Timespan: All years. Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC. 
 
PsychInfo = 6 records 
Any Field : (Any Field : (breast cancer ) OR Any Field : (breast neoplasms ) ) ) AND (Any Field : (change ) 
OR Any Field : (longitudinal change ) OR Any Field : (difference ) ) ) AND (Any Field : (diet ) OR Any Field 
: (fruit ) OR Any Field : (vegetable ) OR Any Field : (dietary fat ) OR Any Field : (total calories ) OR Any 
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Field : (caloric intake ) OR Any Field : (alcohol ) OR Any Field : (drinking ) OR Any Field : (physical activity 
) OR Any Field : (moderate to vigorous activity ) OR Any Field : (sedentary activity ) OR Any Field : 
(exercise ) OR Any Field : (smoking ) OR Any Field : (cigarette ) OR Any Field : (weight ) OR Any Field : 
(body mass index ) ) ) 
 
Embase = 576 records 
('diet' OR 'fruit' OR 'vegetable' OR 'dietary fat' OR 'total calories' OR 'caloric intake' OR 'alcohol' OR 
'drinking' OR 'physical activity' OR 'moderate to vigorous activity' OR 'sedentary activity' OR 'exercise' OR 
'smoking' OR 'cigarette' OR 'weight' OR 'body mass index') AND ("change" OR "longitudinal change" OR 
"difference") AND ('breast cancer survivors' OR 'breast cancer diagnosis') 
 
Medline = 250 records 
('diet' or 'fruit' or 'vegetable' or 'dietary fat' or 'total calories' or 'caloric intake' or 'alcohol' or 'drinking' or 
'physical activity' or 'moderate to vigorous activity' or 'sedentary activity' or 'exercise' or 'smoking' or 
'cigarette' or 'weight' or 'body mass index') and ("change" or "longitudinal change" or "difference") and 
('breast cancer survivors' or 'breast cancer diagnosis')).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary concept word, 




Appendix 2. Critical Appraisal Skills Program for cohort study56 
 
Appraisal questions 
1. Was the cohort recruited in an acceptable way?  
Look for selection bias which might compromise the generalizability of the findings:  
Was the cohort representative of a defined population?  
Was there something special about the cohort?  
Was everybody included who should have been included?  
2. Was the exposure accurately measured to minimize bias?  
Look for measurement or classification bias:  
Did they use subjective or objective measurements?  
Do the measurements truly reflect what you want them to (have they been validated)?  
Were all the subjects classified into exposure groups using the same procedure 
3. Was the outcome accurately measured to minimize bias?  
Look for measurement or classification bias:  
Did they use subjective or objective measurements?  
Do the measures truly reflect what you want them to (have they been validated)?  
4.  (a) Have the authors identified all important confounding factors? 
List the ones you think might be important, that the author missed. 
(b) Have they taken account of the confounding factors in the design and/or analysis? 
Look for restriction in design, and techniques e.g. modelling, stratified-, regression-, or 
sensitivity analysis to correct, control or adjust for confounding factors 
5. Was the follow up of subjects long enough? 
The good or bad effects should have had long enough to reveal themselves  
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6. (a) Was the follow up of subjects complete enough? 
(b) Did the study assessed influence of missing data? 
The persons that are lost to follow-up may have different outcomes than those available 
for assessment  
In an open or dynamic cohort, was there anything special about the outcome of the 



















P1 Variable n %   n %   n % 
Age          
<50 39 12%  202 17%  285 21% <0.001 
50-59 94 29%  293 25%  381 28%  
60-70 127 40%  402 34%  393 29%  
70+ 60 19%  283 24%  306 22%  
Race/ethnicity          
White 240 75%  881 75%  862 63% <0.001 
Black 15 5%  64 5%  84 6%  
Asian 33 10%  129 11%  185 14%  
Hispanic 25 8%  81 7%  196 14%  
Other 7 2%  25 2%  38 3%  
Education          
HS or less 28 9%  110 9%  264 19% <0.001 
Some college 76 24%  372 32%  516 38%  
College or above 216 68%  696 59%  584 43%  
Household income          
<$50K 122 38%  478 41%  659 48% <0.001 
$50K-$89K 162 51%  600 51%  556 41%  
$90K+ 36 11%  102 9%  150 11%  
Menopausal status          
Premenopausal 71 22%  304 26%  383 28% 0.08 
Postmenopausal 249 78%  876 74%  982 72%  
Tumor stage          
I 189 59%  670 57%  741 54% 0.16 
II 99 31%  396 34%  471 35%  
III 28 9%  98 8%  144 11%  
IV 4 1%  16 1%  9 1%  
Number of positive nodes          
0 8 3%  54 5%  64 5% 0.23 
1 77 24%  261 22%  275 20%  
2+ 235 73%  865 73%  1026 75%  
HER2 positivity          
Negative 271 89%  996 88%  1113 85% 0.06 
Positive 34 11%  140 12%  198 15%  
ER/PR positivity          
Negative 53 17%  171 15%  222 16% 0.40 
Positive 267 83%  1008 85%  1139 84%  
Surgery type          
Lumpectomy 162 51%  554 47%  605 44% 0.01 
Mastectomy 156 49%  611 52%  756 55%  
None 2 1%  15 1%  4 0%  
Received chemotherapy          
Yes 135 42%  516 44%  669 49% 0.01 
No 185 58%  661 56%  692 51%  
Received hormonal therapy          
Yes 225 71%  908 77%  1024 76% 0.04 
No 94 29%  264 23%  332 24%  
Received radiation          
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Yes 159 50%  558 47%  566 41% <0.01 
No 161 50%  622 53%  798 59%  
Depressive symptom          
Low 262 83%  924 80%  979 73% <0.001 
High 54 17%  234 20%  367 27%  
Dispositional optimism          
Low 175 55%  762 66%  961 71% <0.001 
High 141 45%  398 34%  386 29%  
Perceived social support          
Low 65 21%  358 31%  479 36% <0.001 
High 251 79%  803 69%  868 64%  
Worse physical well-being  
at 6 months          
No 230 79%  858 79%  928 76% 0.11 
Yes 61 21%  222 21%  294 24%  
Worse CIPN at 6 months          
No 171 72%  532 64%  573 66% 0.07 
Yes 65 28%   293 36%   297 34%   
Note          
Abbreviations: HER2, human epidermal growth factor receptor 2; ER, estrogen 
receptor; PR, progesterone receptor; CIPN, chemotherapy-induced peripheral 
neuropathy  
1. Chi-squared test determined whether the distributions of demographic, clinical and 
psychosocial characteristics were independent of trajectory groups.  
2. Trajectory groups were labeled by the relative level of baseline behavior (high, 
medium, low), direction of change (increase or decrease), and the persistence of 
change (temporary or stable). 
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P-value1 Variable n %   n %   n %   n % 
Age                         
<50 67 17%  191 19%  194 20%  74 15% 0.12 
50-59 105 27%  265 26%  267 27%  131 27%  
60-70 144 37%  320 32%  315 32%  143 30%  
70+ 76 19%  226 23%  216 22%  131 27%  
Race/ethnicity             
White 257 66%  688 69%  678 68%  360 75% 0.06 
Black 26 7%  62 6%  56 6%  19 4%  
Asian 57 15%  132 13%  116 12%  42 9%  
Hispanic 41 10%  92 9%  118 12%  51 11%  
Other 11 3%  28 3%  24 2%  7 1%  
Education             
HS or less 61 16%  150 15%  131 13%  60 13% 0.52 
Some college 142 36%  333 33%  330 33%  159 33%  
College or above 189 48%  519 52%  530 53%  258 54%  
Household income             
<$50K 165 42%  450 45%  420 42%  224 47% 0.05 
$50K-$89K 195 50%  466 47%  450 45%  207 43%  
$90K+ 32 8%  86 9%  122 12%  48 10%  
Menopausal status             
Premenopausal 99 25%  265 26%  280 28%  114 24% 0.30 
Postmenopausal 293 75%  737 74%  712 72%  365 76%  
Tumor stage             
I 224 57%  516 51%  573 58%  287 60% 0.07 
II 125 32%  368 37%  327 33%  146 30%  
III 40 10%  108 11%  83 8%  39 8%  
IV 3 1%  10 1%  9 1%  7 1%  
Number of positive nodes             
0 22 6%  37 4%  42 4%  25 5% 0.13 
1 69 18%  206 21%  235 24%  103 22%  
2+ 301 77%  759 76%  715 72%  351 73%  
HER2 positivity             
Negative 333 88%  827 86%  827 87%  393 86% 0.78 
Positive 46 12%  136 14%  126 13%  64 14%  
ER/PR positivity             
Negative 54 14%  152 15%  169 17%  71 15% 0.40 
Positive 338 86%  847 85%  821 83%  408 85%  
Surgery type             
Lumpectomy 181 46%  442 44%  476 48%  222 46% 0.58 
Mastectomy 210 54%  551 55%  508 51%  254 53%  
None 1 0%  9 1%  8 1%  3 1%  
Received chemotherapy             
Yes 181 46%  480 48%  457 46%  202 42% 0.22 
No 209 54%  521 52%  531 54%  277 58%  
Received hormonal therapy             
Yes 298 77%  766 77%  743 75%  350 73% 0.35 
No 91 23%  225 23%  246 25%  128 27%  
Received radiation             
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Yes 171 44%  439 44%  447 45%  226 47% 0.61 
No 221 56%  563 56%  545 55%  252 53%  
Depressive symptom             
Low 309 80%  745 76%  739 75%  372 79% 0.14 
High 79 20%  236 24%  244 25%  96 21%  
Dispositional optimism             
Low 248 64%  685 69%  648 66%  317 68% 0.19 
High 139 36%  301 31%  334 34%  151 32%  
Perceived social support             
Low 131 34%  315 32%  316 32%  140 30% 0.68 
High 257 66%  671 68%  666 68%  328 70%  
Worse physical well-being  
at 6 months             
No 273 77%  698 76%  703 78%  342 80% 0.52 
Yes 81 23%  215 24%  195 22%  86 20%  
Worse CIPN at 6 months             
No 169 65%  435 63%  441 66%  231 73% 0.02 
Yes 92 35%   254 37%   223 34%   86 27%   
Note             
Abbreviations: HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, 
progesterone receptor; CIPN, chemotherapy-induced peripheral neuropathy  
1. Chi-squared test determined whether the distributions of demographic, clinical and psychosocial 
characteristics were independent of trajectory groups.  
2. Trajectory groups were labeled by the relative level of baseline behavior (high, medium, low), 
direction of change (increase or decrease), and the persistence of change (temporary or stable). 
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(n=1045)   
Low-stable 
(n=1736) 
P1 Variable n %   n %   n % 
Age          
<50 52 24%  203 19%  308 18% <0.001 
50-59 70 32%  297 28%  430 25%  
60-70 70 32%  354 34%  537 31%  
70+ 27 12%  191 18%  461 27%  
Race/ethnicity          
White 160 73%  766 73%  1153 66% <0.01 
Black 12 5%  54 5%  116 7%  
Asian 21 10%  107 10%  227 13%  
Hispanic 18 8%  92 9%  205 12%  
Other 8 4%  26 2%  35 2%  
Education          
HS or less 21 10%  101 10%  304 18% <0.001 
Some college 70 32%  327 31%  619 36%  
College or above 128 58%  616 59%  811 47%  
Household income          
<$50K 80 37%  401 38%  836 48% <0.001 
$50K-$89K 128 58%  552 53%  696 40%  
$90K+ 11 5%  92 9%  204 12%  
Menopausal status          
Premenopausal 73 33%  301 29%  421 24% <0.01 
Postmenopausal 146 67%  744 71%  1315 76%  
Tumor stage          
I 135 62%  597 57%  928 53% <0.01 
II 71 32%  358 34%  595 34%  
III 11 5%  86 8%  187 11%  
IV 2 1%  4 0%  26 1%  
Number of positive nodes          
0 9 4%  29 3%  93 5% 0.01 
1 47 21%  244 23%  354 20%  
2+ 163 74%  772 74%  1289 74%  
HER2 positivity          
Negative 189 90%  874 87%  1429 86% 0.37 
Positive 22 10%  134 13%  231 14%  
ER/PR positivity          
Negative 32 15%  162 16%  279 16% 0.81 
Positive 187 85%  882 84%  1453 84%  
Surgery type          
Lumpectomy 93 42%  489 47%  799 46% 0.06 
Mastectomy 125 57%  554 53%  918 53%  
None 1 0%  2 0%  19 1%  
Received chemotherapy          
Yes 91 42%  486 47%  808 47% 0.34 
No 128 58%  557 53%  922 53%  
Received hormonal therapy          
Yes 164 76%  780 75%  1306 76% 0.97 
No 53 24%  256 25%  419 24%  
Received radiation          
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Yes 100 46%  479 46%  762 44% 0.60 
No 119 54%  566 54%  972 56%  
Depressive symptom          
Low 163 75%  810 79%  1276 75% 0.09 
High 53 25%  217 21%  419 25%  
Dispositional optimism          
Low 123 57%  637 62%  1224 72% <0.001 
High 93 43%  391 38%  472 28%  
Perceived social support          
Low 57 26%  286 28%  608 36% <0.001 
High 159 74%  744 72%  1087 64%  
Worse physical well-being  
at 6 months          
No 153 80%  751 78%  1184 77% 0.67 
Yes 39 20%  212 22%  352 23%  
Worse CIPN at 6 months          
No 105 70%  506 69%  727 64% 0.06 
Yes 46 30%   229 31%   409 36%   
Note          
Abbreviations: HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, 
progesterone receptor; CIPN, chemotherapy-induced peripheral neuropathy  
1. Chi-squared test determined whether the distributions of demographic, clinical and psychosocial 
characteristics were independent of trajectory groups.  
2. Trajectory groups were labeled by the relative level of baseline behavior (high, medium, low), 
direction of change (increase or decrease), and the persistence of change (temporary or stable). 
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P1 Variable n %   n %   n %   n % 
Age             
<50 52 10%  144 20%  139 17%  225 25% <0.001 
50-59 101 19%  184 25%  217 27%  296 32%  
60-70 218 41%  239 33%  243 30%  260 28%  
70+ 165 31%  161 22%  217 27%  136 15%  
Race/ethnicity             
White 443 83%  514 71%  561 69%  558 61% <0.001 
Black 24 4%  60 8%  51 6%  46 5%  
Asian 28 5%  74 10%  91 11%  160 17%  
Hispanic 24 4%  66 9%  84 10%  142 15%  
Other 17 3%  14 2%  29 4%  11 1%  
Education             
HS or less 55 10%  101 14%  121 15%  144 16% <0.01 
Some college 177 33%  230 32%  307 38%  303 33%  
College or above 303 57%  396 54%  388 48%  469 51%  
Household income             
<$50K 261 49%  328 45%  353 43%  370 40% 0.03 
$50K-$89K 225 42%  333 46%  365 45%  453 49%  
$90K+ 50 9%  67 9%  98 12%  94 10%  
Menopausal status             
Premenopausal 76 14%  199 27%  201 25%  315 34% <0.001 
Postmenopausal 460 86%  529 73%  615 75%  602 66%  
Tumor stage             
I 322 60%  386 53%  446 55%  509 56% 0.13 
II 167 31%  255 35%  297 36%  302 33%  
III 43 8%  75 10%  66 8%  97 11%  
IV 4 1%  12 2%  7 1%  9 1%  
Number of positive nodes             
0 23 4%  28 4%  28 3%  51 6% 0.22 
1 110 21%  147 20%  177 22%  211 23%  
2+ 403 75%  553 76%  611 75%  655 71%  
HER2 positivity             
Negative 455 88%  595 85%  680 87%  761 86% 0.59 
Positive 62 12%  102 15%  102 13%  120 14%  
ER/PR positivity             
Negative 78 15%  126 17%  125 15%  143 16% 0.57 
Positive 456 85%  601 83%  691 85%  772 84%  
Surgery type             
Lumpectomy 287 54%  323 44%  365 45%  406 44% 0.01 
Mastectomy 248 46%  400 55%  445 55%  501 55%  
None 1 0%  5 1%  6 1%  10 1%  
Received chemotherapy             
Yes 206 38%  365 51%  370 45%  440 48% <0.001 
No 330 62%  357 49%  445 55%  476 52%  
Received hormonal therapy             
 
174 
Yes 400 75%  535 74%  622 76%  694 77% 0.60 
No 134 25%  187 26%  192 24%  211 23%  
Received radiation             
Yes 273 51%  311 43%  351 43%  408 45% 0.02 
No 263 49%  417 57%  464 57%  508 55%  
Depressive symptom             
Low 424 81%  538 75%  614 76%  673 76% 0.05 
High 99 19%  183 25%  189 24%  214 24%  
Dispositional optimism             
Low 318 61%  484 67%  546 68%  629 71% <0.01 
High 205 39%  238 33%  259 32%  258 29%  
Perceived social support             
Low 134 26%  241 33%  249 31%  326 37% <0.001 
High 389 74%  482 67%  554 69%  563 63%  
Worse physical well-being  
at 6 months             
No 374 78%  502 76%  580 78%  633 78% 0.82 
Yes 105 22%  156 24%  161 22%  180 22%  
Worse CIPN at 6 months             
No 254 67%  304 62%  367 65%  413 70% 0.05 
Yes 124 33%   185 38%   195 35%   177 30%   
Note             
Abbreviations: HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, 
progesterone receptor; CIPN, chemotherapy-induced peripheral neuropathy  
1. Chi-squared test determined whether the distributions of demographic, clinical and psychosocial 
characteristics were independent of trajectory groups.  
2. Trajectory groups were labeled by the relative level of baseline behavior (high, medium, low), 
direction of change (increase or decrease), and the persistence of change (temporary or stable). 
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(n=459)   
Low-stable 
(n=2269) 
P-value1 Variable n %   n %   n % 
Age          
<50 15 11%  79 17%  432 19% 0.02 
50-59 49 36%  115 25%  604 27%  
60-70 49 36%  144 31%  729 32%  
70+ 24 18%  121 26%  504 22%  
Race/ethnicity          
White 130 95%  392 85%  1461 64% <0.001 
Black 1 1%  17 4%  145 6%  
Asian 2 1%  17 4%  328 14%  
Hispanic 2 1%  23 5%  277 12%  
Other 2 1%  10 2%  58 3%  
Education          
HS or less 12 9%  38 8%  352 16% <0.001 
Some college 47 34%  135 29%  782 34%  
College or above 78 57%  285 62%  1133 50%  
Household income          
<$50K 42 31%  167 36%  1050 46% <0.001 
$50K-$89K 87 64%  257 56%  974 43%  
$90K+ 8 6%  35 8%  245 11%  
Menopausal status          
Premenopausal 22 16%  119 26%  617 27% 0.02 
Postmenopausal 115 84%  340 74%  1652 73%  
Tumor stage          
I 89 65%  269 59%  1242 55% 0.20 
II 39 28%  143 31%  784 35%  
III 9 7%  43 9%  218 10%  
IV 0 0%  4 1%  25 1%  
Number of positive nodes          
0 1 1%  22 5%  103 5% 0.15 
1 37 27%  95 21%  481 21%  
2+ 99 72%  342 75%  1685 74%  
HER2 positivity          
Negative 119 89%  390 88%  1871 86% 0.33 
Positive 15 11%  52 12%  305 14%  
ER/PR positivity          
Negative 21 15%  49 11%  376 17% 0.01 
Positive 116 85%  410 89%  1888 83%  
Surgery type          
Lumpectomy 79 58%  227 49%  1015 45% 0.01 
Mastectomy 58 42%  231 50%  1234 54%  
None 0 0%  1 0%  20 1%  
Received chemotherapy          
Yes 57 42%  183 40%  1080 48% 0.01 
No 79 58%  275 60%  1184 52%  
Received hormonal therapy          
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Yes 107 79%  364 79%  1686 75% 0.08 
No 29 21%  94 21%  567 25%  
Received radiation          
Yes 71 52%  237 52%  975 43% <0.001 
No 66 48%  221 48%  1294 57%  
Depressive symptom          
Low 109 80%  359 80%  1697 76% 0.19 
High 28 20%  92 20%  535 24%  
Dispositional optimism          
Low 79 58%  294 65%  1525 68% 0.02 
High 58 42%  160 35%  707 32%  
Perceived social support          
Low 35 26%  128 28%  739 33% 0.03 
High 102 74%  325 72%  1495 67%  
Worse physical well-being  
at 6 months          
No 104 82%  348 82%  1564 77% 0.04 
Yes 23 18%  78 18%  476 23%  
Worse CIPN at 6 months          
No 61 66%  233 72%  982 65% 0.05 
Yes 31 34%   91 28%   533 35%   
Note          
Abbreviations: HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, 
progesterone receptor; CIPN, chemotherapy-induced peripheral neuropathy  
1. Chi-squared test determined whether the distributions of demographic, clinical and psychosocial 
characteristics were independent of trajectory groups.  
2. Trajectory groups were labeled by the relative level of baseline behavior (high, medium, low), 
direction of change (increase or decrease), and the persistence of change (temporary or stable). 
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Appendix 8.  Multinomial logistic regression of tumor characteristics and treatment and health 
behavior change trajectory 
 
Predictors OR (95% CI) P   OR (95% CI) P   OR (95% CI) P 
 Fruit/vegetable intake trajectory groups (referent group=low increase-stable) 
 High increase-stable   Medium increase-stable     
Stage         
Stage II vs. Stage I 0.99 (0.67, 1.49) 0.98  1.08 (0.84, 1.41) 0.54    
Stage III vs. Stage I 1.07 (0.56, 2.04) 0.83  0.84 (0.55, 1.28) 0.42    
Stage IV vs. Stage I 3.73 (0.68, 20.41) 0.13  1.83 (0.51, 6.64) 0.36    
Positive node removed         
1 vs. 0 2.58 (0.80, 8.36) 0.11  1.36 (0.73, 2.51) 0.33    
2+ vs. 0 2.73 (0.88, 8.5) 0.08  1.22 (0.68, 2.19) 0.50    
ER/PR         
Positive vs. negative 1.45 (0.78, 2.68) 0.24  0.85 (0.54, 1.33) 0.47    
Surgery         
Mastectomy vs. lumpectomy 0.81 (0.56, 1.17) 0.27  1.02 (0.80, 1.3) 0.87    
None vs. lumpectomy 1.20 (0.08, 18.69) 0.89  3.83 (0.66, 22.18) 0.13    
Chemotherapy (yes vs. no) 1.38 (0.89, 2.13) 0.15  1.16 (0.87, 1.55) 0.31    
Hormonal therapy (yes vs. no) 1.85 (1.14, 3) 0.01  0.90 (0.62, 1.31) 0.59    
Radiation (yes vs. no) 1.06 (0.73, 1.56) 0.75   0.83 (0.65, 1.07) 0.15       
 Dietary fat intake trajectory groups (referent group=low-stable) 
 High-stable   Medium high-stable   Medium low-stable 
Stage         
Stage II vs. Stage I 1.30 (0.84, 2.02) 0.25  1.41 (0.98, 2.03) 0.06  1.05 (0.73, 1.52) 0.79 
Stage III vs. Stage I 1.12 (0.56, 2.23) 0.75  1.05 (0.60, 1.85) 0.86  0.82 (0.46, 1.47) 0.50 
Stage IV vs. Stage I 0.56 (0.09, 3.57) 0.54  0.53 (0.14, 2.08) 0.36  0.46 (0.10, 2.03) 0.30 
Positive node removed         
1 vs. 0 0.79 (0.32, 1.97) 0.61  1.39 (0.64, 3.04) 0.41  2.37 (1.01, 5.56) 0.05 
2+ vs. 0 0.91 (0.39, 2.14) 0.84  1.43 (0.69, 2.99) 0.34  2.22 (0.98, 4.99) 0.05 
ER/PR         
Positive vs. negative 0.81 (0.39, 1.67) 0.57  0.65 (0.35, 1.2) 0.17  0.57 (0.31, 1.04) 0.07 
Surgery         
Mastectomy vs. lumpectomy 1.04 (0.70, 1.56) 0.84  1.04 (0.75, 1.45) 0.81  0.79 (0.57, 1.1) 0.17 
None vs. lumpectomy 0.76 (0.05, 11.37) 0.85  2.55 (0.38, 17.19) 0.34  0.96 (0.10, 9.12) 0.97 
Chemotherapy (yes vs. no) 1.12 (0.69, 1.81) 0.64  1.06 (0.72, 1.57) 0.76  1.07 (0.72, 1.59) 0.73 
Hormonal therapy (yes vs. no) 1.05 (0.59, 1.86) 0.88  0.74 (0.46, 1.19) 0.21  0.83 (0.52, 1.34) 0.45 
Radiation (yes vs. no) 0.97 (0.64, 1.47) 0.88   1.11 (0.79, 1.55) 0.56   1.09 (0.78, 1.54) 0.61 
 Moderate to vigorous physical activity trajectory groups (referent group=low-stable) 
 High decrease-temporary   Medium decrease-temporary     
Stage         
Stage II vs. Stage I 0.82 (0.51, 1.3) 0.40  1.04 (0.81, 1.34) 0.76    
Stage III vs. Stage I 0.35 (0.14, 0.86) 0.02  0.72 (0.48, 1.09) 0.12    
Stage IV vs. Stage I 0.77 (0.14, 4.17) 0.76  0.31 (0.07, 1.48) 0.14    
Positive node removed         
1 vs. 0 0.78 (0.27, 2.2) 0.63  2.50 (1.24, 5.04) 0.01    
2+ vs. 0 0.87 (0.33, 2.3) 0.78  2.03 (1.03, 3.99) 0.04    
ER/PR         
Positive vs. negative 0.74 (0.32, 1.67) 0.47  1.13 (0.74, 1.74) 0.56    
Surgery         
Mastectomy vs. lumpectomy 1.50 (0.97, 2.32) 0.07  1.08 (0.86, 1.37) 0.51    
None vs. lumpectomy 0.73 (0.07, 7.77) 0.79  NE NE    
Chemotherapy (yes vs. no) 1.75 (1.06, 2.89) 0.03  1.11 (0.84, 1.46) 0.47    
Hormonal therapy (yes vs. no) 0.71 (0.35, 1.43) 0.34  1.10 (0.77, 1.57) 0.59    
Radiation (yes vs. no) 1.17 (0.75, 1.84) 0.48   1.09 (0.86, 1.4) 0.47       
  Sedentary time trajectory groups (referent group=low-stable) 
 High-stable   Medium increase-stable   Medium decrease-stable 
Stage         
Stage II vs. Stage I 0.85 (0.59, 1.21) 0.36  0.89 (0.64, 1.23) 0.48  0.94 (0.69, 1.28) 0.69 
Stage III vs. Stage I 0.78 (0.44, 1.38) 0.39  0.77 (0.47, 1.27) 0.31  0.50 (0.30, 0.84) 0.01 
Stage IV vs. Stage I 1.32 (0.24, 7.14) 0.75  1.95 (0.47, 8.15) 0.36  1.26 (0.30, 5.31) 0.75 
Positive node removed         
1 vs. 0 1.29 (0.56, 2.96) 0.55  1.74 (0.80, 3.79) 0.17  1.43 (0.69, 2.95) 0.33 
2+ vs. 0 1.81 (0.82, 3.97) 0.14  2.00 (0.95, 4.19) 0.07  1.62 (0.81, 3.21) 0.17 
ER/PR         
Positive vs. negative 0.94 (0.52, 1.7) 0.83  1.08 (0.63, 1.85) 0.78  0.86 (0.51, 1.48) 0.59 
Surgery         
Mastectomy vs. lumpectomy 0.87 (0.63, 1.21) 0.41  1.10 (0.82, 1.48) 0.53  1.06 (0.80, 1.42) 0.67 
None vs. lumpectomy NE NE  0.48 (0.08, 2.9) 0.42  0.72 (0.14, 3.62) 0.69 
Chemotherapy (yes vs. no) 0.85 (0.57, 1.26) 0.42  0.77 (0.54, 1.09) 0.14  0.81 (0.58, 1.14) 0.23 
Hormonal therapy (yes vs. no) 1.03 (0.63, 1.68) 0.90  1.13 (0.72, 1.78) 0.60  0.78 (0.50, 1.23) 0.29 
Radiation (yes vs. no) 1.02 (0.72, 1.43) 0.92   1.15 (0.84, 1.56) 0.39   1.16 (0.86, 1.57) 0.32 
 Alcohol intake trajectory groups (referent group=low-stable) 
 High decrease-temporary   Medium decrease-temporary     
Stage         
Stage II vs. Stage I 0.69 (0.38, 1.27) 0.23  0.89 (0.64, 1.25) 0.51    
Stage III vs. Stage I 0.95 (0.37, 2.41) 0.91  0.87 (0.50, 1.52) 0.63    
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Stage IV vs. Stage I NE NE  1.34 (0.37, 4.8) 0.65    
Positive node removed         
1 vs. 0 NE NE  0.80 (0.38, 1.68) 0.56    
2+ vs. 0 NE NE  0.83 (0.41, 1.68) 0.60    
ER/PR         
Positive vs. negative 0.75 (0.26, 2.19) 0.60  1.36 (0.77, 2.41) 0.29    
Surgery         
Mastectomy vs. lumpectomy 0.55 (0.33, 0.94) 0.03  1.02 (0.75, 1.38) 0.90    
None vs. lumpectomy NE NE  0.39 (0.04, 3.77) 0.42    
Chemotherapy (yes vs. no) 1.44 (0.76, 2.73) 0.26  1.19 (0.83, 1.72) 0.34    
Hormonal therapy (yes vs. no) 0.60 (0.24, 1.47) 0.26  0.97 (0.62, 1.5) 0.88    
Radiation (yes vs. no) 1.38 (0.80, 2.39) 0.25   0.79 (0.58, 1.08) 0.14       
Note         
Abbreviations: OR, odds ratio; CI, confidence interval; NE, not estimable 
1. Other variables included in the model were age, race, menopausal status, baseline depressive symptoms, dispositional optimism, social support, 
worsening of physical well-being chemotherapy induced peripheral neuropathy 
2. Trajectory groups were labeled by the relative level of baseline behavior (high, medium, low), direction of change (increase or decrease), and the 






Appendix 9. Population characteristics comparing early vs. late enrollees 
 
 
0-2 months after 
diagnosis 
(n=2447)  
2-3 months after 
diagnosis 
(n=1512)  
3+ months after 
diagnosis 
(n=546) 
Variable n %   n %   n % P1 
Age          
<50 523 21%  345 23%  128 23% 0.78 
50-59 715 29%  437 29%  164 30%  
60-70 712 29%  428 28%  157 29%  
70+ 497 20%  302 20%  97 18%  
Race/ethnicity          
White 1622 66%  934 62%  338 62% 0.12 
Black 171 7%  137 9%  50 9%  
Asian 303 12%  204 13%  71 13%  
Hispanic 293 12%  194 13%  70 13%  
Other 58 2%  43 3%  17 3%  
Education          
HS or less 397 16%  230 15%  80 15% 0.44 
Some college 832 34%  528 35%  208 38%  
College or above 1211 50%  753 50%  258 47%  
Household income         
<$50K 1066 44%  656 43%  227 42% 0.92 
$50K-$89K 1096 45%  674 45%  250 46%  
$90K+ 285 12%  182 12%  69 13%  
Menopausal status         
Premenopausal 729 30%  457 30%  166 30% 0.94 
Postmenopausal 1718 70%  1055 70%  380 70%  
Tumor stage          
I 1333 54%  793 52%  306 56% 0.80 
II 837 34%  543 36%  181 33%  
III 240 10%  149 10%  50 9%  
IV 37 2%  27 2%  9 2%  
Number of positive nodes        
0 118 5%  66 4%  18 3% 0.35 
1 538 22%  312 21%  128 23%  
2+ 1791 73%  1134 75%  400 73%  
HER2 positivity          
Negative 2022 87%  1242 86%  462 88% 0.51 
Positive 315 13%  209 14%  66 13%  
ER/PR positivity          
Negative 410 17%  252 17%  89 16% 0.97 
Positive 2036 83%  1257 83%  456 84%  
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Surgery type          
Lumpectomy 1151 47%  643 43%  223 41% 0.01 
Mastectomy 1266 52%  852 56%  319 58%  
None 30 1%  17 1%  4 1%  
Received chemotherapy         
Yes 1181 48%  741 49%  223 41% <0.01 
No 1257 52%  770 51%  320 59%  
Received hormonal therapy        
Yes 1836 76%  1104 74%  397 73% 0.29 
No 594 24%  397 26%  144 27%  
Received radiation         
Yes 1080 44%  654 43%  238 44% 0.87 
No 1367 56%  857 57%  307 56%  
Depressive symptom         
Low 1730 74%  1047 73%  372 74% 0.85 
High 610 26%  385 27%  132 26%  
Dispositional optimism         
Low 1607 69%  977 68%  361 71% 0.43 
High 738 31%  456 32%  146 29%  
Perceived social support         
Low 777 33%  449 31%  168 33% 0.47 
High 1569 67%  985 69%  336 67%  
Worse PWB at 6 months         
No 1169 76%  691 77%  241 84% 0.02 
Yes 365 24%  201 23%  47 16%  
Worse CIPN at 6 months         
No  670 64%  490 67%  190 73% 0.02 
Yes 380 36%   241 33%   70 27%   
Note          
Abbreviations: HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, 
progesterone receptor  
1. Chi-squared test compared the distribution of demographic, clinical and psychosocial 




Appendix 10. Exclusion of extreme diet data based on total energy intake 
 
  
Mean total energy 
intake (Kcal/day) 
Standard deviation 
(Kcal/day) Mean+3*SD N excluded 
Baseline 1483.8 638.2 3398.3 51 
6 months 1362.6 574.0 3084.6 27 





































stable   
Kap
pa 
High increase-stable 317 3 0  0.99 
Medium increase-
stable 1 1150 2    
Low increase-stable 0 12 1321     







High-stable 130 0 0 0 0.98 
Medium high-stable 0 1087 0 0   
Medium low-stable 0 27 1298 0   









temporary 128 0 0  0.99 
Medium decrease-
temporary 4 454 0    






























Appendix 12. Average change in subcategories of diet and physical activity by behavior 
change trajectories.  
The figure shows the mean and 95% CI of changes in each subcategory of fruit/vegetable (A) and 








Appendix 13. Average change in subcategories of physical activity by behavior change 
trajectories.  
The figure shows the mean and 95% CI of changes in each subcategory of moderate to vigorous 










Appendix 14. Missing data pattern for key analytical variables.  
The figure displays the overall pattern of missing data for the 4505 participants in the Pathways Study.  
The color of each pixel represents the standardized values of each variable, with darker color 
indicating higher standardized value. Missing data points are shown as a black pixel. Observations are 




































































































































































































Chapter 4 APPENDICES 
Appendix 15.  Linear regression analysis of BMI at 6 and 24 months following a breast cancer diagnosis 
       
 6 months  24 months 
 Minimally adjusted
1  Fully adjusted
2  Minimally adjusted
1  Fully adjusted
2 
Behavior trajectory groups Difference (95% CI) P   Difference (95% CI) P   Difference (95% CI) P   Difference (95% CI) P 
Fruit/vegetable (ref=Low increase-stable)           
High increase-stable  0.27 (-0.30, 0.84) 0.35   0.52 (-0.21, 1.25) 0.16  -0.33 (-1.14, 0.48) 0.42  -0.30 (-1.23, 0.64) 0.53 
Medium increase-stable -0.15 (-0.52, 0.22) 0.42   0.03 (-0.46, 0.53) 0.89  -0.43 (-0.97, 0.11) 0.12  -0.63 (-1.28, 0.02) 0.06 
Dietary fat (ref=Low-stable)            
High-stable 0.65 (0.01, 1.29) 0.05   0.68 (-0.14, 1.50) 0.10  1.32 (0.41, 2.23) <0.001   1.12 ( 0.06, 2.17) 0.04 
Medium high-stable 0.50 (-0.01, 1.02) 0.05   0.42 (-0.25, 1.08) 0.22  0.93 (0.19, 1.67) 0.01   0.32 (-0.54, 1.19) 0.46 
Medium low-stable 0.43 (-0.09, 0.95) 0.10   0.30 (-0.35, 0.96) 0.37  0.46 (-0.28, 1.20) 0.22   0.60 (-0.26, 1.45) 0.17 
Moderate to vigorous physical activity (ref=Low-stable)          
High decrease-temporary 0.46 (-0.24, 1.17) 0.19   0.45 (-0.42, 1.33) 0.31  0.02 (-0.95, 1.00) 0.97  -0.14 (-1.26, 0.97) 0.80 
Medium decrease-temporary 0.21 (-0.17, 0.60) 0.28   0.18 (-0.31, 0.67) 0.48  0.30 (-0.25, 0.86) 0.28   0.05 (-0.59, 0.68) 0.88 
Sedentary activity (ref=Low-stable)           
High-stable -0.02 (-0.54, 0.51) 0.95   0.26 (-0.42, 0.93) 0.46  0.57 (-0.19, 1.32) 0.14   0.89 ( 0.03, 1.75) 0.04 
Medium high-stable  0.16 (-0.32, 0.63) 0.52   0.23 (-0.38, 0.84) 0.45  0.00 (-0.69, 0.70) 0.99   0.09 (-0.72, 0.90) 0.83 
Medium low-stable -0.11 (-0.57, 0.35) 0.64   0.00 (-0.58, 0.59) 1.00  0.45 (-0.21, 1.12) 0.18   0.29 (-0.47, 1.04) 0.45 
Alcohol  (ref=Low-stable)            
High decrease-temporary  0.18 (-0.63, 0.98) 0.67   0.01 (-1.06, 1.07) 0.99  -0.06 (-1.22, 1.10) 0.92   0.15 (-1.25, 1.56) 0.83 
Medium decrease-temporary -0.14 (-0.61, 0.33) 0.56   -0.11 (-0.71, 0.49) 0.72    0.08 (-0.59, 0.75) 0.81    0.01 (-0.76, 0.78) 0.99 
Note            
Abbreviations: CI, confidence interval 
1. The minimally adjusted analysis controlled for baseline weight 
2. The fully adjusted analysis controlled for age, race/ethnicity, education, income, menopausal status, tumor stage, receipt of surgery, chemotherapy, hormonal therapy, radiation, 









Appendix 16.  Multinomial logistic regression of change in dietary trajectory and BMI trajectory after exclusion of extreme dietary data 
and adjusted for baseline total energy intake 
 
 BMI trajectory groups (Referent=Healthy weight) 
Behavior trajectory groups Severely obese   Overweight/obese 
 OR (95% CI) P   OR (95% CI) P 
Fruit/vegetable (ref=Low increase-stable)     
High increase-stable 0.42 (0.37, 0.48) <0.01  0.81 (0.58, 1.14) 0.23 
High decrease-stable 0.62 (0.43, 0.91) 0.01  0.68 (0.54, 0.87) <0.01 
Dietary fat (ref=Low-stable)      
High increase-stable 2.34 (2.11, 2.60) <0.01  2.24 (1.76, 2.86) <0.01 
Low increase-stable 2.14 (1.72, 2.66) <0.01  1.51 (1.20, 1.90) <0.01 
High decrease-stable 1.30 (1.03, 1.64) 0.03  1.22 (0.97, 1.53) 0.09 
Alcohol intake (ref=Low-stable)      
High increase-stable 0.18 (0.18, 0.18) <0.01  0.51 (0.36, 0.73) <0.01 
High decrease-stable 0.33 (0.31, 0.35) <0.01   0.57 (0.43, 0.78) <0.01 
Note      
Abbreviations: OR, odds ratio; CI, confidence interval; NE, not estimable 
These analyses were simultaneously controlled for group membership of all other health behaviors (moderate to vigorous physical activity and 
sedentary time), baseline energy intake, age, race/ethnicity, education, income, menopausal status, tumor stage, receipt of surgery, 




Appendix 17. Correlation between clinical classification of BMI and BMI trajectory groups 
 
    BMI trajectory groups   






























Baseline    <0.01 
Normal 0 2 1176   
Overweight/obese 1 911 478   
Class II obesity 242 145 0   
6 months    <0.01 
Normal 0 10 1107   
Overweight/obese 6 865 453   
Class II obesity 214 111 0   
24 months    <0.01 
Normal 0 5 840   
Overweight/obese 6 632 342   
Class II obesity 142 84 0   
Clinical cutoff for BMI are as follows: normal: <25 kg/m2, overweight: 25-30 kg/m2, obese: ≥30 kg/m2, 













Appendix 18. Missing data pattern for key analytical variables. The figure displays the overall 
pattern of missing data for the 4505 participants in the Pathways Study.  The color of the pixels 
represents the standardized values of each variable, with darker color indicating higher standardized 




































































































































































































































Appendix 19. Boxplot of total energy intake by alcohol intake trajectory. The boxplots show that 
the mean total energy intakes (the dark center bar within each box plot) were higher in women who 
maintained high alcohol intake vs. non-drinkers. However, extremely high energy intake was more 
frequent in women in the low-stable group, as evidenced by the number of data points greater than the 
mean+3 standard deviations of total energy intake (the red horizontal line). 
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